Recent Advances in Drug Addiction Research and Clinical Applications by unknown
Recent Advances in Drug 
Addiction Research and 
Clinical Applications
Edited by William M. Meil and Christina L. Ruby
Edited by William M. Meil and Christina L. Ruby
Photo by turk_stock_photographer / iStock
Although it is well-accepted that drug addiction is a major public health concern, how 
we address it as a society continues to evolve as recent advances in the lab and clinic 
clarify the nature of the problem and influence our views. This unique collection of 
eight chapters reviews key findings on the neurobiology and therapeutics of addiction 
while capturing the diversity of perspectives that shape these concepts, which range 
from evolutionary biology to psychiatry to the legal system. This book discusses in 
depth how technological advances have led to important discoveries and how these 
discoveries, in turn, are increasingly being translated into clinical practice. It also 
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Drug addiction represents a major public health concern. This statement has been echoed at
the beginning of many of our papers and presentations over the last 20 years, and we imag‐
ine this has been the same for the majority of our colleagues. Indeed, substance use disor‐
ders have taken and continue to take a major toll on individuals, families, clinicians, and
society at large. However, beyond this beginning statement, the majority of this book does
not resemble one that might have been written 20 years ago. Technological advances and the
findings that have followed from their application have allowed our understanding of drug
addiction to progress. Moreover, we are seeing an emphasis on translating our growing
knowledge to advances into clinical practice. This book includes eight chapters that not only
review the past and present status of various topics related to drug addiction, but also illus‐
trate how our increasing understanding of the neurobiological basis of drug addiction is lay‐
ing the foundation for future clinical approaches that will benefit those suffering from
addictive disorders.
This book opens with a discussion of the neurocircuitry underlying addictive behavior
through the lens of evolution. From this unique perspective, Chapter 1 describes the roles of
the lateral and medial habenula in modulating the activity of the monoaminergic reward
pathways (classically the primary focus of addiction research) and the stress/anxiety path‐
ways (increasingly recognized as central to addiction). The authors present an anatomical
model in which the lateral habenula gates reward-seeking depending on the valence of the
expected reward, and the medial habenula activates misery-fleeing behavior and dysphoria
that accompany drug craving. Consequently, the authors postulate that the habenula has a
dual-role in transition to addiction and relapse during abstinence. Chapter 2 continues with
epigenetic mechanisms in addiction, a relatively nascent, but intriguing field of study. Epi‐
genetic modifications, such as DNA methylation, histone modification, and non-coding
RNAs, induce long-lasting, even intergenerational, changes in gene expression and are thus
poised to contribute uniquely to the relapsing nature of addiction. Although studies to date
have focused primarily on alcohol and cocaine, evidence that epigenetic modifications medi‐
ate many of the persistent molecular changes in the brain occurring with repeated drug ex‐
posure, or life experiences that confer risk for addiction (such as stress), is compelling.
Chapter 3 summarizes the commonly used rodent models of alcohol intake and seeking be‐
havior and discusses how they have combined with recent methodological advances to re‐
veal neurobiological substrate regulating aspects of alcohol use disorders. The authors
present the strengths and limitations of drinking paradigms as well as operant self-adminis‐
tration and place conditioning, which reflect the importance of environmental cues in re‐
lapse. Chapter 3 then describes the classical and modern techniques used to elucidate the
molecular mechanisms and neural structures that mediate alcohol-related behavior. Finally,
the authors discuss some key findings in the alcohol research field made possible by these
approaches. Chapter 4 further develops the well-established role of dopaminergic signaling
in alcohol drinking and reward. It reviews the efficacy and tolerability of pharmacological
treatments targeting dopamine transmission and suggests that newer agents that stabilize or
indirectly modulate the mesolimbic dopamine system may be superior therapies, reflecting
the paradigm shift from potent selective pharmaceuticals to more moderate approaches that
target drug reward with fewer side effects. Chapter 5 further illustrates how our under‐
standing of addiction now extends well beyond the mesolimbic dopamine system. This
chapter highlights how dysregulation of serotonin and noradrenaline within the basolateral
amygdala results in stress-induced negative emotional states upon alcohol withdrawal and
subsequent craving and vulnerability to relapse. The potential of several putative pharmaco‐
therapies for alcohol use disorders that target these transmitter systems are addressed.
Despite being endorsed by the majority of psychological and medical organizations, the
medical or disease model of drug addiction remains overshadowed by the view that drug
addiction represents a moral failing among wide swaths of the population. The continued
controversy surrounding these theoretical perspectives can be seen across Chapter 6, which
provides an overview of major approaches to treating substance use disorders, outlining
their origins and core features. Moreover, this chapter provides the reader with a platform
to consider advances in clinical practices, the importance of evidence-based approaches to
treating addiction, and considers how drug courts may represent a potential reconciliation
of the medical and moral approaches to addressing substance use disorders. The value of
appreciating the dynamic nature of factors related to the development of drug addiction is
well illustrated in Chapter 7, which compares two cohorts of dual diagnosis patients admit‐
ted to an acute psychiatry ward 10 years apart. This chapter highlights that while our cur‐
rent knowledge of substance use disorders can be informed by past research, we cannot
solely rely on our previous understanding as a variety of changing demographic, societal,
and pharmacological influences can shape the nature of problems faced by addicts and
healthcare professionals alike. Chapter 8 reviews recent neuroimaging studies examining
the effects of prenatal exposure across of a variety of addictive drugs on brain structure,
function, developmental trajectory, and behavior. While emphasizing the challenges associ‐
ated with research examining the effects of prenatal drug exposure this chapter also raises
the possibilities that biomarkers will emerge that might ultimately inform prevention and
intervention programs.
Perhaps believing we will one day be saying that drug addiction is no longer a major public
health concern is both optimistic and unrealistic? It is our hope that in coming decades we
will see many of the ideas and translational approaches articulated here come to fruition
and the next wave of technological advances will build upon our cumulative understanding
of addictive processes and reduce the suffering of those directly and indirectly impacted by
substance use disorders.
William M. Meil Ph.D.
Professor of Psychology
Indiana University of Pennsylvania
Christina L. Ruby Ph.D.
Assistant Professor of Biology
Indiana University of Pennsylvania
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Chapter 1
Circuits Regulating Pleasure and Happiness: A Focus on
Addiction, Beyond the Ventral Striatum
Anton J.M. Loonen, Arnt F.A. Schellekens and
Svetlana A. Ivanova
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62707
Abstract
A recently developed anatomical model describes how the intensity of reward-seeking
and misery-fleeing behaviours is regulated. The first type of behaviours is regulated within
an extrapyramidal cortical–subcortical circuit containing as first relay stations, the caudate
nucleus, putamen and core of the accumbens nucleus. The second type of behaviours is
controlled by a limbic cortical–subcortical circuit with as first stations, the centromedial
amygdala, extended amygdala, bed nucleus of the stria terminalis and shell of the
accumbens nucleus. We hypothesize that sudden cessation of hyperactivity of the first
circuit results in feelings of pleasure and of the second circuit in feelings of happiness.
The insular cortex has probably an essential role in the perception of these and other
emotions. Motivation to show these behaviours is regulated by monoaminergic neurons
projecting to the accumbens from the midbrain: dopaminergic ventral tegmental nuclei,
adrenergic locus coeruleus and serotonergic upper raphe nuclei. The activity of these
monoaminergic nuclei is in turn regulated through a ventral pathway by the prefrontal
cortex and through a dorsal pathway by the medial and lateral habenula. The habenula
has this role since the first vertebrate human ancestors with a brain comparable to that of
modern lampreys. The lateral habenula promotes or inhibits reward-seeking behav‐
iours depending upon the gained reward being larger or smaller than expected. It is
suggested that the ventral pathway is essential for maintaining addiction based on the
observation of specific cues, while the dorsal pathway is essential for becoming addicted
and relapsing during periods of abstinence.
Keywords: addiction, mood, habenula, basal ganglia, amygdala, insula
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
The dominant view on the neuro-pathology of addiction is that of deficient control processes
resulting from impaired prefrontal cortex function and increased saliency of drug-related cues
over normal rewarding stimuli [1]. The latter results from altered reward processing in the
ventral striatum [1]. An important starting point in this respect has been the work of Koob [2,
3], who integrated knowledge from different fields of science in order to describe a scheme for
the neuro-circuitry of addiction. An important component of the work of Koob [4] is the
characterization of anti-reward or negative reinforcement in particularly in the more ad‐
vanced stages of addiction. In his work, he assigns a major role to the activation of the brain
stress systems, the amygdala, in particular, in addiction. In line with Koob’s work, we pro‐
pose additional neuro-circuitry to be involved in addiction. In this review, we apply a neuro-
evolutionary  approach to  addiction,  in  order  to  identify  potential  additional  subcortical
structures that might have relevance for addiction.
Two basic principles of animal life are essential for survival of the individual and as a species.
Firstly, the animal should be motivated to obtain food, warmth, sexual gratification and
comfort. Secondly, the animal should be motivated to escape from predators, cold, sexual
competitors and misery. As the human species currently exists, even our oldest ocean-dwelling
ancestors living over 540 million years ago must have been capable to react to the environment
to feed, evade predators, defend territory and reproduce. Thus, their primitive nervous
systems must have regulated the necessary behaviours and incorporated the most essential
structures of all today’s freely moving Animalia. However, since then the human brain passed
through a long evolutionary pathway during which particularly the forebrain showed major
changes. The earliest vertebrate’s brain almost completely lacked the human neocortex and
the dorsal parts of the basal ganglia [5, 6]. These newer parts of the brain are believed to
determine human behaviour to a high extent and consequently receive most attention in
research of processes explaining the genesis of mental disorders. This contrasts the involve‐
ment in psychiatric disorders of those behavioural processes described above as also being
displayed by the most primitive vertebrates. We want to suggest that these actions are still
regulated in humans by brain structures derived from the primitive forebrain of the earliest
vertebrates. Therefore, we describe the anatomy of the forebrain of the earliest human
vertebrate ancestors [6]. From a comparison of the striatum of lampreys to that of anuran
amphibians and younger vertebrates, it can be concluded that the striatum of lampreys is the
forerunner of the human centromedial (i.e. nuclear) amygdala. In anuran amphibians (frogs
and toads), the lamprey’s striatum is retrieved as central and medial amygdaloid nuclei, while
a dorsal striatum for the first time appears in its direct vicinity [6, 7]. The lampreys forebrain
also contains a structure of which the connections are very well conserved in more recent
human ancestors: the habenula. The habenula constitutes—together with the stria medullaris
and pineal gland—the epithalamus and consists of medial and lateral parts [8]. The habenula
has received much attention because of it asymmetry in certain vertebrate species [9] and its
role in mediating biorhythms [10]. The habenula regulates the intensity of reward-seeking and
misery-fleeing behaviour probably in all our vertebrate ancestors. In lampreys, the activity of
the lateral habenula is in turn regulated by a specific structure: the habenula-projecting globus
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pallidus. It is tempting to speculate that this structure has a similar role in humans, but a clear
anatomical human equivalent with the same function has not yet been identified. Based upon
the evolution of the basal ganglia in vertebrates and the mechanism of the emotional response,
we postulate the existence of two systems regulating the intensity of the aforementioned
behaviours [11]. These two circuits include the extrapyramidal and limbic basal ganglia, which
are collaborating in a reciprocal (i.e. Yin-and-Yang) fashion. The two basal ganglia systems are
linked together by the core and shell parts of the nucleus accumbens (NAcb), which regulates
motivation to show reward-seeking and misery-fleeing behaviour, respectively. Hijacking of
the reward-seeking mechanism by certain substances such as alcohol or illicit drugs is
considered the essential mechanism behind addiction.
In this chapter, we will describe the evolution of the vertebrate forebrain and the functioning
of the described regulatory circuits in somewhat more detail. Thereafter, the putative role of
the habenula in initiating addiction and causing relapse after abstinence is depicted. The
described model also explains the mood and anxiety symptoms that accompany the addictive
process. We will start with a brief description of the mechanism of the emotional process [11,
12].
2. Model for emotional regulation
A suitable model for the regulation of the emotional response can be derived from the paper
of Terence and Mark Sewards [13]. According to their model, the control centre for emotional
response types such as sexual desire, hunger, thirst, fear, nurturance and sleep-need drives and
power-dominance drives is the hypothalamus. The output of the hypothalamus proceeds along
three channels. The first route projects via the thalamus to the cortex, including a pathway that
contributes to the perception of emotion and one for the initiation and planning of cognitive
and motor responses (drives). The second output pathway is a projection at least partly via the
periaqueductal grey (PAG) to several brainstem nuclei, including nuclei that regulate the
autonomic components of the emotional response (e.g. increased circulation and respiration).
The PAG also activates the serotonergic raphe nuclei, the adrenergic locus coeruleus complex
and the dopaminergic ventral tegmental area. From these nuclei, projections pass back to the
hypothalamus (e.g. regulating hypophysiotropic hormones) and through the medial forebrain
bundle to the forebrain (activating the frontal cortex). The PAG also constitutes an important
input structure generating signals to the emotional forebrain. Apart from hormone release
mediated through various brainstem nuclei, a third direct hypothalamic projection system
regulates the endocrine component of the emotional response (also by releasing hypophysio‐
tropic hormones), enabling adaptation of the milieu interne, or correction of a possible
misbalance. The hypothalamus also exerts a receptor function for various substances in the
circulating blood.
This model corresponds to a significant extent with the model of Liotti and Panksepp [14].
However, they follow a different approach, describing seven emotional systems for seeking,
rage, fear, panic (separation distress and social bonding), care (nursing and empathy), lust
Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum
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 (sexual love) and play (joy and curiosity), which are not all regulated by the autonomic
hypothalamus. Within the context of this article, the first three systems of Liotti and Panksepp
deserve a more detailed description.
The appetitive motivation-seeking system stimulates the organism to acquire the many things
needed for survival. This motivation is coupled to a reward feeling that can—but not neces‐
sarily does—result from these activities. The nature of the specific rewards is of a lesser
importance; the system works equally well for seeking food, water, warmth, and illicit drugs,
as well as for social goals such as sexual gratification, maternal engagement and playful
entertainment. The system promotes interest, curiosity and desire for engagement with
necessary daily life activities. The process of reward pursuing consists of at least three
psychological components: learning to value (attentive salience), incentive salience or ‘want‐
ing’ and experiencing pleasure resulting in ‘liking’. The first component is believed to be
addressed by the amygdala. The amygdala can ‘learn’ by conditioning to appreciate sensory
appetitive information within the context of external and internal circumstances and to initiate
a proper response. Incentive salience is regulated by mesocorticolimbic mechanisms, with a
central role for the NAcb. Later, in this chapter, we will describe that the insula plays an
essential role in perceiving pleasure.
The amygdala additionally takes a central position with respect to valuing aversive stimuli,
playing a critical role in anxiety and aggression. The anger-promoting rage system is associated
with irritation and frustration. In this system, the emotional circuit is stimulated by projections
Figure 1. Simplified model for the regulation of emotional response. The hypothalamus is considered to be the prin‐
ciple controller and the amygdala the initiator of emotional response. In this depiction, the amygdala represents all
limbic structures involved in emotional response. The amygdala is inhibited by the mPFC (blue arrow). MC = motor
cortex, PAG = periaqueductal grey substance, dPFC = dorsolateral prefrontal cortex, mPFC = medial prefrontal cortex,
PMC = premotor cortex, SMC = supplementary motor cortex.
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between the medial amygdala and the medial hypothalamus via the stria terminalis. Neurons
also project reciprocally between specific parts of the PAG in the mesencephalon and the
medial hypothalamus. The fear system is organized in a fashion parallel to the rage system, in
which both the amygdala and the PAG project to the medial hypothalamus. Activity within
this system can lead to freezing or flight behaviour. Sustained fear (anxiety) is also mediated
by the amygdala but follows a slightly different anatomical route and links the fear and stress
systems.
Taken together, the regulation of the described forms of emotional output can be summarized
and simplified into the scheme in Figure 1. The hypothalamus can be considered one of the
principle control centres for emotional (non-behavioural) output (especially gratification, fear
and aggression-driven). The hypothalamus regulates three components of this response: a
thalamic one, a brainstem one and a pituitaric one. As explained above, the hypothalamus
itself receives a stimulating input function from the amygdala, among other regions. The
amygdala is responsible for the initiation of a suitable response type. In this process of initiating
the emotional response, the amygdala is inhibited by the medial prefrontal cortex. This scheme
describes the process of response selection, but another mechanism is regulating the level of
motivation to exhibit the selected response type.
3. Perception of feelings of pleasure and happiness
According to Terence and Mark Sewards [13], the cortical representations of their emotional
response types are located on the medial prefrontal and anterior cingulate areas. However,
these cortical areas represent the fields initiating the corresponding drives for finding relief
and are unlikely directly involved in the perception of feelings of thirst, hunger, sleepiness,
somatic pain, etcetera, as these anterior cerebral areas are generally implicated in generating
output. A better candidate for the perception of feelings of pleasure (reward) and happiness
(euphoria) would be the insular cortex (Figure 2) as the posterior part of the insula contains
areas for gustation, thermo-sensation, pain, somato-sensation, and viscera-sensation [15].
Indeed, the insular cortex has been demonstrated to be involved in processing emotions, such
as anger, fear, happiness, sadness or disgust, and has been shown to display treatment-
responsive changes of activity in different mood disorders [16]. However, the exact position
of the insular cortex with respect to the perception of the discussed feelings remains unclear.
The insular cortex, being located in the centre of the cerebral hemisphere, is reciprocally
connected with almost every other input and output structure of the emotional response
system. It could also be suggested that the insula’s most important role is the integration and
adjustment of the activities of such other brain structures without being primarily involved in
the perception of emotional feelings itself.
However, yet another possibility comes into mind, which can be considered a revival of the
late nineteenth century hypothesis developed independently by the US American William
James (1842–1910) and the Dane Carl Lange (1834–1900) [17]. Their theories on the origin and
nature of emotions states that once we become aware of the physiological bodily changes
induced by, for example, danger, we feel the corresponding emotion of fear [18, 19]. So, the
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basic premise of this theory is that the perception of interoceptive stimuli instigates the
experience of an emotional feeling as well as its phenomenal consciousness. This could easily
be expanded with the perception of other changes including environmental factors, which then
would induce exteroceptive stimuli [19]. The anteriorly directed processing stream within the
insula would make the anterior insula perfectly suitable to fulfil the requirements for the
neuronal representative of such functions [20]. The upper part of the anterior insula is strongly
and reciprocally connected with the anterior cingulate cortex, and the lower part is functionally
linked to the adjacent caudal orbitofrontal cortex, which makes the anterior insula involved in
food-related stimuli and the urge to take drugs as well [15].
The orbitofrontal cortex is the neuronal structure, which is most intricately involved in
motivating for reward bringing behaviours [21, 22]. Perhaps the insula is involved in experi‐
encing pleasure, but in our opinion, this is unlike to occur directly as sensing these positive
feelings. As a matter of fact, the orbitofrontal cortex induces motivation to go for the possibility
to obtain food, sex or drugs, which results in an unpleasant urge to exhibit this behaviour,
called ‘craving’ [2–4]. This craving feeling results from hyperactivity of the motivational
cortical–striatal–thalamic–cortical (CSTC) reentry circuit, running from the orbitofrontal
cortex, through the core part of the NAcb, ventral pallidum and thalamus back to the orbito‐
frontal cortex [23]. It has been suggested that the NAcb itself is responsible for sensing pleasure,
Figure 2. Position of the insular cortex. The human insular cortex forms a distinct, but entirely hidden cerebral lobe,
situated in the depth of the Sylvian fissure. It is a phylogenetically ancient part of the cerebral hemisphere and entirely
overgrown by adjacent regions of the hemispheres and the temporal lobe (cf. [15]).
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but this is unlike to be true. Probably, the nucleus accumbens core (NAcbC) has a classical role
of adapting the activity when reward is expected based upon information about other
significant factors [24]. We want to hypothesize that the experience of pleasure is more likely
related with the sudden ceasing of the urge to obtain the delightful objects once they are
acquired.
Evidence for this last proposal can be derived from investigating neuro-activation during a
very pleasurable activity; that is having sex. The activity pattern during sexual activity has
been extensively studied [24, 25]. In women, first the medial amygdala and insula become
activated, among other structures; then, the cingulate cortex is added to this activation; and
then, at orgasm itself, the NAcb, paraventricular nucleus of the hypothalamus (secretes
oxytocin) and hippocampus become active [25]. Specific experiments by Georgiadis and
colleagues [26, 27] have shown that during orgasm, which is the moment that true pleasure is
perceived, the activation of brain structures is very much the same in men and women. What
is particularly interesting is that they found a profound deactivation in the anterior part of the
orbitofrontal cortex (and also in the temporal lobe). Georgiades and colleagues [27] interpret
the decreased activity of the orbitofrontal cortex and the temporal lobe to reflect the occurrence
of satiety. But this idea may be too limited. In our opinion, they also make a case that the relief
that accompanies the disappearance of the urge to reach orgasm is indeed the most important
representation of pleasure itself. The reaction within the orbitofrontal cortex may be due to the
loss of anticipating achieving the important goal (because it has been reached). The profound
deactivation of the motivational reentry circuit would result in abrupt ceasing of craving, what
in itself could result in pleasure. This would also indicate that without craving also pleasure
cannot occur.
A prefrontal structure that has consistently been implicated in negative mood states (i.e.
dysphoria) is the subgenual part of the anterior cingulate cortex (Brodmann’s areas 25 and the
caudal portions of Brodmann’s areas 32 and 24). Anatomical studies have shown that the
volume of the infralimbic sgACC is reduced in certain depressed groups [28]. Moreover, the
activity of the sgACC is affected following successful treatment with SSRIs, electroconvulsive
therapy, transcranial magnetic stimulation (rTMS), ablative surgery and deep brain stimula‐
tion [29]. Moreover, this sgACC has been found to be metabolically overactive in depressed
states and reacts to the treatment with a decrease of its activity [30].
As shown in Figure 3, the infralimbic subgenual part of the anterior cingulate cortex is one of
the structures, which feeds the shell part of the NAcb [31]. Hyperactivity of this structure might
well result in hyperactivity within a putative emotional reentry circuit, which starts and ends
within the anterior cingulate cortex. The subgenual cingulate gyrus sends efferents to all
subcortical structures of our limbic basal ganglia and receives afferents from several hypo‐
thalamic and thalamic nuclei [32]. This hyperactivation of the subgenual cingulate gyrus might
in turn results in increased stimulation of the anterior insula [32], which might lead to
experiencing feelings of dysphoria. Abrupt termination of this hyperactivity might result in
happiness in the same manner as ending craving would result in pleasure.
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Figure 3. Stimulation of the core and shell of the nucleus accumbens. (Adapted from Ref. [31], reproduced with per‐
mission of the author). VTA = ventral tegmental area; LC = locus coeruleus. Red = glutamatergic, blue = GABAergic,
grey = dopaminergic and green = adrenergic.
In conclusion, we want to hypothesize that two parallel cortical–subcortical reentry circuits
regulate motivation to exert reward-bringing and misery-escaping behaviours, respectively.
These circuits are involved in causing pleasure and happiness. Hyperactivity of the NAcb core-
containing CSTC circuit induces craving and its abrupt ending is experienced as pleasure.
Hyperactivity of the NAcb shell-containing CSTC circuit induces dysphoria and abrupt
termination of the activity within this circuit would induce happiness.
4. Two complementary regulating circuits
In a previous paper, we have proposed to distinguish two separate circuits regulating skilled
(cognitively controlled) and intuitive (emotionally controlled) behaviour: extrapyramidal and
limbic circuits [11].
The ‘extrapyramidal’ circuit is often mainly associated with motor activity but also regulates
other behavioural responses. The first relay station of this cortical–subcortical circuit is formed
by the striatum, which consists of three parts that correspond to three parallel divisions of the
extrapyramidal system: the caudate nucleus (cognitive system), putamen (motor system) and
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ventral striatum (emotional/motivational system) [23, 33–35]. This last part is formed by the
NAcb, which consists of a core (NAcbC) and a shell (NAcbS). The core belongs to the extrap‐
yramidal basal ganglia and is primarily involved in motivating the organism to exhibit skilled
behaviour. The shell belongs to the limbic basal ganglia and is primarily involved in facilitating
intuitive (emotional) behaviour [23, 35].
Figure 4. Position of the limbic basal ganglia (centromedial amygdala, extended amygdala, bed nucleus of the stria
terminalis and nucleus accumbens shell) relative to the extrapyramidal basal ganglia (caudate nucleus, putamen,
nucleus accumbens core) and hippocampus. The figure only shows the first relay stations of the extrapyramidal (light
and dark blue) and limbic (orange and green) cortical–subcortical circuits.
The ‘limbic’ circuit is for a significant extent covered by the amygdala. The amygdala consists
of a heterogeneous group of nuclei and cortical regions and is divided into cortical (basolateral)
and ganglionic (centromedial) sections [36–38]. The various nuclei differ in the number and
type of brain areas to which they are connected. Apart from extensive connectivity with a
variety of cortical areas [37], the various parts of the complex are mutually massively connected
with each other [37, 38]. Nevertheless, it is possible to consider the centromedial (ganglionic)
part as an output channel to the diencephalon and brain stem, while the basolateral (cortical)
part is more easily regarded as an input channel for cortical information. Moreover, the
amygdaloid complex has widespread connectivity with many subcortical regions [37],
including the dorsal and ventral striatum, the bed nucleus of the stria terminalis, and the basal
forebrain nuclei. The centromedial amygdala is continuous with the extended amygdala,
which is in turn continuous through the bed nucleus of the stria terminalis with the shell part
of the NAcb [23, 39]. This extended amygdala takes a position to the allocortex (olfactory cortex
and hippocampus) that is similar to that which the neocortex takes to the striatum [39]. This
idea can be extended to distinguishing limbic and extrapyramidal basal ganglia. The
centromedial amygdala, proper extended amygdala, bed nucleus of the stria terminalis, and
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the shell of the NAcb form the limbic basal ganglia, with a function for the limbic cortex that
reflects that of the extrapyramidal basal ganglia for the rest of the neocortex (Figure 4).
5. The evolution of the forebrain in vertebrates
We have developed an anatomical model how the intensity of reward-seeking and misery-
fleeing behaviours is regulated. We propose that the first type of reward-seeking behaviours
is controlled within a converging extrapyramidal neocortical–subcortical–frontocortical circuit
containing as first stations, the caudate nucleus, putamen and core of the accumbens nucleus
(NAcbC). The second type of misery-fleeing behaviours is then regulated by a limbic cortical–
subcortical–frontocortical circuit containing as first relay stations, the centromedial amygdala,
extended amygdala, bed nucleus of the stria terminalis and shell of the accumbens nucleus
(NAcbS). As these types of behaviours must also have been exhibited by our most ancient
ancestors, we studied the evolutionary development of the forebrain [6]. We found out that
the earliest vertebrates, supposed to have a brain comparable with the modern lamprey, had
an olfactory bulb, forebrain, diencephalon, brain stem and spinal cord, but not yet a true
cerebellum. The forebrain of the lamprey contains a striatum with a modern extrapyramidal
system, which is activated by dopaminergic mesostriatal fibres coming from the nucleus of
the tuberculum posterior (NTP) [5], which is comparable with human ventral tegmental area
Figure 5. Simplified representation of the extrapyramidal system of lampreys (left) and humans (right). In lamp‐
reys, the internal and external parts of the globus pallidus are intermingled within the dorsal pallidum but functional‐
ly segregated. For further explanations, consult Refs. [33, 40, 41]. GPe = globus pallidus externa; GPi = globus pallidus
interna; NTP = nucleus tuberculi posterior; PPN = pedunculopontine nucleus; SNr = substantia nigra pars reticulata;
STh = subthalamic nucleus. Left figure: red = glutamatergic, blue = GABAergic, green = dopaminergic, orange = choli‐
nergic; Right figure: red = excitatory, blue = inhibitory.
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(VTA). An extrapyramidal circuit has not yet been developed and the extrapyramidal output
ganglia directly activate motor control centres of the brainstem (Figure 5). In addition, the
dorsal thalamus is very small and the forerunner of the neocortex has hardly developed.
It has been suggested that during evolution of vertebrates, the development of the cerebral
cortex resulted in the successive addition of concise modules to the extrapyramidal basal
ganglia, each regulating a newly acquired function of the species (Figure 6) [5]. What happened
on the limbic side is not entirely clear. The amygdaloid complex was moved laterally to the
pole of the temporal lobe. The centromedial amygdaloid nuclei can be considered to be a
remaining part of the lampreys striatum, but whether the extended amygdala and the bed
nucleus of the stria terminalis also evolved from this structure is uncertain. Amphibians
already have a bed nucleus of the stria terminalis, which is closely associated with the central
and medial nuclear amygdala [42]. The nucleus accumbens can be considered to be the
interface between motor and limbic basal ganglia [35]. So, our theory is to a certain extent
supported by these evolutionary considerations. We suggest that the core of the accumbens
nucleus regulates the motivation to exhibit reward-driven (approach) behaviour and the shell
of the accumbens nucleus regulates the motivation to exhibit misery-driven (avoidance)
behaviour.
Figure 6. Modular expansion of the basal ganglia during evolution of vertebrates (adapted from [5]). The figure only
shows the first relay stations of the extrapyramidal (light and dark blue) and limbic (yellow and green) cortical–sub‐
cortical circuits.
But how is this motivation to show these two types of behaviours adapted to the changing
demands of environment? At this point, again, considering the forebrain of lampreys can shed
some light on this matter. Within the lamprey’s forebrain, a specific nuclear structure has been
identified within the subhippocampal region, called the habenula-projecting globus pallidus
(GPh) [6]. This nucleus receives inhibitory control from the striatum and excitatory input from
both thalamus and pallium. It activates the lateral habenula, and from there, glutamatergic
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fibres run directly to the dopaminergic NTP (excitatory) or indirectly via the GABAergic
rostromedial tegmental nucleus (inhibitory). These dopaminergic fibres of the NTP regulate
the activity of the striatum. So, in lampreys, the activity of the dopaminergic NTP is under the
control of an evaluative system with input from the striatum and pallium in order to decide
whether the locomotor activity should be increased or not (Figure 7). These structures increase
activity during reward situations and decrease activity when an expected reward does not
occur. A cholinergic circuitry from the medial habenula to the interpeduncular nucleus and
periaqueductal grey regulates the fear/flight response.
Figure 7. Circuitry of habenula-projecting globus pallidus of lampreys. Red = glutamatergic, blue = GABAergic,
green = dopaminergic.
6. The habenula
The habenula in the epithalamus has recently received much attention for possibly playing a
role in depression and addiction [43–47]. This is strongly related to the influence of the
habenula on the activity of monoaminergic control centres of the brainstem [46, 47]. The
habenula is subdivided into two nuclei: the medial habenula and lateral habenula. In lampreys,
a direct pathway runs from the homologue of the lateral habenula to the nucleus of the
tuberculum posterior (NTP; considered to be a homologue of the SNc/VTA), next to a pathway
to a homologue of the GABAergic rostromedial tegmental nucleus (RMTg; which inhibits the
NTP) [5, 48]. Other efferents of the lateral habenula run to (diencephalic) histaminergic and
serotonergic areas. In lampreys, a projection system from the homologue of the medial
habenula to the interpeduncular nucleus was also identified. These habenular output struc‐
tures are well conserved across species. All the vertebrates examined possess the same efferent
pathway, called fasciculus retroflexus, running to the ventral midbrain [9, 46, 47]. In mammals,
the medial habenula projects, almost exclusively, to the cholinergic interpeduncular nucleus
[49], whereas the lateral habenula projects to a variety of nuclei including the rostromedial
tegmental nucleus (RMTg), raphe nuclei, substantia nigra, ventral tegmental area, and the
Recent Advances in Drug Addiction Research and Clinical Applications12
fibres run directly to the dopaminergic NTP (excitatory) or indirectly via the GABAergic
rostromedial tegmental nucleus (inhibitory). These dopaminergic fibres of the NTP regulate
the activity of the striatum. So, in lampreys, the activity of the dopaminergic NTP is under the
control of an evaluative system with input from the striatum and pallium in order to decide
whether the locomotor activity should be increased or not (Figure 7). These structures increase
activity during reward situations and decrease activity when an expected reward does not
occur. A cholinergic circuitry from the medial habenula to the interpeduncular nucleus and
periaqueductal grey regulates the fear/flight response.
Figure 7. Circuitry of habenula-projecting globus pallidus of lampreys. Red = glutamatergic, blue = GABAergic,
green = dopaminergic.
6. The habenula
The habenula in the epithalamus has recently received much attention for possibly playing a
role in depression and addiction [43–47]. This is strongly related to the influence of the
habenula on the activity of monoaminergic control centres of the brainstem [46, 47]. The
habenula is subdivided into two nuclei: the medial habenula and lateral habenula. In lampreys,
a direct pathway runs from the homologue of the lateral habenula to the nucleus of the
tuberculum posterior (NTP; considered to be a homologue of the SNc/VTA), next to a pathway
to a homologue of the GABAergic rostromedial tegmental nucleus (RMTg; which inhibits the
NTP) [5, 48]. Other efferents of the lateral habenula run to (diencephalic) histaminergic and
serotonergic areas. In lampreys, a projection system from the homologue of the medial
habenula to the interpeduncular nucleus was also identified. These habenular output struc‐
tures are well conserved across species. All the vertebrates examined possess the same efferent
pathway, called fasciculus retroflexus, running to the ventral midbrain [9, 46, 47]. In mammals,
the medial habenula projects, almost exclusively, to the cholinergic interpeduncular nucleus
[49], whereas the lateral habenula projects to a variety of nuclei including the rostromedial
tegmental nucleus (RMTg), raphe nuclei, substantia nigra, ventral tegmental area, and the
Recent Advances in Drug Addiction Research and Clinical Applications12
nucleus incertus [9]. Moreover, the medial habenula has direct output to the lateral habenula
and may regulate the latter’s activity [46, 47] (Figure 8).
However, the input to the epithalamus appears to be less well conserved during evolution. In
lampreys, the input of the homologue of the medial habenula comes from the medial olfactory
bulb, the parapineal organ, the pretectum and the striatum [48]. The input of the lateral
habenula comes from subhippocampal lobe (habenula-projecting globus pallidus; GPh) and
the lateral hypothalamus, but not from the diagonal band of Broca. Mammals do not have a
distinct GPh. It has been suggested that its homologue in primates is localized in the border
of the globus pallidus interna (GPb) [5, 50]. Whether the function of the lampreys’ GPh is
retained within this GPb, is far from certain. The mammalian habenula receives input via the
stria medullaris from the posterior septum, as well as from the medial septum, the nucleus of
the diagonal band and midbrain structures [47, 49]. Major input to the medial habenula arises
from septal nuclei, which in turn receive the majority of their input from the hippocampus [48].
Afferents of the lateral habenula come from the hippocampus, ventral pallidum, lateral
hypothalamus, globus pallidus and other basal ganglia structures [46]. It is hypothesized that
during evolution from lampreys to mammals, the originally direct sensory innervation of the
habenula has been replaced by inputs from the so-called limbic system (i.e. the septum and
diagonal band of Broca) [48]. We prefer to say that this is not a replacement, but a maintainment
as the human limbic system is considered to be a derivative of the lamprey’s forebrain.
Figure 8. Connectivity through the epithalamus. GPh = habenula-projecting globus pallidus, IPN = interpeduncular
nucleus, RMTg = rostromedial tegmental nucleus, SNc = substantia nigra, pars compacta, VTA = ventral tegmental nu‐
cleus (adapted from Ref. [47]).
In our opinion, the amygdala plays an essential role in value-based selection of behaviour
(salience attribution) and this idea is supported by the history of the amygdaloid complex in
our ancestors. When the habenula-projecting globus pallidus still exists and functions in
humans, this structure should receive input from the amygdala and hippocampus and give
glutamatergic output to the lateral habenula. The amygdala and hippocampus would then
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regulate both the activity of the medial habenula (misery-fleeing behaviour) via septal nuclei
as well as the activity of the lateral habenula (reward-seeking behaviour) via the homologue
of the GPh. The amygdala and hippocampus should then be in an essential position for
response selection of behaviour.
7. Idea for a possible role of habenula in addiction
In order to be considered to have a substance addiction, the individual must start to abuse a
drug, he/she should maintain this abuse and/or he/she should relapse to abuse after a period
of abstinence. Several lines of evidence suggest that indeed patients go through different stages
of substance use, from intoxication, through repeated cycles of withdrawal and increasing
tolerance to an end stage of addiction and relapse [3, 4]. It has also been shown that during
this process, the motivation to use substances develops from ‘liking’ to ‘wanting/needing’ [3,
4]. In line with these findings, the neurobiological changes develop from more ventral striatal,
reward-related, circuits to more dorsal striatal circuits involved in habit formation and stress
[3, 4]. Moreover, addicted patients no longer use substances because it is nice (positive
reinforcement), but because it reduces a negative affective state, related to increased activity
of the brain stress systems, including the amygdala and hypothalamus-pituitary axis (negative
reinforcement). This theory describes a development of addiction in three stages: binge/
intoxication, withdrawal/negative affect and preoccupation/anticipation [3, 4].
Our proposal of staging is slightly different in order to let it correspond better to the described
primitive subcortical regulation of behaviour. Abuse is probably largely maintained by the
pathological process of craving for drugs, which is activated by the observation of certain
phenomena (cues), the getting involved in social and emotional circumstances or executing
specific habits which all are related to the individuals’ personal circumstances of drug abuse.
We want to suggest that this mechanism (i.e. activation of craving by cues) explains the usage
of the illicit drug by the individual on a regular basis. It has been described that the craving
process is activated by stimulation of the dopaminergic input to the NAcb from the VTA. This
VTA is in turn activated by glutamatergic fibres from the prefrontal cortex by a ventral
connection, which are reacting upon analysis of the circumstances that predict the availability
of the illicit drug [51]. The glutamatergic synapses with mesencephalic dopaminergic neurons
carry nicotinic cholinergic receptors, which allow long term potentiation of this excitatory
synaptic transmission [51].
The above mechanism explains how addiction is maintained, but not how it is initiated. We
want to hypothesize that in this second process, the habenula is involved (for a description of
the role of the habenula in addiction see Refs. [46, 47]). The lateral habenula stimulates or
inhibits the VTA depending upon the result of the behaviour. It stimulates the behaviour when
the result is more rewarding than expected [52, 53] and inhibits it when the behaviour has
more or less disappointing results [54]. The lateral habenula also encodes reward probability,
reward magnitude and the upcoming availability of information about reward [54, 55]. So,
when an individual uses an illicit drug and the results are very rewarding (biological, psy‐
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reward magnitude and the upcoming availability of information about reward [54, 55]. So,
when an individual uses an illicit drug and the results are very rewarding (biological, psy‐
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chological or social) the habenula disinhibits the VTA to continue and expand this behaviour.
The same is true concerning the rapid reactivation of craving for example tobacco, cocaine or
GHB in the case of relapse after a period of abstinence. The lateral habenula could then signal
vividly that the individual likes these effects very much. So it could be interesting to study the
activity of the pathways during a phase of active drug abuse and after re-usage after a period
of abstinence. This could also shed some light on the pharmacological mechanisms to prevent
relapse.
Besides craving for the positive effects of substances, craving for addictive substances is also
often accompanied by dysphoria and anxiety. This process has been described as the ‘dark
side of addiction’ and has been associated with the development of a powerful negative
reinforcement process [4]. This dysphoria is particularly true during relatively long-lasting
periods of abstinence when even a clear depression can develop. Koob [4] has introduced the
term ‘anti-reward’ to describe the background of this phenomenon. This is unfortunate,
because it suggests a fictitious relationship with the reward-seeking system. However, this
dysphoria could very well result from a dysfunction of another pathway connecting amyg‐
daloid complex and hippocampus through the epithalamus with the midbrain. The misery-
fleeing (fear/flight) response could be regulated via septal nuclei and medial habenula with
the interpeduncular nucleus. Through this pathway, the medial habenula regulates the activity
of the adrenergic locus coeruleus and the serotonergic dorsal raphe nucleus [47]. This could
result in the activation of the misery-fleeing mechanism, causing dysphoria. The reward-
seeking response could be regulated by a parallel pathway via a homologue of GPh and lateral
habenula with the ventral tegmental area [56]. Hypoactivity of the reward-driven reentry
circuit with as first station NAcbC would result in anhedonia and lack of energy, two main
symptoms of depression.
8. Conclusions
Studying the evolution of the vertebrate’s forebrain offers interesting clues about the mecha‐
nism of addiction. In lampreys, motor activity is regulated by a striatum, which can be
considered to be the forerunner of the nuclear amygdala. The lamprey’s striatum contains a
quite modern extrapyramidal system (Figure 5). The activity of this striatum is regulated by
dopaminergic fibres coming from the forerunner of the VTA in the midbrain. The activity of
the VTA is in turn regulated by the habenula, with a connectivity that is very well conserved
during the evolution into finally humans. During this evolution, the basal ganglia developed
in a modular fashion with the addition of new layers on the dorsal side of the basal ganglia
once new functions developed (Figure 6). The evolution of the ventral part of the basal ganglia
is less certain, but these structures also became connected with parts of the (limbic) neocortex
via the diencephalon. Therefore, it is possible to distinguish extrapyramidal and limbic CSTC
circuits, which regulate the magnitude of reward-seeking and misery-fleeing behaviours.
Motivation to express these two behaviours is regulated by the NAcbC and NAcbS, respec‐
tively. In turn, the VTA determines the activity of NAcb, and the locus coeruleus only of the
NAcbS (Figure 3). Directly and indirectly, the upper raphe nuclei also determine the activity
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of both parts of the NAcb [57]. As part of a dorsal pathway, the lateral habenula controls the
activity of the VTA and the medial habenula the activity of locus coeruleus and raphe nuclei.
The activity of both lateral and medial habenula is controlled by the amygdala and hippo‐
campus. Via a ventral route, the prefrontal cortex also influences the activity of the VTA. We
hypothesize that this ventral route is involved in maintaining substance abuse, while the dorsal
route is primarily involved in initiating addiction and causing relapse into dependence after
using illicit drugs after a period of abstinence.
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Abstract
Gene expression and inheritance are not only a function of the DNA code, but also
epigenetic mechanisms that regulate DNA accessibility, transcription, and translation
of the genetic code into a functional protein. Epigenetic mechanisms are invoked by life
experiences, including stress and exposure to drugs of abuse, and the resulting changes
in gene expression can be inherited by future generations. This chapter highlights recent
research demonstrating epigenetic changes in response to drug exposure with a focus
on three different mechanisms: DNA methylation, histone modification, and noncod‐
ing RNAs. We briefly describe each of these mechanisms and then provide key examples
of drug-induced changes involving these mechanisms, as well as epigenetic manipula‐
tions that alter effects of drugs. We then review cutting-edge technologies, including
viral-mediated gene  transfer  and gene  editing,  that  are  being  used to  manipulate
epigenetic  processes with temporal  and cell-type specificity.  We also describe and
provide  examples  of  intergenerational  epigenetic  modifications,  a  topic  that  has
interesting implications for how addiction-related traits may be passed down across
generations. Finally, we discuss how this research provides a greater understanding of
drug addiction and may lead to novel molecular targets for preventions and interven‐
tions for drug abuse.
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1. Introduction
One of the most compelling questions in the field of drug abuse is why some individuals who
experiment with drugs go on to develop substance use disorders (SUDs) while others do not.
Both a family history of SUDs and stressful life events increase one’s vulnerability to develop
SUDs [1, 2]. Historically, these risk factors were viewed as “nature and nurture” making separate
contributions to an addiction phenotype. However, recent advances in the field of epigenetics
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
demonstrate that “nurture” changes “nature” by modifying whether or not a given gene will
be expressed. Understanding how one’s environment (e.g., drug-taking behavior, stress, and
learning) can alter gene expression in the brain may give insight into how drug addiction
develops, how it may be passed down into future generations, and perhaps, how it can be better
treated.
While the DNA sequence of a gene can be modified directly (e.g., mutations, deletions,
insertions, translocations, etc.) resulting in altered gene expression, epigenetics regulates gene
expression by mechanisms other than changes to the DNA sequence. It has long been known
that epigenetic mechanisms largely control cell differentiation by allowing some genes to be
expressed and others to be silenced at various points in time during development. Indeed,
even though all human cells possess the same DNA (with the exception of egg and sperm cells),
what differentiates a given cell type from others (e.g., a neuron versus a liver cell) is the
epigenetic mechanisms that permit or deny its genes to be transcribed and translated into cell
type-specific functional proteins [3]. Beyond the hard-wire epigenetic programming of gene
expression during development, epigenetic mechanisms also provide dynamic and heritable
means of altering gene expression in response to environmental change. For example, either
stressful life experiences or a history of chronic drug intake can invoke chemical modifications
to either the DNA or the histone proteins that are involved in storing the DNA. Such epigenetic
changes have an impact on how accessible the DNA is for gene transcription. Epigenetic
changes can also be long lasting and passed down to future generations. In this way, not only
does experience with stress and/or drugs place one’s self at risk for SUDs, but also one’s
offspring due to heritable epigenetic modifications. Even in the more proximal time frame of
an individual’s lifespan, epigenetic mechanisms provide a “working memory” for gene
expression changes that are involved in brain plasticity [4]. Brain plasticity changes resulting
from drug exposure are thought to be the crux of the dysfunction underlying addiction [5]. An
exciting implication of understanding the role of epigenetic changes in drug-induced brain
plasticity is that new strategies for therapeutic interventions may be discovered.
In this chapter, we review three epigenetic mechanisms that have been found to impact drug
abuse-related behaviors in animal models: (1) chemical modifications to DNA, (2) chemical
modifications to histones, and (3) the induction of noncoding RNAs that regulate gene
expression. We will begin with a brief explanation of how drugs modify intracellular signaling
pathways that propagate to the cell nucleus, leading to epigenetic changes. We will then
provide a brief description of the epigenetic mechanisms listed above, followed by examples
of how drugs of abuse invoke these mechanisms and how pharmacologically targeting the
epigenome can alter drug-abuse-related behavior. Next, we will cover the latest developments
in genetic tools that provide precise manipulation of epigenetic enzymes, further elucidating
the roles of these specific molecules. We will also review literature supporting transgenera‐
tional inheritance of epigenetic changes associated with a history of drug intake. We conclude
by discussing important future directions for research investigating epigenetic mechanisms
associated with drug addiction.
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2. The link between drug action, intracellular signaling, and epigenetic
changes
Both endogenous neurotransmitters and drugs interact with neuronal proteins, such as
neurotransmitter receptors, proteins involved in synaptic homeostasis (e.g., neurotransmitter
metabolic enzymes, transporters, etc.), and proteins involved in intracellular signaling
pathways. These intracellular signaling pathways can propagate to the cell nucleus, leading
to changes in gene expression [6]. Often, the first change observed in the cell nucleus following
an environmental perturbation (e.g., drug use, stress, novelty, etc.) is the expression of
immediate early genes (IEGs). Common IEGs encode transcription factors that increase
expression of other target genes by binding to the genes’ promoter region, which is a sequence
in the DNA that signals the cell to initiate transcription [7, 8]. IEGs are rapidly induced and
are often used as a marker of changes in neuronal signaling activity [9]. Both IEGs and target
genes may undergo epigenetic modifications that regulate their expression. Thus, either
natural signaling in response to environmental stimuli or drug-induced changes in signaling
can invoke epigenetic mechanisms that alter gene expression. The dynamics of the epigenetic
changes may be specific to the degree and phase of drug exposure, where particular epigenetic
marks may only arise (or disappear) following acute or chronic drug administration, or during
a period of withdrawal from drug use [10].
3. DNA epigenetic modification
A given gene is composed of a sequence of nucleotide base pairs in the DNA that are unique
to that gene. For coding genes, the DNA sequence of base pairs serves as the blueprint for
making a particular protein. Given that proteins are the machinery for cell structure and
function, gene expression changes in a neuron can alter cell protein composition and, in turn,
change the way that the neuron functions and communicates with other neurons.
There are four different nucleotide bases that compose the sequence portion of the DNA
molecule, including the pyrimidines cytosine (C) and thymine (T), and the purines adenine
(A) and guanine (G). Due to the structures of these nucleotides, the chemical bond responsible
for base pairing can only form between C and G or A and T, respectively. Cs followed by Gs
in the DNA sequence (i.e., CpGs) can be modified by a reaction in which DNA methyltrans‐
ferases (DNMTs) add a methyl group (CH3) to the 5-position of the C to form 5mC. Intracellular
signals may initiate newly synthesized de novo DNA methylation, which is mediated by DNMT
subtypes DNMT3a and DNMT3b. Subtype DNMT1, on the other hand, maintains DNA
methylation patterns across cell replication, such that the newly synthesized DNA has the exact
methylation pattern that existed before DNA replication. In general, DNA methylation is
correlated with a decrease in DNA accessibility and therefore is thought to be a mechanism of
silencing gene expression. Methylated DNA can silence gene expression by interfering with
the binding of transcriptional activators or by binding to proteins with a methyl-CpG-binding
domain (MBD), such as methyl-CpG binding protein 2 (MECP2), that then form a complex
with other proteins that together repress DNA accessibility [11].
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Historically, DNA methylation was believed to be a permanent modification. However,
demethylation of DNA can occur and also contributes to dynamic changes in gene expression.
While passive demethylation in dividing cells may be due to malfunctioning of DNMT1, active
demethylation occurs in both dividing and nondividing cells by enzymatic reactions. One
reaction changes 5mC into a T, which is then recognized as a G/T mismatch. The mismatch
activates a base excision repair (BER) pathway that utilizes thymine DNA glycosylase (TDG)
and ultimately replaces T with a nonmethylated C [12]. Another reaction catalyzed by 10–11
translocation enzymes (TET) adds a hydroxyl (–OH) group to 5mC forming 5hmC. 5hmC itself
has effects on gene expression and it can undergo further reactions that convert it back to a
nonmethylated C [13]. Therefore, demethylation of DNA is generally correlated with an
increase in DNA accessibility.
4. DNA methylation changes associated with drugs of abuse
Although DNA methylation is typically a stable epigenetic process, drugs of abuse have been
shown to alter both DNA methylation and its associated enzymes. Much of this research has
focused on DNA methylation in the nucleus accumbens (NAc), a brain region involved in
reward and motivation learning [14]. A well-established marker of repeated exposure to drugs
of abuse is an increase in the transcription factor ∆FosB protein in the NAc [15]. Acute or
repeated cocaine administration decreases methylation at the fosB promoter in the NAc of
rodents, which co-occurs with increases in fosB mRNA expression [16]. This may serve as a
mechanism by which exposure to drugs of abuse produces stable increases in ∆FosB protein
expression. Acute or chronic cocaine administration also increases Dnmt3a mRNA and MeCP2
protein expression in the NAc [16–18]. These increases are accompanied by decreases in
psychostimulant reward as measured by conditioned place preference (CPP), a procedure in
which an animal experiences a drug state while confined to one compartment of an apparatus
and a neutral state while confined to an alternate compartment during conditioning, resulting
in a shift in the animal’s preference for the drug-paired compartment when given free access
to both compartments. The decreased CPP effects are believed to be mediated by Dnmt3a- and
MeCP2-induced silencing of genes that encode proteins that are needed for adaptation and
functioning of NAc neurons [17, 18]. In addition, the TET enzyme that catalyzes DNA
demethylation and subsequent transcriptional activation via conversion of 5mC to 5hmC [19]
is decreased in the NAc in both rodents following cocaine administration and in postmortem
tissue from human cocaine addicts [20]. Paradoxically, this decrease in TET is associated with
increases in 5hmC expression at specific gene loci that have previously been linked to addiction
[20]. Further investigation is needed to explain this complex pattern of epigenetic changes.
5. Histone modification
In order for the long strands of DNA to fit within a cell’s nucleus, DNA is tightly condensed
into chromatin. Chromatin is made up of nucleosomes that contain a histone protein core
comprised of two copies of each of four different histone proteins, H2A, H2B, H3, and H4, as
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well as 147 base pairs of DNA that is wrapped around the histone core (Figure 1). Chromatin
can either be tightly (i.e., heterochromatin) or loosely packaged (i.e., euchromatin), where the
former restricts and the latter permits gene expression. Chromatin is able to undergo dynamic
remodeling by chemical modification of amino acid residues of the histone core proteins.
Similar to DNA methylation, histone proteins can undergo post-translational addition or
removal of one of several chemical groups via enzymatic reactions. There are more than 100
different posttranslational modifications that may occur and these changes correlate with
either the activation or the suppression of gene expression.
Figure 1. DNA and histone chemical modifications. DNA (blue lines) wraps around pairs of histone proteins H2A,
H2B, 3, and 4 (light pink and tan) that form an octomer histone protein core. (A) Closed chromatin, due to DNA meth‐
ylation (Me; red) and histone dimethylation on H3K9 (Me; orange), leads to transcriptional repression. (B) Open chro‐
matin, due to DNA hydroxymethylation (hMe; yellow) and histone acetylation (Ac; green), allows for transcription
factors (TF; purple) to recruit RNA polymerase for transcription initiation.
A powerful technique for studying post-translational histone modifications is chromatin
immunoprecipitation (ChIP). ChIP utilizes antibodies that bind specifically to chemically
modified histone proteins, which can then be isolated along with the associated DNA (i.e.,
promoter regions, gene bodies, etc.) from the rest of the tissue. Next, histones and DNA
segments are denatured and levels of specific DNA sequences are measured. This technique
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can be used to (1) determine which gene or gene promoter may be associated with a specific
histone modification, (2) correlate changes in histone modification with expression of specific
genes, and (3) suggest possible mechanisms for how a gene is turned on or off following an
experimental manipulation (e.g., drug administration).
6. Histone modifications associated with drugs of abuse
6.1. Acetylation
Acetyl groups are added to histone proteins, typically on a lysine residue, by histone acetyl
transferases (HATs). Addition of acetyl groups leads to a more relaxed, less condensed
chromatin state by negating the positive charge of the histone protein that is attracted to the
negatively charged DNA (Figure 1B). Indeed, increases in drug-induced gene expression often
positively correlate with the levels of histone acetylation.
Previous work has found widespread changes in acetylation of histone H3 and H4 subunits
in the NAc following acute and repeated psychostimulant administration in rodents [21, 22],
suggesting that many genes in the NAc may be primed for transcription, while others are
suppressed. Acute cocaine administration induces expression of the IEGs c-fos and fosB in
rodents [16, 23], and ChIP analysis revealed increases in H4 acetylation at the respective
promoter regions of these genes [21]. With repeated cocaine administration, the increase in
fosB expression is maintained and is associated with increases in H3 acetylation at the fosB
promoter region [21]. This mechanism likely contributes to ∆FosB protein accumulation in the
NAc following repeated drug exposure. Repeated cocaine administration also reduces the
ability of cocaine to induce c-fos and this is accompanied by a reduction in H4 acetylation at
the c-fos promoter region [21, 24]. Furthermore, chronic opiate administration decreases
expression of another IEG, brain-derived neurotrophic factor (Bdnf), and decreases H3
acetylation at the Bdnf promoter in the ventral tegmental area (VTA) [25]. Bdnf is critical for
the development and maintenance of synaptic structure and function [26, 27] and drugs of
abuse exert their reinforcing effect primarily by activating mesocorticolimbic dopamine
neurons that originate in the VTA and project to the NAc, prefrontal cortex (PFC), amygdala,
and hippocampus [28, 29].
Additionally, alcohol withdrawal in rodents reduces expression of the IEGs activity-regulated
cytoskeleton protein (Arc) and Bdnf in the amygdala along with decreases in H3 acetylation at
the respective gene promoters [30]. The amygdala is involved in processing emotional
memories and it plays a critical role in alcohol-related behavior and anxiety [31]. Although
these examples suggest functional links between degree of acetylation and associated gene
expression, histone acetylation may occur even without changes in gene expression [32].
Therefore, further work into the causal role of acetylation in drug-induced gene expression is
required.
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6.2. Methylation
In contrast to histone acetylation, methylation can be associated with both transcriptional
activation and repression, depending on which histone residue is modified. For example,
dimethylation of histone H3 Lysine 9 (i.e., H3K9me2) is commonly associated with transcrip‐
tional repression. One histone methyltransferase that catalyzes H3K9me2, G9a, is decreased
in the NAc following both chronic cocaine and opiate administration [33, 34]. It should be
noted that this also occurs following chronic social stress in mice that produces depressive-
like behavioral phenotypes, including decreased social interaction and increased anhedonia
[35]. Similarly, G9a is decreased in postmortem NAc tissue of clinically depressed patients [35].
Decreases in G9a are associated with increases in cocaine and morphine CPP [33, 34]. Inter‐
estingly, G9a opposes expression of ∆FosB [33, 34]. In turn, ∆FosB represses G9a expression,
creating a feedback loop that perpetuates its own expression through disinhibition. Similarly,
postmortem NAc brain tissue of human cocaine addicts exhibits decreases in G9a expression
[36] and increases in ∆FosB expression [37], providing further support for a functional link
between these two molecules. In addition to specific genes, compelling work using ChIP and
high-throughput sequencing of the associated genome has shown that cocaine-induced
downregulation of H3K9me2 expression preferentially occurs in nongenic regions of chromo‐
somes [38], suggesting additional roles of histone methylation that may be independent of
traditional effects on specific protein-coding genes.
7. Noncoding RNAs
Before the 1990s, noncoding RNA was often referred to as “junk DNA” that was thought to
have little relevance to biological function. A growing body of research over the past 25 years
has shown that noncoding RNAs have pivotal roles in almost every cellular process investi‐
gated. One class of noncoding RNAs that has received much attention is microRNAs (miR‐
NAs). miRNAs are small transcripts (~22 nucleotides) that regulate gene expression post-
transcriptionally. They are transcribed from DNA in a manner similar to protein-coding
transcripts, where transcription factors recognize promoter sequences upstream of miRNA
genes and initiate transcription (Figure 2). Once transcribed, the several hundred nucleotide
long transcript folds and binds to itself, producing a stem-loop hairpin structure referred to
as a pri-miRNA. The enzyme, Drosha, trims the pri-miRNA into a smaller form known as pre-
miRNA (~70 nucleotides long). Pre-miRNA is then transported out of the nucleus into the
cytoplasm, where the loop portion of the pre-miRNA is cleaved by the enzyme Dicer [39]. Now
as a double-stranded RNA molecule, it is unwound and one strand joins with several proteins
to form the miRNA-induced silencing complex (miRISC). The mature miRNA binds to
complementary sequences in the 3′ untranslated region (UTR) of a target mRNA where
miRISC causes either translational repression, deadenylation, or endonucleolytic cleavage of
the target mRNA, preventing its expression [40]. Importantly, the mature miRNA needs only
~6–8 complementary nucleotides for which to base pair with the 3′ UTR of the target mRNA,
and therefore, one miRNA can target several hundreds of different mRNAs in a given cell. For
this reason, miRNAs have been regarded as “master regulators” of gene expression. Changes
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in miRNA expression can therefore lead to widespread changes in gene expression and
alteration in several cellular signaling cascades. Other types of noncoding RNAs include: (1)
PIWI-interacting RNA (piRNA), which regulates sperm development, (2) small nuclear RNA
(snRNA), which regulates mRNA splicing, and (3) long noncoding RNA (lncRNA), which has
widespread effects on chromatin modification and transcription [41].
Figure 2. MicroRNA processing and function. MicroRNAs are transcribed similarly to protein-coding RNAs, except
they form a stem-loop structure following transcription (i.e., pri-miRNA). The enzyme, Drosha, trims the ends of the
stem (i.e., pre-miRNA) to prepare for exportation from the nucleus via Exportin 5. Once in the cytoplasm, Dicer cleaves
the loop of the pre-miRNA that produces a double-stranded RNA. One strand (i.e., mature miRNA) is chosen to be
incorporated into the miRNA-induced silencing complex (miRISC). Upon binding to a complementary sequence in the
3′ untranslated region of a target mRNA, either translational repression, deadenylation, or endonucleolytic cleavage
may occur. All three mechanisms lead to decreases in protein product.
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8. Noncoding RNA changes associated with drugs of abuse
Given that most drug abuse research has focused on miRNAs, we will focus on this subclass.
One approach to finding candidate addiction-related miRNAs is to examine miRNA expres‐
sion changes within brain regions implicated in addiction following varying levels of drug
exposure. Using this approach, Hollander and colleagues [42] found that rats given extended
(6 h/day), but not restricted (2 h/day), access to cocaine self-administration exhibited upregu‐
lation of miR-212 in the dorsal striatum, a region involved in establishing habitual behavior
[43]. Since the extended access self-administration model produces a behavioral phenotype
that mimics the escalation of drug intake observed in human drug addicts, the findings suggest
that upregulated miR-212 may play a role in the development of compulsive drug taking. One
gene target of miR-212 is MeCP2 [44], a protein whose increased expression in the NAc is
associated with reductions in amphetamine reward CPP [17]. However in the dorsal striatum,
decreases in MeCP2 via miR-212 regulation are associated with decreases in compulsive-like
cocaine self-administration [44]. These findings highlight the importance of examining the
roles of epigenetic modulators across different drug classes, brain regions, and drug abuse
models.
Another approach to identify candidate miRNAs is through bioinformatics. Databases exist
that identify predicted targets of miRNAs and their distribution within the brain. We recently
identified miR-495 as a lead candidate that has targets enriched in the Knowledgebase of
Addiction-Related Genes database [45] and exhibits high expression in the NAc [46]. We found
that cocaine self-administration decreases levels of NAc miR-495 and increases expression of
several addiction-related genes. These effects suggest that cocaine dysregulates NAc miR-495,
leading to disinhibition of addiction-related gene expression.
miRNAs and other noncoding RNAs have also been implicated in brain changes observed
with other drugs of abuse. Alcohol-dependent rats exhibit increases in miR-206 in the medial
PFC (mPFC) [47], a brain region involved in executive control of drug-seeking behavior [48].
miR-206 directly targets and suppresses BDNF expression in the mPFC [47], where increases
in BDNF in this region are associated with inhibiting motivation for cocaine [49, 50]. This
suggests increases in miR-206 likely contribute to the development of alcohol dependency
through suppression of BDNF. Additionally, several lncRNAs exhibit expression changes in
the NAc of heroin addicts postmortem [51]. These promising findings suggest that noncoding
RNAs provide a treasure trove of novel targets for regulating addiction-related gene changes
and behaviors.
9. Pharmacological manipulations of epigenetic mechanisms
Pharmacological agents that target specific epigenetic machinery have been used to further
understand the role of epigenetic mechanisms in the effects of drugs of abuse and to explore
their potential use as treatments for drug addiction. Most preclinical studies have utilized both
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systemic and intracranial administration of these compounds, where the former has a more
human translational value, while the latter allows for greater brain region specificity.
9.1. Methyl supplementation and DNMT inhibitors.
DNA methylation can be altered pharmacologically by using methionine or DNMT inhibitors.
Methionine is an amino acid commonly found in diet, where methionine metabolism yields
methyl groups that serve as donors for methylating DNA. DNMT inhibitors exert the opposite
effect by preventing DNMT from catalyzing DNA methylation. Daily, systemic administration
of methionine has been shown to reduce both the rewarding and motivating effects of cocaine
in rodents [18, 52]. In contrast, intracranial administration of a DNMT inhibitor (i.e., RG108)
into the NAc increases the rewarding effects of cocaine [18]. However, this same manipulation
decreases drug-seeking behavior following a prolonged abstinence period [53]. These findings
suggest that the effect of DNA methylation in the NAc may depend on whether or not there
has been a period of abstinence following cocaine exposure. Indeed, our lab and others have
shown that dynamic changes occur during forced abstinence from cocaine in animal models,
and that these changes can result in opposing effects of pharmacological challenge on cocaine
abuse-related behavior depending on whether the manipulation occurs during active drug
intake versus abstinence [54–56]. It should be noted that work using DNA methyl supple‐
mentation and DNMT inhibitors has primarily been done with cocaine and needs to be tested
on other drug classes.
9.2. Histone deacetylase inhibitors
The removal of an acetyl group from a histone is catalyzed by histone deacetylases (HDACs).
This reaction results in condensing the chromatin and repressing transcription. HDAC
inhibitors prevent this reaction from occurring, thereby maintaining DNA accessibility. There
are five different classes of HDACs (e.g., I, IIa, IIb, III, and IV) and each class contains multiple
HDAC enzymes (e.g., HDAC1, HDAC8, SIRT1, etc.). HDAC inhibitors range in their selectivity
for specific HDAC classes. Drugs that target both class I and II HDACs (e.g., Tricostatin A,
sodium butyrate, and SAHA) have been found to enhance cocaine locomotor sensitization [21,
57, 58], cocaine and opiate CPP [21, 58, 59], and cocaine self-administration [60] when admin‐
istered systemically prior to cocaine exposure. In contrast, administration of HDAC com‐
pounds following cocaine exposure attenuates cocaine CPP [61]. Similarly, these compounds
appear to produce mixed effects with alcohol, with some reporting increases [62] and others
reporting decreases [63, 64] in consumption. While these effects were found during active drug
administration, HDAC inhibitors have also been shown to alleviate anxiety symptoms during
alcohol withdrawal [30, 65]. Additionally, several studies have found that the effects of the
class I/II HDAC inhibitors were specific to drug self-administration, as no effects were found
with these drugs on food reinforcement [60, 63, 64]. Collectively, it appears that class I/II HDAC
inhibitors can produce both increases and decreases in drug-abuse-related behavior, and that
the effects may vary depending on whether testing occurs during drug exposure or with‐
drawal.
Recent Advances in Drug Addiction Research and Clinical Applications30
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More consistent effects have been observed with selective HDAC inhibitors. For instance, the
selective class I HDAC inhibitor, MS-275, decreases both alcohol and cocaine abuse-related
behavior in rodents [63, 64, 66, 67]. Also, the highly selective HDAC3 inhibitor, RGF-P966,
decreases cocaine CPP [68]. These findings suggest that the use of more selective HDAC
inhibitors may improve behavioral outcomes.
10. Genetic tools for uncovering epigenetic roles in drug-abuse-related
behavior
While pharmacological approaches have translational value for development of therapeutic
agents, efficacy may be compromised by the widespread drug distribution if the effects of an
epigenetic manipulation vary depending on the brain region of interest. Also, pharmacological
manipulations used to date have widespread effects on the genome, whereas sharpening the
mechanism/location targeted may improve desired outcomes. Recent preclinical research has
shed light on this area with technologies that selectively manipulate genes in specific brain
pathways and cell types.
10.1. Viral vectors
One approach to manipulating a certain gene within a particular brain region is the use of viral
vectors. Viral vectors are constructed to be nonreplicative so that they do not produce more
viral particles after infecting the cell. They enter the cell through endocytosis and insert a gene
of interest (i.e., transgene) into the genome of specific neurons (Figure 3). There are many
different modes of transfection that vary in length from days to months. In order to achieve
high levels of expression in a particular cell type, within the viral vector the transgene is
typically downstream from a promoter sequence that is specific to that cell. Thus, upon viral
transfection, the cells own transcriptional machinery will recognize and bind to the promoter
that will then activate transcription of the transgene. The direction of regulation (i.e., increase
vs. decrease expression) is determined by the sequence of the transgene. For instance, an
increase in gene expression is obtained by inserting the sequence of the transgene into the viral
vector with a strong upstream promoter. In order to decrease gene expression, a couple of
methods may be used. One involves transfecting a short-hairpin RNA (shRNA) that is
processed into a mature short-interfering RNA (siRNA). siRNAs are similar to miRNAs, except
that they are perfectly complementary to the target mRNA and will therefore selectively
downregulate only one target gene, in contrast to the multiple targets of most miRNAs. This
is referred to as a ‘knockdown,’ rather than a ‘knockout,’ as it is preventing translation of the
gene rather than completing deleting it from the genome. In order to accomplish a ‘knockout’
using viral vectors, transgenes that express a new gene editing approach, called the CRISPR-
Cas9 system, can be used. The latter uses a guide RNA that is complementary to specific
sequences in the DNA (e.g., gene of interest) that directs enzymes to that site and excises the
sequence from the DNA, therefore deleting it.
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Figure 3. Viral-mediated gene transfer. Viral particles are infused into a region of interest and infect local cells through
receptor-mediated endocytosis. Once viral particles are released from the vesicle inside the infected cell, viral RNA is
reverse-transcribed into DNA (via reverse transcriptase; dark blue) and transported into the nucleus, where it becomes
integrated into the genome (via integrase; yellow). By using a strong promoter (orange line) upstream of the transgene,
the cell’s transcriptional machinery produces an abundance of viral transgene expression in the cell. TF = transcription
factor.
Research using viral vectors has furthered our understanding of the impact of epigenetic
manipulations on drug-abuse-related behavior. As previously described, DNA methylation is
thought to inhibit cocaine abuse-related behaviors in animal models [16, 18, 52]. To test
whether Dnmt3a expression in the NAc specifically mediates these effects, LaPlant et al. [18]
infused viral vectors into this region that either increased or decreased Dnmt3a levels. Increas‐
ing NAc Dnmt3a expression countered cocaine CPP in mice, while decreasing expression
increased this behavior [18]. Interestingly, this same manipulation also increases depressive-
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like behavior following repeated social stress in mice [18], suggesting the blunted rewarding
effects of cocaine may be due to increases in anhedonia. This illustrates the importance of
testing the role of epigenetic modulators in both drug abuse and mood disorder models.
Another exciting use of viral vectors is to express synthetically engineered transcription factors
that bind to specific sequences in the DNA and regulate histone modifications at one specific
gene loci. Heller and colleagues [69] recently used this approach and found that histone
acetylation or methylation near the fosB gene locus increases or decreases cocaine reward CPP,
respectively. Again, this same manipulation produces either anti- or pro-depressive behaviors,
respectively, following repeated social stress [69], further demonstrating the complex role of
these molecules in both reward and emotional regulation processes. Bidirectional manipula‐
tion of cocaine self-administration in rats has also been demonstrated for miR-212 levels in the
dorsal striatum where viral-mediated increases prevent escalation of cocaine self-administra‐
tion, whereas knockdown increases cocaine self-administration [42]. In some cases, decreasing
miRNA levels may be needed to attenuate addiction-related behavior. For instance, viral-
mediated increases in miR-206 expression in the prefrontal cortex create an alcohol-dependent
phenotype in rats [47], and, therefore, it is possible that decreasing miR-206 levels in the PFC
may be protective against alcoholism. These examples suggest that the development of new
therapeutics that target epigenetic mechanisms have potential for treating addiction. Current‐
ly, there are no pharmacological agents for manipulating miRNAs, although development is
in the initial stages for their delivery in drug compounds [70]. A future challenge for this
avenue of research will be to develop methods of site-selective drug delivery.
10.2. Cre-Lox recombination
Another approach to manipulating gene expression is the use of Cre-Lox recombination
(Figure 4). Cre recombinase is an enzyme that identifies sequences in the DNA called LoxP
sites. When Cre recognizes these sites, it catalyzes a reaction that can either excise or invert the
DNA sequence contained between the two sites, depending on which direction the LoxP sites
are oriented. If the two LoxP sites are in the same direction, Cre will excise the DNA, effectively
deleting a gene that is between those two sites. If the LoxP sites are in the opposite direction,
Cre will then invert the two LoxP sites along with inverting the flanked DNA sequence. This
latter effect allows for gene activation, where a previous nonfunctional inverted gene sequence
becomes functional after Cre-Lox mediated-inversion.
Cre-lox recombination is carried out in rodents that are bred to have LoxP sites at specific
locations in the DNA that flank a gene of interest (e.g., Bdnffl/fl). A viral vector expressing Cre
recombinase can then be infused into a specific brain region and Cre-expressing infected cells
will recognize the LoxP sites and either excise or invert the flanked gene. This will result in
region- and temporal-specific manipulation of gene expression. Another approach with even
greater precision involves breeding mice to express Cre in only certain cell types. This is
accomplished by breeding rodents that express Cre downstream from a promoter that is
specific for only one type or subtype of cells. For instance, Cre can be expressed specifically in
catecholamine neurons when used downstream of a promoter for tyrosine hydroxylase (TH).
TH is an enzyme involved in synthesizing catecholamines (e.g., dopamine). Only cells with
Epigenetics and Drug Abuse
http://dx.doi.org/10.5772/101986
33
TH will have the transcriptional machinery to recognize the TH promoter and express Cre.
Next, there are two methods for manipulating gene expression in a cell-type-specific manner.
The first is to crossbreed two transgenic mice: the one that expresses Cre only in certain cell
types (e.g., TH+ neurons) and the other that ubiquitously expresses a LoxP-flanked Bdnf gene
(i.e., Bdnffl/fl). The offspring will no longer express Bdnf in TH-expressing cells. A limitation of
this technique is that Cre recombination occurs at conception and the transgene is either
expressed or deleted permanently. Therefore, changes may occur during development to
compensate for the gene modification, making it difficult to know whether subsequent
functional differences are due to the gene modification or the compensatory changes that
ensued thereafter. Another way to overcome this limitation is to inject a viral vector into a
brain region that contains the gene of interest in a plasmid with the gene flanked by inverted
LoxP sites. While the virus will infect all the cells in that region, only the cells that are expressing
Cre recombinase (e.g., TH+) will recognize the LoxP sites. In this case, Cre recombination will
only occur in specific cell types in a particular brain region and, importantly, during a specific
time point during development.
Figure 4. Cre-lox recombination. The top panel illustrates how Cre-lox recombination can result in gene excision,
where Cre recombinase (red) recognizes two loxP sites in the same orientation and joins the two ends of DNA, then
cleaves one end to join the other, resulting in excision of the flanked gene between the two loxP sites. The middle panel
illustrates how Cre recognizes two loxP sites in opposite orientations and inverts the intervening DNA sequence (e.g.,
Gene X). Gene inversion can be used to turn on a gene that is initially inverted and inactive. The bottom panel depicts
how crossbreeding two transgenic mice that express Cre recombinase only in tyrosine hydroxylase-expressing cells
(TH-Cre) with mice that ubiquitously express Bdnf with flanked loxP sites (Bdnffl/fl) results in mice with deficient Bdnf
expression only in TH+ cells.
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Research employing the Cre-Lox recombination approach has shown that the effect of
epigenetic mechanisms can be cell-type specific. For instance, the histone methytransferase
G9a has differential roles in cocaine-related behaviors depending on whether it is expressed
in striatal neurons that contain dopamine D1 (D1R) versus D2 (D2R) receptors. G9a is down‐
regulated by cocaine in both D1R and D2R-containing neurons; however, Cre-mediated
downregulation of G9a selectively in D1R-neurons is associated with decreasing cocaine CPP
and locomotor behavior in mice, while the opposite effects occur with selective down-
regulation in D2R-neurons [36]. These effects were observed using both Cre-Lox recombinase
procedures described above, providing strong evidence for the cell-type-specific role of G9a
in cocaine abuse-related behavior.
11. Transgenerational epigenetic inheritance of addiction-like phenotypes
Perhaps the most intriguing discovery in epigenetics is that epigenetic marks acquired due to
experience can be passed along to future generations. Unfortunately, this may include
epigenetic changes that make one vulnerable to addiction. The phrase “it runs in the family”
is often spoken in social circles regarding the seeming ability of addiction to be inherited. While
much is known about inheritance based on classical Mendelian genetic inheritance, much less
is known about transgenerational epigenetic inheritance.
Several criteria must be met for transgenerational epigenetic inheritance. First, in order to pass
down epigenetic changes across generations, the changes need to be present in the germ cells
(i.e., sperm or egg). In other words, the epigenetic changes must occur in future generations
independent of behavioral and social transfer, relying only on the molecular transmission of
epigenetic information [71]. Second, the behavioral phenotypes need to persist across several
generations, depending on the sex and pregnancy status of the parent exposed to the initial
environmental trigger. In males and nonpregnant females, an environmental trigger that
affects the parent generation (i.e., F0) and their germ cells, will directly impact the next (i.e.,
F1) generation. This is referred to as multi- or inter-generational inheritance [72]. However, if
the behavioral phenotype persists into the third generation (i.e., F2), which had no direct
exposure to the trigger, it can be regarded as transgenerational inheritance. With pregnant
females, not only is the parent and embryo directly affected, but also the germ cells of the
embryo that will develop into the F2 generation. Therefore, the F3 generation must exhibit the
phenotype to be considered transgenerational. Third, epigenetic modifications present in the
parents need to persist into future generations (see Figure 5). Interestingly, most epigenetic
marks (particularly DNA methylation) are erased immediately in the embryo following
fertilization [73]. Very few exceptions are currently known, but some include imprinted genes
(i.e., methylation-induced silencing of genes in one parent’s allele and not in the others), certain
histone and protamine (i.e., histone-like proteins found in sperm) modifications, and reserve
pools of coding and noncoding RNA [72]. Although narrowing the field of investigation, the
complex pattern of changes required for transgenerational epigenetic inheritance still remains
poorly understood [72, 74].
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Figure 5. Epigenetic inheritance. For pregnant F0 females (top left panel), drug exposure directly affects (red-outlined
symbols) both the F0 female and the fetus, including the brain and germ cells of the upcoming F1 generation. Howev‐
er, the F2 generation also receives direct effects of drug exposure from the F0 generation via the germ cells of the F1
generation. For males (top right panel), drug exposure directly affects both the F0 generation and the germ cells that
lead to the F1 generation. Therefore, the F3 and F2 generation of the pregnant female and male, respectively, can re‐
ceive transgenerational epigenetic inheritance from the F0 generation without having been in direct contact with drugs
of abuse (orange-outlined symbols).
11.1. Drug abuse-related traits passed across generations
The idea that addiction-like phenotypes can be passed down across generations based on
experiences of the parents is compelling in terms of uncovering potential biomarkers that could
be used to predict one’s risk of developing drug addiction. Only a few studies have investi‐
gated this possibility in the context of drug abuse models. Vassoler and colleagues [75] found
that male adult rats with a history of cocaine self-administration passed an addiction-resist‐
ant phenotype onto male, but not female, offspring. One potential mediator of these effects is
mPFC BDNF expression, where both the male F0 generation’s sperm and the mPFC of the
male, but not female, offspring exhibited increased H3 acetylation at the BDNF promoter, as
well as increased BDNF expression in the mPFC of the male offspring. Consistent with this
idea, mPFC BDNF is associated with resilience to drug effects [47, 49, 50]. These data are
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particularly compelling given that it was the father who received the initial trigger (i.e., drug
exposure), thereby avoiding potential confounds of maternal care, social/behavioral transfer,
and in utero environment changes that may occur following drug exposure in the females.
Nonetheless, one cannot rule out potential stress effects during copulation. Gapp et al. [76]
avoided this potential confound by isolating the sperm of the affected F0 males and artificially
inseminating the F0 females. They found that sperm noncoding RNAs from fathers subjected
to early life stress sufficiently passed on molecular and behavioral phenotypes to the next two
generations. Interestingly, early life stress is also a strong predictor for developing drug
addiction [1]. Other studies have shown that repeated morphine administration in F0 female
adolescents produces male offspring that are more sensitive to the analgesic and tolerance
effects of morphine [77]. Furthermore, ethanol exposure to F0 males decreases ethanol intake
and increases sensitivity to the inhibitory effect of ethanol on anxiety-like behavior in F1
offspring [78]. Reduced methylation at the Bdnf promoter was also observed in this study in
both the F0 male sperm and in the F1 males’ VTA. The VTA sends dopaminergic projections
to the NAc and BDNF in the VTA has a facilitating effect on drug-abuse-related behavior [79].
These few examples provide some evidence of multi-generational inheritance of drug abuse-
related traits and associated changes to the epigenome. However, further research is required
to examine if these traits persist into additional generations and whether blocking or reversing
the epigenetic changes in the germline will prevent transmission of these traits. The latter effect
would have very exciting implications for approaches to prevent the development of addiction
in future generations.
12. Concluding remarks
The studies reviewed provide compelling evidence for a link between drug-induced epigenetic
regulation of gene expression and drug abuse-related behavior in animals. The epigenetic
changes in gene expression occur in brain regions involved in reward learning and motivation.
This leads to plasticity-related changes within the neurocircuitries that mediate these processes
and is associated with aberrant behaviors that resemble hallmark symptoms of human drug
addiction, such as escalation of drug intake [42, 44, 80, 81] and increased willingness to exert
effort to obtain drug [46, 82]. Given that epigenetic mechanisms can produce long-lasting
changes in gene expression, they are likely candidate explanations for the persistent nature of
drug addiction in humans.
Current understanding of experience-dependent epigenetic changes is in its infancy. One
notable limitation in this field is the dearth of research on drugs of abuse other than psychos‐
timulants and alcohol. This is a particularly important gap to fill given that regulatory changes
in addiction-related genes can have opposite effects on abuse-related behaviors depending on
drug class [25, 83, 84]. The field also faces many challenges in discerning the involvement of
epigenetic mechanisms in drug addiction given the vast number of molecular regulatory
events that are altered by stress and drug experience, the complex interactions that can occur
among these regulatory events, and their drug-, region-, and time-specificity. Indeed, high
comorbidity exists between drug addiction and stress-related emotional disorders (e.g., PTSD
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and depression) [85, 86]; therefore, additional work is needed to test whether epigenetic factors
underlie the co-occurrence or are specific for one disorder over the other. It will be vital to test
the generalizability versus specificity of epigenetic modifications in drug abuse-related
behavior.
Despite the challenges that lie ahead, growing knowledge in this field will provide opportu‐
nities for novel preventions and interventions of drug abuse and dependence. New technol‐
ogies for identifying and specifically targeting epigenetic processes hold promise not only for
understanding the complex interactions between drug exposure, life experiences, and gene
expression, but also as treatment strategies designed to counter epigenetic dysregulation. For
instance, the use of synthetic transcription factors may allow drug-induced or inherited
epigenetic marks to be erased in order to increase resilience when one is exposed to addictive
drugs [69]. Future epigenetics research may also identify biomarkers of vulnerability that may
aid prevention strategies. Collectively, these new avenues of drug abuse research are exciting
given the urgent need for better treatments of this devastating disorder.
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Abstract
Alcoholism is a chronic relapsing and remitting disorder, where relapse to drinking is
often triggered by an intense desire for alcohol (craving) and the consequent motiva‐
tion to obtain alcohol (seeking). Environmental stimuli (cues) associated with past alcohol
use are believed to strongly contribute to relapse, as exposure to these cues can trigger
intense feelings of craving and drive alcohol seeking. Over the past several decades, much
progress has been made in identifying the neurobiological correlates of alcohol seeking
and relapse. Much of this progress is owed to the development of animal models and
advanced techniques to manipulate neural activity. In this chapter, we describe some of
the most commonly used rodent models of alcohol intake and seeking as well as the
methods used to identify the neural structures and circuits involved in alcohol-mediat‐
ed behavior. Several of the most routinely identified brain structures in alcohol seeking
are also described.
Keywords: alcohol, ethanol, relapse, amygdala, accumbens, VTA
1. Introduction
Alcohol use disorders (AUDs) constitute a major global health concern. In 2013 alone, 5.9% of
all deaths worldwide were attributed to alcohol intake (WHO, 2015). This statistic combined
with the social, emotional, and other physical consequences of excessive alcohol use makes it is
difficult to deny the ongoing need for preclinical research. Of greatest interest is identifying the
treatments  to  promote and maintain abstinence in individuals  diagnosed with an AUD.
Remission, however, is often characterized by a chronic vulnerability to relapse, which is poorly
understood. In fact, estimates of long-term relapse rates following remission are as high as 60%,
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
depending on the treatment sought [1]. Lack of information on the neurobiological antece‐
dents and psychological determinates of relapse makes AUDs all the more problematic to
address.
Further complicating our understanding of the persistent risk of relapse are the complex
interactions between internal processes and the external environment. Most noted are the
relationships that develop between environmental stimuli (cues), both contextual and discrete,
and the internal states produced by alcohol. Over the course of alcohol use, specific cues
become associated with the effects of alcohol through a Pavlovian learning process, whereby
an associative (alcohol-cue) relationship is formed. Once the relationship has been acquired,
these associative cues are able to autonomously produce psychological and physiological
states that are powerful enough to elicit behavior responses. These responses have been
suggested to play an important role in the development of AUDs and relapse.
Even after lengthy periods of abstinence, exposure to drug-associated cues can trigger intense
feelings of craving and drive drug seeking [2–5], leading to relapse to drug use. When
considering alcohol in particular, this lingering sensitivity to related cues is especially prob‐
lematic given the omnipresent nature of alcohol and alcohol-related cues in society. Therefore,
it is important that the neurobiology of this phenomenon be understood so that more effective
and durable treatments for alcoholism can be designed.
In the following sections, we describe common methodologies used to probe the neurobiology
underlying primary and conditioned ethanol reward. Specifically, these methodological
sections detail several commonly used animal models and tools to manipulate the brain. We
then discuss the neural substrates that have been identified in ethanol-seeking behavior using
these models and tools.
2. Animal models
To gain an understanding of the neurobiological mechanisms underlying AUDs, numerous
animal models have been developed. These models are designed to reflect various aspects of
alcoholism. The most widely used procedures assess ethanol reward and reinforcement and
include drinking, self-administration, and conditioned place preference (CPP). These animal
models share significant homology to certain elements of AUDs in humans, such as the
patterns of alcohol consumption, responses to alcohol-associated cues, and alcohol-seeking
behavior. Note that, in this review, the terms reward and reinforcement are distinguished from
one another. Although reward is used to refer to the appetitive nature of a stimulus as indicated
by the ability of environmental stimuli to elicit approach behavior, reinforcement will refer to
experimental contingencies that increase the likelihood of behavior(s) occurring [6, 7]. It should
be noted that no animal model could fully emulate all aspects of human alcoholism. However,
animal models allow for unparalleled access to the brain and thus provide a means to evaluate
neural mechanisms involved in the aspects of alcohol reward and dependence. These models
therefore represent invaluable preclinical tools for identifying potential biological correlates
of and treatments for AUDs.
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2.1. Drinking
For nearly a century, it has been known that rodents, like humans, will voluntarily consume
alcohol [8, 9]. For this reason, rodents have long been used in drinking procedures that involve
home-cage access to alcohol (ethanol). This represents the simplest way to gauge ethanol
reward, through consumption, which is done simply by providing rodents with a bottle and
measuring the amount they drink. Although alcohol is occasionally the only solution provided
in drinking studies, two-bottle choice procedures are more commonly used in rodents and
yield an additional measure of preference for alcohol. In a two-bottle choice drinking proce‐
dure, home-cage access to alcohol and another alcohol-free fluid (typically water) is provided
continuously or at temporally controlled intervals. Evidence of ethanol reward is then
indicated by the amount consumed and preference for the alcohol-containing solution over
the other available fluid. Manipulations that affect alcohol consumption and/or preference but
not water or total fluid intake are believed to have interfered with the rewarding properties of
ethanol [10].
Although these studies have high face validity (as humans voluntarily consume alcohol orally),
they are often limited by the fact that, like humans, rodents are sensitive to the aversive taste
of ethanol. At higher concentrations, the aversive taste of ethanol makes it difficult for rodents
to drink to the state of intoxication. Therefore, procedures requiring oral intake of ethanol may
require water deprivation, slow increases in ethanol concentration, and/or the addition of a
sweetener such as sucrose to the ethanol-containing solution to help rodents overcome the
aversive taste [11, 12]. For instance, modified sucrose fading techniques [13] are a common
strategy that has been used to achieve voluntary consumption of high concentration of ethanol
in rodents. With this technique, sweeteners such as sucrose or saccharin are initially added to
an ethanol solution then slowly faded out. However, this illustrates a pitfall of these proce‐
dures, which is that the underlying motivation for ethanol consumption is not always
understood. For example, rodents may freely consume ethanol for the sweetened taste or for
its caloric value. Therefore, it is not always evident that ethanol is being consumed in this
procedure for its postabsorptive pharmacological effects. Additionally, intervention-induced
decreases in alcohol intake in this procedure do not always indicate that a manipulation
decreased the ethanol reward. It is possible that a reduced intake may reflect an enhancement
of the pharmacological effects of ethanol, resulting in a leftward shift in the dose-response
curve, which translates to an increased effect of ethanol at lower amounts. Furthermore,
rodents tend to titrate their dose of ethanol consumption and often do not reach blood ethanol
concentrations (BECs) of intoxication unless induced to consume greater volumes via sucrose
fading or limited access to ethanol [14]. As a result, care must be taken when interpreting results
in drinking studies, as the underlying reasons for decreased intake may not always be
apparent.
2.2. Self-administration
In self-administration procedures, rodents must successfully perform an operant response
(e.g., lever press or nose poke) to receive a small volume of an ethanol solution [15]. With this
method, requisite responding is used to assess the reinforcing value of ethanol. A major
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advantage of self-administration procedures is that they allow for the assessment of ethanol
reinforcement at distinct phases. Methodological manipulations in these procedures allow for
the evaluation of the development of and enhancement in ethanol responding, including in
the absence of drug (extinction) and the reemergence of responding to various environmental
stimuli after responding has been extinguished (cue-, stress-, and ethanol-induced reinstate‐
ment). Thus, this procedure can be successfully used as a model aspect of alcohol seeking (rate
of responding or latency to bar press for alcohol). Also, self-administration studies can be used
to assess the animal’s motivation to receive ethanol by increasing the difficulty of the requisite
responding (a progressive ratio schedule, in which responding requirements are increased
after every the delivery of reinforcer) and thus evaluating the willingness of the animal to work
for an ethanol reinforcer [16]. As with humans, rodents will exert effort to obtain ethanol and
this effort or seeking behavior can be reduced by administration of therapeutic agents
indicated for the treatment of AUDs, such as naltrexone [17]. As such, reinstatement proce‐
dures have been shown to be highly useful for the preclinical evaluation of pharmacotherapies
aimed at reducing ethanol relapse in humans (reviewed in [18]).
In addition to the rate and pattern of responding, self-administration procedures also yield an
additional measure of amount of alcohol consumed. However, similar to drinking studies, the
aversive taste of ethanol may be difficult to overcome in self-administration procedures.
Therefore, liquid deprivation and fading strategies have also been used to establish operant
responding for and consumption of ethanol. This similarly compromises straightforward
interpretations of the underlying purpose for the behavior. Interpretation of studies using
operant oral paradigms may also be complicated because it is difficult to distinguish between
the phases of intake. As training procedures are necessary to establish ethanol self-adminis‐
tration and responding or intake serves as the primary dependent variable, it can be challeng‐
ing to separate acquisition and learning from seeking, for example.
2.3. Place conditioning
Another approach to modeling reward in rodents is the CPP procedure. With this Pavlovian
(classical) conditioning procedure, a distinct environmental stimulus [conditioned stimulus
(CS)] can acquire incentive salience after being paired with a motivationally significant
stimulus [unconditioned stimulus (US)]. Ultimately, the previously neutral stimulus (CS)
develops the ability to elicit a conditioned motivational response similar to the response
elicited by the US. This mimics the ability of cues or contexts associated with alcohol (e.g.,
alcohol containers, odors, advertisements, and drinking establishments) to elicit craving and
seeking for alcohol in humans with AUDs. In addition, drug-induced CPP can be established
in humans in a laboratory setting, further validating this model [19]. As such, the CPP
procedure is widely used to study the motivational properties of many abused drugs, and
given its numerous benefits, the popularity of this procedure continues to grow. In the last
decade alone, there has been a greater than two-fold increase in the total number of publica‐
tions reporting its use (Figure 1). Thus, this procedure is considered one of the most popular
models of drug reward [20, 21].
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Figure 1. Annual number of CPP studies published over the last 20 years. Values were obtained from PubMed using
the search term “CPP” OR “place preference” OR “place conditioning”. Adapted from Tzschentke [20, 21].
In a standard ethanol CPP procedure, a discrete cue [e.g., visual or tactile stimulus; referred
to as the positive CS (CS+)] presented in one spatial location is repeatedly paired with ethanol,
usually administered by the investigator (i.e., noncontingently). On alternating sessions, a
different stimulus not paired with ethanol [typically paired with saline, the negative CS (CS-)]
is presented in a location adjacent to where the CS+ was presented. During this acquisition
phase, an association develops between the CS+ and the subjective effects of ethanol (US). In
the subsequent drug-free expression phase, animals are given access to the entire conditioning
apparatus and thus to both cues (CS+ and CS-). When given the choice between the CS+ and
CS-, animals assess the memory formed in the acquisition phase and will generally approach
and maintain contact with (i.e., prefer) the CS+ when a US is rewarding. In other words, if an
animal spends a greater amount of time with the ethanol-paired stimulus (CS+) in relation to
the nondrug-paired stimulus (CS-), this is taken as an indication of the positive motivational
effects of alcohol. Conversely, a greater amount of time spent with the saline-paired stimulus
compared to the ethanol-paired stimulus would be considered conditioned place aversion
(CPA) and taken to indicate a negative motivational effect of ethanol. The ability of alcohol to
produce CPP or CPA depends on many factors, such as past history of ethanol exposure, route
of administration, injection timing, and dose (e.g., [22–26]). A result of conditioned reward or
aversion can vary by species and strain. Although conditioned ethanol responses have been
reported in some strains of rat (e.g., [27–29]), studies overall have shown conflicting results
ranging from lack of CPP [30] to CPA [31, 32]. However, ethanol CPP has been found in a wide
array of mouse strains [33] and thus has much utility as a model of ethanol reward in this
species.
Unlike self-administration, CPP does not require a lengthy training phase. In fact, in an inbred
st rain of mouse (DBA/2J) commonly used in ethanol CPP, a significant place preference can
be conditioned after only two ethanol-cue pairings [34–36]. Another advantage to this
procedure is that it does not involve oral intake of ethanol, which is required in drinking and
self-administration procedures. This is highly beneficial in cases where manipulations, such
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as pharmacology agents, reduce general consummatory behavior in addition to ethanol
reward or reinforcement. For example, erroneous conclusions may be made when a drug with
anorectic liability reduces the oral intake of ethanol. However, because CPP involves noncon‐
tingent ethanol administration, the effect of anorectic drugs on ethanol reward can be assessed
more accurately [35]. The place preference paradigm also permits for the evaluation of
manipulations on the various phases of learning an ethanol-paired cue that are often difficult
to isolate in other procedures, and an understanding of these various phases of learning is
important for understanding the progression of alcohol addiction. These phases include the
acquisition, conditioned expression, extinction, and reinstatement of the conditioned effects
of ethanol. Acquisition and conditioned expression of CPP are described in the paragraph
above. Extinction occurs following repeated exposures to the CS+ unpaired with the US
(ethanol), which results in a loss of conditioned responding as the animal learns that the CS+
and US are no longer associated and the CS+ loses its rewarding value. Reinstatement, the
phase most comparable to relapse in the human condition of addiction, is the reemergence of
ethanol-seeking behavior following extinction, usually elicited by a priming injection of a low
dose of ethanol (US), stress, or ethanol cues before being placed within the conditioning
apparatus. Specifically, when a manipulation disrupts the expression of ethanol CPP, this is
generally taken to indicate that it interfered with the conditioned rewarding effect of ethanol
or ethanol seeking. Indeed, because CPP can be used to gauge the conditioned rewarding or
motivational value of stimuli, it also serves as an effective method to measure cue-induced
ethanol-seeking behavior. On the other hand, manipulations that disrupt the development
(acquisition) of CPP are thought to impact either associative learning or the primary rewarding
effect of ethanol. To distinguish between these two possibilities, this procedure can also be
used to assess whether the manipulation also disrupts the acquisition of other associations
such as CPA induced by ethanol or other drugs (e.g., [34]). However, if a manipulation
specifically affects the extinction of CPP, it is thought to impair the formation of an inhibitory
memory, which relies on different neural structures than those required for the acquisition of
CPP. If a manipulation impairs the reinstatement of CPP, it is thought to either impair
mechanisms that allow for evaluation updating or reemergence of behavior, but manipulations
could also prevent access to the original acquisition memory and manipulations must be
assessed for specificity to reinstatement.
One disadvantage of the CPP procedure is that the drug is administered by the investigator
and therefore delivered noncontingently. Although this may be considered an advantage
given the control over the dose it provides, it reduces the face validity of this model. Unlike
humans, in this procedure, rodents do not consume alcohol of their own volition. Similarly,
humans do not take alcohol via intraperitoneal injections, as is used in this animal model.
Moreover, this procedure does not typically involve an escalation in intake, as is usually
observed in humans. Comparable to self-administration procedures, manipulations that affect
locomotor activity may also nonspecifically impact CPP expression. It has been previously
demonstrated that increases in activity may disrupt ethanol CPP expression, thereby obscuring
its detection [37]. Hence, results obtained by manipulations that increased or decreased
preference test activity must be cautiously interpreted. Despite these drawbacks, this model
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Recent Advances in Drug Addiction Research and Clinical Applications52
presents a rapid and efficient method to evaluate the primary and conditioned motivational
effects of ethanol in rodents.
2.4. Summary
In summary, animal models have been used extensively in alcohol research, with several
models designed to study the various aspects of ethanol-mediated behavior. The most
standard used procedures to model ethanol seeking are self-administration and CPP. Al‐
though it should be noted that no one procedure is able to mimic all features of human alcohol
use, these models allow for the investigation of the underlying neural mechanisms involved
in distinct alcohol-related behaviors. Furthermore, the paradigms described here do not
encompass all models of AUDs available. Additional models include operant runway models,
vapor chamber exposure, intracranial self-stimulation, and locomotor sensitization. In the
following sections, several commonly used techniques to probe the neural structures and
circuits involved in rodent behavior and their application to animal models of ethanol seeking
are described.
3. Tools to manipulate neural structures
Many techniques have been developed to evaluate distinct brain structures. These methods
allow for the direct manipulation of a defined brain area to manipulate their activity during
behavior. Thus, they require intracranial access typically gained through stereotaxic surgery.
Of these methods, the most widely used are lesions and microinjection. However, more
modern tools have been developed that harness the capabilities of viral gene transfer to more
precisely control cells and circuits. Each of these techniques, classic and contemporary,




A classical method used to study brain function involves the removal or destruction of neural
tissue. With this method, experimental lesions are made to defined brain structures through
manual, chemical, or electrical means and can also be neurotransmitter specific. Popular
neurotransmitter-specific lesioning agents include 6-hydroxydopamine (dopaminergic and
noradrenergic neurons), 5,7-dihydroxytryptamine (serotonergic neurons), ibotenic acid [N-
methyl-D-aspartate (NMDA) receptor-containing neurons], kainic acid (kainate receptor-
containing neurons), and many others. Behavior is then examined in the absence of this tissue,
thus providing insight into the involvement of the lesioned structure. Histology, such as simple
cresyl violet stains or for markers of neuronal damage, is performed on neural tissue after
behavior to confirm the location of damage. One issue that arises is the propensity for other
brain structures to compensate for the damaged region. This may severely compromise the
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interpretation of results obtained from studies using a lesion procedure. Another issue is the
difficulty encountered when using lesions to assess the effects at distinct phases of a behavior,
as lesions cause irreversible damage to the region. Thus, with many animal models, it is
difficult to determine whether ablation of a structure impacted the development (acquisition),
performance (expression), extinction, or reinstatement of behavior. To affect a distinct phase
of behavior, lesions can be made at specific times in the model. However, phase-specific lesions
can unintentionally alter later behavior and can even impair the memory of earlier phases.
Criteria Classical tools Contemporary tools
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Table 1. Comparison of commonly used classical and contemporary tools in behavioral neuroscience.
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3.1.2. Intracranial microinjections
The local administration of pharmacological agents into discrete brain targets is another
strategy to control neural activity. This technique typically requires permanent surgical
placement of guide cannula to allow for later access to otherwise inaccessible brain structures
while animals are awake and behaving. Small volumes of drug solutions are then administered
directly into the brain by threading a smaller gauge injector through the guide cannula. These
solutions typically contain drugs that bind to distinct membrane proteins (receptors) expressed
within the target brain region to enhance or inhibit local cellular activity during behavior.
Similar to lesions, histology is performed afterwards to verify the site of microinjection. This
procedure has several major advantages compared to lesions, most of which relate to its ability
to produce more temporally specific effects. Unlike lesions, the effects of most pharmacological
antagonists and agonists are temporary and can therefore be more precisely controlled and
administered during distinct phases of behavioral procedures. This allows for more straight‐
forward interpretation of the effects of this manipulation on behavior. Additionally, this
technique can provide insight into the neurochemical signals involved, as agents selective for
distinct receptor types can be infused. To a lesser extent than lesions, microinjections also
produce damage resulting in reactive gliosis from cannula installation and injector placement.
Finally, it is difficult to ascertain the exact extent of diffusion of the administered solution. As
diffusion may depend on a variety of factors, such as the volume injected and the nature of
the solution (polarity, hydrophobicity), it is difficult to predict. Thus, it is not always clear that
the site of infusion is the region directing the observed behavior. For this reason, it is often
necessary to include additional groups that receive drug injections in locations proximal to the
target structure.
3.2. Contemporary tools
In recent years, there has been a rapid emergence of novel tools engineered to control neuronal
activity. Of benefit to these tools have been the advancements in recombinant viruses that are
capable of gene transfer in the central nervous system (CNS). For example, viruses with low
immunogenicity and cytotoxicity such as adeno-associated virus (AAV) can be delivered
directly into the brain to safely and efficiently express recombinant genes [38]. This provides
a means to site-specifically express proteins in the CNS that can be used to modulate the activity
of cells in target brain tissue. Optogenetics and chemogenetics represent the two most widely
used contemporary tools in behavioral neuroscience, as they can be applied in vivo to modulate
neural activity in awake behaving mice and rats. As with the classical tools described above,
these modern methods have inherent advantages and disadvantages (Table 1), which are
detailed below.
3.2.1. Optogenetics
In this technique, neurons are genetically modified through intracranial injection of a viral
vector to express photosensitive proteins. The most commonly used photosensitive receptors
are channelrhodopsin (ChR; excitatory ion channel), halorhodopsin (NpHR; inhibitory ion
pump), and archaerhodopsin (ArchT; inhibitory proton pump; reviewed in [39]). These light-
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gated proteins are activated by targeted illumination, causing rapid (millisecond timescale)
depolarization or hyperpolarization of neurons (reviewed in [40]). By evoking or inhibiting
spike activity with this light-protein interaction, the activity of distinct brain regions and cell
types can be experimentally controlled, including during the performance of behavioral tasks
[39]. Because these engineered opsins can be controlled by different light wavelengths, neural
activity and behavior can be modulated bidirectionally (i.e., multiplexed), offering a major
advantage to this technique. Moreover, the high temporal resolution afforded by this tool
makes it ideal to examine the discrete phases of behavior. However, a major issue posed by
optogenetics is the possibility of desensitization of the opsin, which can occur within seconds
of photoactivation [41]. Thus, this is especially problematic for studies that require inhibition
or activation of longer durations, such as is required in certain behavioral tasks that occur on
the order of minutes. Repeated stimulation leading to the desensitization of the opsin may
even produce opposing results. This is especially problematic in the case of the excitatory opsin
ChR, as the desensitization of this receptor and repeated stimulation of the cell may result in
a net inhibition, the opposite effect of what is initially intended. The extent of viral diffusion
and resulting protein expression is easily measurable with this technique, as most viral
constructs contain a fluorescent tag. However, similar to microinjections, implantable
hardware is necessary to allow for intracranial insertion of fiber-optic probes. This technique
also requires specialized equipment such as fiber-optic probes and programmable light
sources, which can be costly. Tethering the animal to the external light source is also necessary,
which may restrict the range of apparatuses that can be used and behaviors that can be assessed
(although for recent developments in wireless technologies; see [42–46]). Recently, questions
regarding the effect of illumination in brain structures have arisen, specifically in regards its
thermal effects on neural tissue. It has been suggested that focal illumination, especially when
intense and prolonged, can result in phototoxicity, heat-induced cell damage, and oxidative
stress that independently alters cellular activity [47]. Even more problematic is evidence
indicating that heat alone can increase neuronal firing rates [48]. In fact, even at commonly
used intensities, the thermal effect of illumination is sufficient to increase cell firing rates [49].
Overall, optogenetics provides a unique tool to control neuronal activity with high
spatiotemporal resolution. However, the required implantable hardware, specialized
equipment, tethering, risk of desensitization, and light induction may render this tool less than
ideal given the experimental question and design.
3.2.2. Chemogenetics
This relatively new technique involves the engineering of G protein-coupled receptors
(GPCRs) to interact exclusively with small molecules that were otherwise unrecognized by the
GPCR [50]. The most common of these mutated GPCRs are designer receptors exclusively
activated by designer drugs (DREADDs) [51]. The engineered GPCRs possess no detectible
constitutive activity and are robustly activated at nanomolar concentrations of otherwise
pharmacologically inert compounds. The first established DREADDs were based on excitatory
Gq-coupled and inhibitory Gi-coupled human muscarinic receptors M3 (hM3Dq) and M4
(hM4Di), respectively [51–53]. Receptors hM3Dq and hM4Di possess no affinity for the
endogenous ligand acetylcholine and are robustly activated by the drug clozapine-N-oxide
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(CNO), a pharmacologically inert metabolite of clozapine, which is highly bioavailable and
produces no pharmacological effect in rodents [51, 54]. Since their inception, other DREADDs
have been engineered, which include a Gs-coupled muscarinic-based (rM3Ds) receptor and
Gi-coupled KOR-based DREADD (KORD) [55–57]. Notably, the development of KORD with
actuator salvinorin B allows for the bidirectional control of behavior when used in combination
with hM3Dq receptors and CNO [57].
Comparable to optogenetics, DREADDs can be ectopically expressed in the CNS by focal
infusion of a vector encoding for these receptors. A major advantage of chemogenetics over
optogenetics, however, is the lack of required specialized equipment and need for permanently
implanted hardware. In fact, DREADDs require just one initial intracranial entry to infuse the
viral vector carrying the DREADD-encoding gene. The receptors can then be activated by a
relatively noninvasive peripheral injection of an actuator. This is highly advantageous when
performing sensitive behavioral procedures that are affected by excessive handling (e.g., CPP
and self-administration) [58]. Similar to optogenetics, a more precise detection of viral spread
and DREADD expression are possible with this technique, as they are designed to encode for
DREADDs as well as a fluorescent marker.
Unlike optogenetics, DREADDs signal through canonical G-protein pathways. Once activated,
the duration of the inhibition or activation produced by the DREADD can be long lasting. The
duration of effect is also determined by the half-life of actuators, which may remain in central
tissue and activate DREADDs for minutes to hours. In some cases, this low temporal resolution
may serve as a major shortcoming of this technique. However, a protracted effect is often highly
valued in studies where behavioral tasks are of longer duration and long-lasting effects of
manipulations are desired. Another issue is that the presence of the receptor does not always
indicate that it is a functionality. Additional measures may be necessary to demonstrate the
function of these receptors in target tissue. Although it is theoretically possible, no studies have
reported DREADD desensitization. However, this presents another reason for including some
form of functional confirmation of DREADD effects.
In summary, DREADDs are a useful technique to control neuronal signaling in vivo. Consid‐
ering the sensitivity and duration of many behavioral tasks, the noninvasive nature of
DREADD activation (i.e., peripheral drug injection) and longer time course of inhibition/
activation make chemogenetic strategies highly desirable in behavioral research.
3.3. Summary
The above-described tools provide a means through which to target and manipulate brain
regions. These tools offer variable degrees of selectivity, with contemporary techniques
typically being associated with higher precision in terms of spatial and neuronal targeting. The
tools mentioned above do not encapsulate all available methods of discovering the neurobi‐
ology behind behaviors. Other commonly used methods not described in this chapter are
intracranial electrical or self-stimulation, intracranial microdialysis, electrophysiology,
immunohistochemistry (IHC), genetic knockout rodents, and many others that similarly assess
the importance of a brain region and specific neurotransmitter systems to behavior.
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4. Tools to manipulate specific neural pathways
Historically, the direct manipulation of neural circuits has been a challenging task, with much
of the difficulty due to limited methodologies. In the past, many of the tools used possessed
relatively low selectivity and provided indirect manipulation. Several strategies, however,
have been designed using both classical and contemporary tools to probe the neural circuitry
underlying behavior. This section describes several commonly used strategies and includes a
discussion of their merits and weaknesses.
4.1. Classical tools
Historically, disconnection procedures involving lesions and pharmacological microinjections
have been used to evaluate neural circuitry. This strategy involves the disruption of two
directly connected brain regions to assess whether their interaction is involved in behavior
(e.g., [59–62]). Typically, a unilateral lesion or inactivating microinjection [e.g., γ-aminobutyric
acid (GABA) agonists or channel blocker] is made in source regions and another lesion or
microinjection is made in the contralateral hemisphere of its terminal target. Thus, if a behavior
is dependent on a source-target interchange, then their contralateral disconnection should be
more disruptive to behavior than ipsilateral disconnection or unilateral manipulation of each
region individually. However, a major weakness of this strategy is the indirect nature of the
manipulation on the circuit. Indeed, the imprecision of this method has at times been proven
problematic resulting in significant reductions in behavior with ipsilateral and unilateral
manipulations alone (e.g., [60]). This is likely due to the inability of this technique to directly
target distinct yet intermixed populations of target-projecting neurons within source regions.
Instead, each region is broadly manipulated leading to the inhibition of their overall activity
and output throughout the brain.
To help visualize and identify the circuit, neuronal tracing has sometimes been used in
conjunction with these classical tools. In these studies, tracing agents are injected into the brain
to label neurons in a manner that is retrograde (axon terminal back to the soma), anterograde
(soma to axon terminal), or transsynaptic (to adjacent neurons retrogradely or anterogradely).
In studies of behavior, circuit involvement is inferred by colabeling of neuronal activity
markers such as c-Fos with the tracer through IHC (e.g., [63]). Cells that are immunopositive
for both the tracer and activity marker are then used to identify afferent or efferent projection
neurons that were activated during behavior. When used in tandem with disconnection
procedures, this provides a means to visually assess the impact of disconnection on circuit
activity (e.g., [62]). Although these procedures help to label neurons within the circuit and
gauge their activity, they still fall short of allowing isolated modulation of the circuit. Overall,
this remains a major weakness of classical techniques, as results only offer an indirect measure
of neural circuit involvement in behavior.
4.2. Contemporary tools
Optogenetic and chemogenetic strategies have provided a refined and more selective means
to directly manipulate neural circuits. This is principally due to viral transduction, as proteins
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(opsins and DREADDs) are trafficked downstream from soma to axon terminals (anterograde)
and therefore expressed on presynaptic boutons as well as to cell bodies [64]. In the case of
optogenetics, illumination can then be targeted to axon terminals, which results in the
depolarization or hyperpolarization of the neuron. This strategy has been successfully
implemented in many behavior studies (reviewed in [64]). However, a concern that arises
when using this method is the possibility of antidromic stimulation of the cell. The stimulation
of terminals may result in the back-propagation of an action potential that activates the neuron
and its collateral inputs to other regions outside the circuit of interest. Therefore, with this
strategy, there is a potential for the activation of multiple circuits, which diminishes the
selectivity of the manipulation.
Several chemogenetic-based strategies have been used to modulate neural circuit activity.
First, a functional disconnection procedure methodologically similar to that used with lesions
or microinjections has been reported by Mahler et al. [65]. In this study, hM4Di receptors were
unilaterally expressed in ventral tegmental area (VTA) dopamine (DA) cells and contralater‐
ally in rostral ventral pallidum (RVP) cells. The contralateral disconnection of RVP-VTA DA
reduced cued reinstatement of cocaine seeking relative to both unilateral RVP inhibition and
unilateral VTA DA inhibition. Despite these positive results, it is unclear whether the simul‐
taneous inhibition of RVP and VTA DA, regardless of hemisphere, would have been sufficient
to produce a similar effect. Thus, with this technique, it is important to include ipsilateral as
well as unilateral controls. In summary, the lack of precision and necessary inclusion of
numerous controls renders this a less desirable strategy for the targeted modulation of neural
circuits.
Another DREADD-based method that has been used involves the intracranial injection of
CNO. The principle behind this strategy is similar to that of the optogenetic circuit-selective
method outlined above. Here, like illumination, CNO is targeted to the terminal region of
DREADD-expressing cells [65, 66]. The focal infusion of CNO therefore serves to activate/
inhibit DREADD-expressing cells and/or presynaptic neurotransmitter release from
DREADD-expressing nerve terminals [66]. In this manner, the activity of defined neural
circuits can be more precisely controlled. However, given that this strategy requires intracra‐
nial microinjections, it also carries with it the disadvantage of requiring permanently indwel‐
ling hardware (i.e., guide cannula and obturators), repeated intracranial entries, and a resulting
increased risk of tissue damage.
An alternative approach to this involves the intersection of multiple viruses that are injected
into serially connected nuclei. Typically, a retrograde virus encoding for cre recombinase is
injected in a target region and a cre-inducible virus encoding for DREADD is injected into the
source region. In this manner, the activity of a specific source’s inputs to the target region (i.e.,
projection neurons) can be controlled by the systemic injection of CNO. This approach has
been successfully implemented using canine adenovirus (CAV-2) to retrogradely infect source
region cells and selectively express DREADDs in a specific neural projection [67–69]. Notably,
this strategy provides an ideal way to control circuits, especially during behavior. Not only
does this method provide a high degree of selectivity, it does not require implantable hardware
and can be robustly activated by a simple peripheral injection of an actuator. Theoretically, it
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is possible for axon collaterals from source region cells to express DREADDs, which given the
systemic nature of DREADD activation may lead to activity in sites outside the circuit. Hence,
studies using this method should be careful to address this potential caveat.
4.3. Summary
Overall, several techniques involving classical and contemporary tools have been used to
manipulate defined neural circuits. On one hand, classical tools provide indirect manipulation
and generally require the use of multiple controls to carefully and appropriately interpret
results derived using these strategies. Conversely, contemporary tools involving viral-
mediated gene transfer confer greater circuit selectivity and have been successfully used to
manipulate serial projections form source to target region.
5. Neural structures involved in ethanol-seeking behavior
In the following sections, several neural structures and circuits involved in ethanol-seeking
behavior are discussed. Building off of earlier sections, the studies that are described below
involved several different animal models and tools to identify the underlying neurobiology of
ethanol seeking. Specifically, this chapter will focus on the neural structures involved in
ethanol self-administration and CPP, as these models specifically assess ethanol-seeking
behavior. A proposed circuit of the key neural structures implicated in cue-induced ethanol
seeking as indexed by self-administration and CPP procedures is included in Figure 2.
5.1. Findings from ethanol self-administration studies
Studies using ethanol self-administration procedures to evaluate the neural mechanisms
underlying ethanol seeking have by and large employed intracranial microinfusions. Most of
the neural regions that have been evaluated in self-administration studies are part of the
mesocorticolimbic system [70] and are typically situated downstream of the VTA. As with
many drugs of abuse, acutely administered ethanol excites DA neurons within the VTA
through direct and indirect mechanisms [71–74]. Furthermore, the VTA is robustly activated
by ethanol-associated cue exposure [75]. Downstream, the nucleus accumbens (NAc) and
amygdala receive dopaminergic input from the VTA [76] and considerable evidence suggests
that this dopaminergic input to each region underlies associative learning and motivated
behavior [77–81]. As such, NAc and amygdala are two of the most well-characterized struc‐
tures in terms of their involvement in ethanol seeking and several of these studies are described
below.
The NAc has been routinely implicated in the drug-seeking behavior [82, 83]. Many studies
have found a differential involvement of core and shell subdivisions in drug seeking depend‐
ing on the drug of abuse, phase of self-administration, and nature of the procedure and/or
stimuli used [84–86]. As with other drugs of abuse, the NAc core and shell have been shown
to be differentially involved in cue-induced ethanol seeking. For example, ethanol self-
administration studies have shown that transient inactivation of the NAc core but not shell
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reduces cue-induced reinstatement [87] and context-induced renewal [88] of ethanol seeking.
Other studies, however, have demonstrated that NAc shell modulates the expression of cue-
induced ethanol seeking [89] and that blockade of DA D1 receptors in the NAc shell but not
core reduces the spontaneous recovery of ethanol-seeking behavior following prolonged
abstinence [90]. In addition, DA D1 receptor antagonism in NAc core and shell has been
reported to block context-induced renewal of extinguished ethanol seeking [91]. These studies
vary in their findings of core versus shell involvement in ethanol seeking, likely indicating that
the role of NAc subdivisions varies by different phases of self-administration (e.g., acquisition,
expression, and reinstatement) and by the use of cues or context. However, this literature
overall supports a role for the NAc in general ethanol-seeking behavior and suggests that DA
input may underlie its involvement.
The amygdala has also been strongly implicated in drug-seeking behavior, specifically the
basolateral amygdala (BLA) and central nucleus of the amygdala (CeA) subdivisions as well
as the bed nucleus of the stria terminalis (BNST) of the extended amygdala [92–94]. In ethanol
Figure 2. Diagram of the neural circuitry involved in ethanol CPP. Previous studies have demonstrated the involve‐
ment of cortex (ACC), amygdala (BLA/CeA), striatum (NAc), and midbrain (VTA) in ethanol CPP. The present work
now demonstrates the involvement of the dorsal and ventral BNST (dBNST and vBNST, respectively) and a direct
BNST-VTA circuit. Each of these regions receives dopaminergic input from the VTA (indicated by blue arrows) and is
part of a broader mesocorticolimbic dopamine system that underlies reward and motivation. Some of the neurochemi‐
cal signals underlying the involvement of each region in ethanol CPP have also been identified. +, excitatory; -, inhibi‐
tory; blue circles, dopamine cells; green rectangles, glutamate cells; red squares, GABA cells; black boxes, unknown
neurochemical signal; green arrows, glutamate projections; μ, μ-opioid receptors; B, GABAB receptor; D1, dopamine
D1-like receptor; D2, dopamine D2-like receptor; iGluR, ionotropic glutamate receptors, NMDA, iGluR subtype.
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self-administration studies, the inactivation of the BLA has been shown to reduce context-
induced renewal of previously extinguished ethanol seeking [95]. The involvement of the BLA
in ethanol seeking may involve a glutamatergic mechanism, as intra-BLA ionotropic glutamate
receptor antagonism reduced the expression of ethanol seeking elicited by a discrete cue and
invigorated by an ethanol-associated context [96]. Notably, the excitatory transmission from
the amygdala to the NAc is believed to underlie reward seeking and suggests that an amyg‐
dala-NAc circuit may be involved in the expression of reward-seeking behavior. For example,
the optical stimulation of BLA glutamate to NAc has been shown to be reinforcing, as mice
worked to earn additional stimulation of BLA-NAc synaptic inputs [97]. Conversely, the
inhibition of BLA-NAc inputs reduced cue-induced responding for sucrose [97]. In addition,
pharmacological disconnection has revealed that an amygdala-NAc interaction underlies a
stimulus-controlled expression or maintenance of cocaine seeking [59].
The CeA and BNST have generally been implicated in stress-induced ethanol-seeking rein‐
statement but may also play a role in cue-induced ethanol reinstatement. For instance, intra-
CeA but not intra-BLA infusion of mifepristone, a glucocorticoid receptor antagonist, has been
reported to suppress reinstated ethanol seeking induced by the pharmacological stressor
yohimbine [98]. Activation of group II metabotropic glutamate receptors blocks stress- and
cue-induced reinstatement of ethanol seeking presumably through CeA and BNST actions [99].
Lastly, additional regions that have been implicated in ethanol seeking using self-administra‐
tion procedures include the dorsomedial striatum [100, 101], medial prefrontal cortex (mPFC)
[75], prelimbic cortex, and VTA [102]. Importantly, the VTA, which is the chief source of DA
input to NAc, amygdala, and cortical regions, has been shown to be explicitly involved in
context- and cue-induced ethanol seeking [103–105]. Overall, self-administration studies have
been important in identifying several key neural substrates involved in ethanol-seeking
behavior. Several of these structures have also been implicated in cue-induced ethanol seeking
through ethanol-induced CPP procedures and thus are discussed in the next section.
5.2. Findings from ethanol CPP studies
Studies on the neural mechanism of ethanol CPP can be grouped into several categories that
include acquisition, expression, extinction, and reinstatement. Acquisition studies are those
that assess the development of ethanol place preference. These typically include procedures
where manipulations occurred during the conditioning or training phase, where animals learn
to associate contextual cues with ethanol reward. Conversely, expression studies involve
manipulations that occur after the conditioning phase and before preference testing. Expres‐
sion studies, in particular, are useful in assessing ethanol-seeking behavior and conditioned
reward. Below, findings from each of these types of ethanol CPP studies are discussed. Of note,
relatively few laboratories study the primary and conditioned rewarding properties of ethanol
using a CPP procedure. This is partly due to the difficult and unreliable nature of ethanol place
conditioning in rats [21, 106] and the relatively weak ethanol CPP obtained with commonly
used inbred mouse strains, such as C57BL/6J [107, 108]. In view of this, many of the studies
described below have used male DBA/2J mice. This inbred strain will rapidly and reliably
develop and ethanol CPP, even with a minimal amount of conditioning sessions [34, 36, 108].
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self-administration studies, the inactivation of the BLA has been shown to reduce context-
induced renewal of previously extinguished ethanol seeking [95]. The involvement of the BLA
in ethanol seeking may involve a glutamatergic mechanism, as intra-BLA ionotropic glutamate
receptor antagonism reduced the expression of ethanol seeking elicited by a discrete cue and
invigorated by an ethanol-associated context [96]. Notably, the excitatory transmission from
the amygdala to the NAc is believed to underlie reward seeking and suggests that an amyg‐
dala-NAc circuit may be involved in the expression of reward-seeking behavior. For example,
the optical stimulation of BLA glutamate to NAc has been shown to be reinforcing, as mice
worked to earn additional stimulation of BLA-NAc synaptic inputs [97]. Conversely, the
inhibition of BLA-NAc inputs reduced cue-induced responding for sucrose [97]. In addition,
pharmacological disconnection has revealed that an amygdala-NAc interaction underlies a
stimulus-controlled expression or maintenance of cocaine seeking [59].
The CeA and BNST have generally been implicated in stress-induced ethanol-seeking rein‐
statement but may also play a role in cue-induced ethanol reinstatement. For instance, intra-
CeA but not intra-BLA infusion of mifepristone, a glucocorticoid receptor antagonist, has been
reported to suppress reinstated ethanol seeking induced by the pharmacological stressor
yohimbine [98]. Activation of group II metabotropic glutamate receptors blocks stress- and
cue-induced reinstatement of ethanol seeking presumably through CeA and BNST actions [99].
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tion procedures include the dorsomedial striatum [100, 101], medial prefrontal cortex (mPFC)
[75], prelimbic cortex, and VTA [102]. Importantly, the VTA, which is the chief source of DA
input to NAc, amygdala, and cortical regions, has been shown to be explicitly involved in
context- and cue-induced ethanol seeking [103–105]. Overall, self-administration studies have
been important in identifying several key neural substrates involved in ethanol-seeking
behavior. Several of these structures have also been implicated in cue-induced ethanol seeking
through ethanol-induced CPP procedures and thus are discussed in the next section.
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to associate contextual cues with ethanol reward. Conversely, expression studies involve
manipulations that occur after the conditioning phase and before preference testing. Expres‐
sion studies, in particular, are useful in assessing ethanol-seeking behavior and conditioned
reward. Below, findings from each of these types of ethanol CPP studies are discussed. Of note,
relatively few laboratories study the primary and conditioned rewarding properties of ethanol
using a CPP procedure. This is partly due to the difficult and unreliable nature of ethanol place
conditioning in rats [21, 106] and the relatively weak ethanol CPP obtained with commonly
used inbred mouse strains, such as C57BL/6J [107, 108]. In view of this, many of the studies
described below have used male DBA/2J mice. This inbred strain will rapidly and reliably
develop and ethanol CPP, even with a minimal amount of conditioning sessions [34, 36, 108].
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In this section, we provide an overview of studies that have directly examined the neural areas
underlying the acquisition and expression of ethanol place preference.
5.2.1. Acquisition
As with self-administration studies, the NAc and amygdala are the two most evaluated regions
in terms of their involvement in ethanol CPP acquisition. Previously, the involvement of the
NAc in ethanol place preference acquisition has been investigated. In one study, bilateral
electrolytic lesions of the NAc before CPP training disrupted the acquisition of CPP [109]. In
a later study, bilateral NAc infusions of the D1-like receptor antagonist SCH-23390 disrupted
the development of ethanol CPP [110]. This finding is similar to a finding reported in rats
showing that nonselective DA antagonism prevented CPP induced by intracerebroventricular
(icv) infusions of ethanol [111]. Combined, these studies indicate that the NAc is necessary for
establishing associative relationships between ethanol reward and environmental cues likely
through a DA D1-like receptor-dependent mechanism. Other work has looked at the role of
the amygdala in ethanol CPP acquisition [109]. Using electrolytic lesions, the amygdala was
ablated bilaterally before CPP training. Amygdala lesions disrupted acquisition (and/or
expression) of ethanol place preference, suggesting that this region is also involved in ethanol
cue learning.
Together, these findings demonstrate that these structures downstream the VTA are necessary
for the development of ethanol CPP. Moreover, NAc involvement in ethanol CPP is directly
attributed to dopaminergic innervation, as activity at D1-like receptors in this region is
necessary for acquisition. One consideration of these results is that acquisition studies
involving microinjections can be problematic, as the additional handling required to focally
administer a drug can interfere with ethanol CPP [110]. Although they do not require added
handling prior, lesions are also problematic when administered preconditioning, as it unclear
whether they affected the acquisition or expression phase.
5.2.2. Expression
Over the last decade, studies have investigated the involvement of several brain areas in
ethanol place preference expression. These include the VTA, NAc, amygdala, and anterior
cingulate cortex (ACC). Each of these structures is thought to be involved in reward and
motivation partly through DA mechanisms, and as such, each is part of a broader mesocorti‐
colimbic DA system.
Although VTA DA cells are initially activated by rewarding stimuli, this activation diminishes
over time with repeated reward exposures and subsequent learning [112]. Eventually, DA cells
are no longer activated by the reward itself and instead become robustly activated by envi‐
ronmental stimuli that have become associated with the reward and predict its delivery [113,
114]. Thus, the involvement of this conditioned DA response in ethanol CPP expression can
be supported by studies focusing on the VTA or downstream sites as are described below.
One pharmacological microinjection study separately infused the nonselective opioid receptor
antagonist methylnaloxonium and the GABAB receptor agonist baclofen into the VTA to assess
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the participation of the VTA in ethanol CPP expression. Methylnaloxonium decreased the
magnitude of ethanol CPP, whereas baclofen blocked preference expression entirely. These
findings suggested that the VTA activity is necessary for the expression of ethanol place
preference. Moreover, GABAergic and opioidergic activity appear to underlie the involvement
of the VTA in ethanol CPP expression, presumably through the local modulation of DA cell
activity.
Although involvement of the NAc in ethanol place preference acquisition is clear, its involve‐
ment in expression is more complicated. In early work, an intra-NAc infusion of methylna‐
loxonium failed to impact ethanol preference expression, suggesting a lack of NAc opioid
receptor involvement in the conditioned ethanol reward [115]. A later study directed bilateral
electrolytic lesions at the NAc after ethanol CPP conditioning and before testing to isolate the
involvement of this structure in expression [109]. Overall, lesions made at this time point did
not affect ethanol place preference, suggesting that the NAc may not be critical in ethanol CPP
expression.
However, additional pharmacological procedures have shown a more specific role for the NAc
in CPP expression. In one study, intra-NAc antagonism of D1- and D2-like receptors prevented
the expression of CPP induced by icv ethanol [111]. In another study, NAc DA (D1- and D2-
like) and glutamate (NMDA) receptors were blocked during the CPP expression test using
either flupenthixol or AP-5, respectively [116]. Although DA receptor antagonism did not
affect ethanol place preference, NMDA receptor antagonism reduced it, suggesting that the
involvement of the NAc in expression is specific to activity at NMDA receptors. This effect
was reproduced in another study using only unilaterally administered AP5, further indicating
the importance of NAc NMDA receptor involvement in ethanol place preference expression
[60]. Notably, this study was designed to examine glutamate input to NAc from amygdala.
Although findings appeared to demonstrate that amygdala disconnection from NAc blocked
ethanol CPP expression, reduced CPP in mice unilaterally infused with AP5 in NAc prevented
this interpretation. Overall, these findings have established a role for NAc NMDA, but not DA
receptors, in ethanol place preference expression and suggest that glutamatergic input from
amygdala may also be involved. Although DA input from VTA to NAc is a hypothesized
mechanism underlying drug seeking, these results suggest that it does not underlie ethanol
seeking, at least as indexed by CPP. Finally, these studies serve to demonstrate that manipu‐
lations more selective than global inactivation or deletion of a structure may be necessary to
appropriately gauge that the importance of structure in behavior.
Accordingly, the role of the amygdala in ethanol CPP expression has also been addressed. Like
lesions made before conditioning, the bilateral electrolytic lesion of the amygdala made before
the test phase blocked ethanol place preference expression [109]. In addition, when bilaterally
infused into the amygdala, the D1- and D2-like DA receptor agonist flupenthixol blocked
ethanol CPP expression [116]. Together, these results illustrate the role of the amygdala in
ethanol-seeking behavior and indicate the importance of dopaminergic input to this structure
for ethanol CPP expression.
The BNST also has a role in modulating the expression of ethanol reward. Exposure to ethanol
causes changes in glutamate synaptic plasticity [117], increases extracellular DA levels in the
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involvement of this structure in expression [109]. Overall, lesions made at this time point did
not affect ethanol place preference, suggesting that the NAc may not be critical in ethanol CPP
expression.
However, additional pharmacological procedures have shown a more specific role for the NAc
in CPP expression. In one study, intra-NAc antagonism of D1- and D2-like receptors prevented
the expression of CPP induced by icv ethanol [111]. In another study, NAc DA (D1- and D2-
like) and glutamate (NMDA) receptors were blocked during the CPP expression test using
either flupenthixol or AP-5, respectively [116]. Although DA receptor antagonism did not
affect ethanol place preference, NMDA receptor antagonism reduced it, suggesting that the
involvement of the NAc in expression is specific to activity at NMDA receptors. This effect
was reproduced in another study using only unilaterally administered AP5, further indicating
the importance of NAc NMDA receptor involvement in ethanol place preference expression
[60]. Notably, this study was designed to examine glutamate input to NAc from amygdala.
Although findings appeared to demonstrate that amygdala disconnection from NAc blocked
ethanol CPP expression, reduced CPP in mice unilaterally infused with AP5 in NAc prevented
this interpretation. Overall, these findings have established a role for NAc NMDA, but not DA
receptors, in ethanol place preference expression and suggest that glutamatergic input from
amygdala may also be involved. Although DA input from VTA to NAc is a hypothesized
mechanism underlying drug seeking, these results suggest that it does not underlie ethanol
seeking, at least as indexed by CPP. Finally, these studies serve to demonstrate that manipu‐
lations more selective than global inactivation or deletion of a structure may be necessary to
appropriately gauge that the importance of structure in behavior.
Accordingly, the role of the amygdala in ethanol CPP expression has also been addressed. Like
lesions made before conditioning, the bilateral electrolytic lesion of the amygdala made before
the test phase blocked ethanol place preference expression [109]. In addition, when bilaterally
infused into the amygdala, the D1- and D2-like DA receptor agonist flupenthixol blocked
ethanol CPP expression [116]. Together, these results illustrate the role of the amygdala in
ethanol-seeking behavior and indicate the importance of dopaminergic input to this structure
for ethanol CPP expression.
The BNST also has a role in modulating the expression of ethanol reward. Exposure to ethanol
causes changes in glutamate synaptic plasticity [117], increases extracellular DA levels in the
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BNST [118], and activates BNST cells [119]. In particular, the inhibition of the BNST during
CPP expression using electrolytic lesions, coinfusion of GABAA and GABAB receptor agonists
muscimol and baclofen, and activation of inhibitory DREADDs (hM4Di-DREADD) lead to a
loss or reduction of the expression of ethanol CPP. All of these studies suggest the importance
of the BNST to ethanol seeking.
Finally, ACC involvement in expression was assessed by bilaterally infusing the nonspecific
opioid receptor antagonist methylnaloxonium into the ACC before the ethanol CPP test [120].
The intra-ACC infusion of methylnaloxonium disrupted ethanol place preference expression,
reducing its magnitude at the lowest dose and abolishing it at the highest dose. Hence, the
ACC appears to modulate ethanol CPP expression through an opioidergic mechanism.
In summary, findings from expression studies have demonstrated that the VTA, NAc,
amygdala, BNST, and ACC are all structures involved in ethanol place preference expression.
Infusion of a mixed opioid receptor antagonist into VTA and ACC but not NAc interfered with
ethanol CPP expression. Similarly, lesions and mixed DA receptor antagonism disrupted
expression when targeted to the amygdala and not NAc. Involvement of the NAc in ethanol
CPP expression appeared to be confined to activity NMDA receptors only, suggesting that a
more explicit neurochemical mechanism underlies its involvement in ethanol place preference
expression.
5.2.3. Extinction and reinstatement
Unlike the acquisition and expression of ethanol CPP, the neural correlates of extinction of
ethanol CPP is relatively understudied. The only region consistently studied for its role in
ethanol CPP is the mPFC.
The mPFC is known to be involved in the acquisition and extinction of Pavlovian conditioned
fear and drug memories [121]; thus, it is not surprising that disruption of its activity impairs
the extinction of ethanol CPP. Several studies found that lesions or inhibition of the mPFC, but
not the ACC, following acquisition blocks the extinction of CPP [122, 123]. These studies
suggest the importance of this mPFC in the formation of inhibitory ethanol seeking memories.
Additionally, one study links the NAc core with extinction of ethanol seeking. Lesions of the
NAc core were found to have no effect on the expression of ethanol CPP but caused a rapid
loss of responding during extinction [109], which suggest that the NAc core is associated with
inhibitory ethanol memory, but further research will be needed to confirm the role of the NAc
in extinction.
Like extinction, the brain regions involved in the reinstatement of ethanol CPP are not well
studied, but there are several studies that implicate particular brain regions. One such study
found an increase in c-Fos activity in the BLA of rats following cued reinstatement of ethanol
seeking in a discriminative stimulus operant paradigm [75]. Although this is not a direct proof
of the necessity of the BLA in ethanol seeking in CPP, another study found that the direct
manipulation of the BLA alters cued reinstatement of cocaine seeking [59]. Together, these
studies suggest the importance of the BLA in ethanol reinstatement and likely in the reinstate‐
ment of ethanol CPP. Other regions, such as the VTA, amygdala, and BNST, are likely involved
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in the extinction and reinstatement of ethanol CPP, as they are important for the extinction
and reinstatement of CPP of other addictive substances. Investigating the involvement of these
regions in extinction and reinstatement of ethanol CPP will be an important step for under‐
standing the circuitry of relapse.
5.3. Summary
In summary, these studies show the importance of several brain regions heavily implicated in
drug reward to ethanol seeking as well. Most of these studies evaluated the structures situated
downstream the VTA that have been implicated in drug seeking based on their efferent
dopaminergic input. In addition to these studies demonstrating that downstream sites are
involved, findings from Bechtholt and Cunningham [115] further illustrate the importance of
the VTA in ethanol-seeking behavior. As opioid receptors are situated presynaptically on local
GABAergic inputs to DA cells, the authors hypothesized that methylnaloxonium disinhibited
VTA GABAergic interneurons. This likely inhibited VTA DA activity, thereby reducing
ethanol place preference expression. Conversely, baclofen presumably reduced CPP by acting
directly on VTA DA cells, as they express GABAB receptors. Thus, the VTA is a critical structure
for drug and, specifically, ethanol cue associations. Although these findings and proposed
mechanisms underscore the importance of VTA DA in ethanol CPP expression, they provide
little information on the inputs to the VTA that modulate DA cell activity. Thus, the origins
and neurochemical sources of VTA DA cell innervation involved in ethanol-seeking behavior
remain unknown. Accordingly, the next section discusses the involvement of VTA input in
reward and identifies several inputs that may be of importance and deserve further study for
their role in ethanol CPP.
5.4. Inputs to the VTA
Excitatory (glutamatergic) afferents of the VTA arise from virtually all structures to which this
region projects, with the exception of the NAc and lateral septum (LS), which provide strong
GABAergic inputs [124]. This suggests that there is a broad network of excitatory reciprocal
projections to and from the VTA, with much of the glutamatergic input to VTA neurons arising
from subcortical regions that include but are not limited to amygdala, mesopontine nuclei,
lateral habenula, and hypothalamus [125]. Although this reciprocal flow of neurotransmission
is also found between the VTA and cortex, the PFC serves as the only cortical source of
glutamate to the VTA [126]. Importantly, these glutamatergic afferents play a critical role in
regulating VTA neuron firing. Specifically, glutamatergic input to the VTA appears to be
critical for behaviorally relevant burst firing of VTA DA neurons [127]. The resulting phasic
release of DA from the VTA is intimately associated with goal-directed behaviors and drug
reward [128].
In addition to the contemporary methods described earlier, recent advances in immunohisto‐
logical techniques have facilitated a more precise mapping of afferent and efferent projections
of the VTA. As a result, an updated view on the role of broad neural circuit activity (including
that of the VTA) in relation to behavior has been formed. In this current view, the net result of
cell-specific projections onto cell-specific targets is accounted for and the subsequent plotting
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GABAergic inputs to DA cells, the authors hypothesized that methylnaloxonium disinhibited
VTA GABAergic interneurons. This likely inhibited VTA DA activity, thereby reducing
ethanol place preference expression. Conversely, baclofen presumably reduced CPP by acting
directly on VTA DA cells, as they express GABAB receptors. Thus, the VTA is a critical structure
for drug and, specifically, ethanol cue associations. Although these findings and proposed
mechanisms underscore the importance of VTA DA in ethanol CPP expression, they provide
little information on the inputs to the VTA that modulate DA cell activity. Thus, the origins
and neurochemical sources of VTA DA cell innervation involved in ethanol-seeking behavior
remain unknown. Accordingly, the next section discusses the involvement of VTA input in
reward and identifies several inputs that may be of importance and deserve further study for
their role in ethanol CPP.
5.4. Inputs to the VTA
Excitatory (glutamatergic) afferents of the VTA arise from virtually all structures to which this
region projects, with the exception of the NAc and lateral septum (LS), which provide strong
GABAergic inputs [124]. This suggests that there is a broad network of excitatory reciprocal
projections to and from the VTA, with much of the glutamatergic input to VTA neurons arising
from subcortical regions that include but are not limited to amygdala, mesopontine nuclei,
lateral habenula, and hypothalamus [125]. Although this reciprocal flow of neurotransmission
is also found between the VTA and cortex, the PFC serves as the only cortical source of
glutamate to the VTA [126]. Importantly, these glutamatergic afferents play a critical role in
regulating VTA neuron firing. Specifically, glutamatergic input to the VTA appears to be
critical for behaviorally relevant burst firing of VTA DA neurons [127]. The resulting phasic
release of DA from the VTA is intimately associated with goal-directed behaviors and drug
reward [128].
In addition to the contemporary methods described earlier, recent advances in immunohisto‐
logical techniques have facilitated a more precise mapping of afferent and efferent projections
of the VTA. As a result, an updated view on the role of broad neural circuit activity (including
that of the VTA) in relation to behavior has been formed. In this current view, the net result of
cell-specific projections onto cell-specific targets is accounted for and the subsequent plotting
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of these circuits suggests a complex topographical map. This map indicates the existence of an
intricate network of connectivity designed to tightly regulate the activity of neuronal ensem‐
bles, which in turn orchestrate complex and divergent behaviors, even from within the same
circuits. In the VTA specifically, not all inputs are alike in their behavioral consequences. Here,
DA activity is governed by a complex network of cell-type-specific neuron-to-neuron connec‐
tions, the net effect of which can result in vastly different motivational states [129, 130].
Several lines of evidence suggest the importance of monosynaptic inputs to VTA DA neurons
(one-step inputs) in governing motivational behaviors. For example, investigation of the
laterodorsal tegmental (LDT) nucleus has revealed that 80% of its glutamatergic afferents
synapse onto VTA DA neurons directly [131]. The importance of these glutamatergic inputs
have been corroborated through electrophysiological analysis, which has shown that this
region is essential to VTA DA cell burst firing [132]. Moreover, in vivo stimulation of LDT
glutamate afferents has been reported to selectively terminate on and stimulate a distinct
population of VTA DA neurons, which thereby generate reward [130].
The BNST is another region upstream the VTA that has been identified as critically involved
in regulating the activity of DA cell activity [133–135]. Specifically, the BNST positively
modulates VTA DA activity putatively through two primary and distinct mechanisms: (1) a
direct glutamate projection to VTA DA and (2) a direct GABA projection to VTA GABA [129,
135–137]. Of note, more recent evidence derived from studies using more advanced and
selective tools suggests that a BNST GABA input to VTA GABA is the predominant source of
the modulation of the BNST of the VTA [129]. Of relevance, behavior in rodents has demon‐
strated that the BNST underlies cue-elicited drug seeking. For example, transient inactivation
of the BNST has been shown to prevent cue-induced reinstatement of cocaine seeking [138].
Direct projections from BNST to VTA appear to be important for cocaine-related behaviors.
For example, disconnection of the BNST-VTA pathway has been shown to reduce expression
of cocaine CPP [62], but the role of that projection in ethanol seeking still remains unknown
and further study of this projection and other VTA inputs will advance our understanding of
the larger neural network driving ethanol seeking.
6. Conclusion
Alcohol is a widely used legal intoxicant that produces a huge financial toll ($223.5 billion in
2006 alone) on the United States (Centers for Disease Control and Prevention, 2014) due to the
workplace, healthcare, legal, and criminal consequences of excessive consumption of alcohol.
Despite the prevalent societal knowledge of the detriment of excessive alcohol use, AUDs
continue to be a common disorder that is difficult to treat. The primary challenge of providing
lasting treatments for AUDs is the high propensity for those with AUDs to relapse into alcohol
use. Relapse is often caused when a cue associated with alcohol (i.e., a bar, alcohol advertise‐
ment) or alcohol itself is presented to a person with an AUD. This cue recalls the associative
effects of ethanol and induces a craving and an internal drive to seek and consume alcohol.
Thus, it is critical to understand how alcohol cue associations are formed and maintained
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despite receiving treatment for alcohol abuse. This chapter has outlined the animal models
that are being used by preclinical researchers to better understand the formation, expression,
extinction, and reinstatement (relapse) of alcohol cue associations that promote ethanol
seeking and has summarized each of their advantages and disadvantages. Of particular use is
the CPP paradigm. CPP allows the experimenter to separate distinct phases of acquiring,
expressing, extinguishing, and reexpressing conditioned ethanol seeking and thus can easily
study the neural mechanisms involved in each. This chapter also presented the classical and
contemporary tools that can be used separately and in conjunction to probe the exact neural
structures and circuitry involved in alcohol cues and seeking. Although classical tools have
given us the greatest insight into the neurobiology of ethanol seeking thus far, contemporary
tools have been and will allow for a much clearer and specific understanding of the structures
involved in animal models of alcohol seeking. Finally, this chapter presented evidence from
ethanol self-administration and ethanol CPP studies of the modulation of ethanol seeking by
the mesolimbic structures (VTA, NAc), the limbic system (amygdala, BNST, ACC), and cortical
structures (mPFC). Of particular importance is the VTA that sends vast dopaminergic input
to many of these structures. The challenge of future research is to identify more structures
critical for the acquisition and expression, and especially the extinction and reinstatement, of
ethanol CPP and the inputs of the VTA that modulate dopaminergic tone and thus ethanol-
seeking behavior (such as the BNST-VTA projection). A better understanding of the whole
circuit driving every aspect of ethanol seeking will improve our knowledge of AUDs and
treatment options.
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Abstract
Alcohol  dependence,  a  chronic  relapsing psychiatric  disorder,  is  a  major  cause  of
mortality and morbidity. The role of dopamine in alcohol‐induced reward as well in the
development of alcohol dependence is reviewed herein. Both preclinical and clinical
studies have suggested that alcohol activates the mesolimbic dopamine system (defined
as  a  dopamine  projection  from  the  ventral  tegmental  area  (VTA)  to  the  nucleus
accumbens  (NAc,  i.e.  ventral  striatum))  leading  to  a  euphoric  sensation.  Alcohol
dependence is characterized by a disruption in the reward‐related brain areas including
fewer dopamine D2 receptors in ventral striatum. Investigations of the underlying
dopaminergic  mechanisms  involved  during  the  development  and  maintenance  of
alcohol  dependence could identify novel  targets.  Human and rodent experimental
studies show that dopamine receptor antagonists, agonists and partial agonists as well
as dopamine stabilizers influencing dopamine transmission,  alter  alcohol‐mediated
behaviours  and  thus  may  be  potential  treatment  targets  for  alcohol  dependence.
Although there exists promising preclinical results, the majority of placebo‐controlled
randomized clinical trials with traditional dopamine antagonists and agonists have so
far have been discouraging. Furthermore, the severe side-effect profiles of many of these
compounds  may limit  their  clinical  use.  Newer  dopamine  agents,  such  as  partial
agonists and dopamine stabilizers, attenuate alcohol‐mediated behaviours in rodents
as well as humans. Preclinical as well as clinical studies have shown that substances
indirectly  targeting the mesolimbic  dopamine system may be potential  targets  for
attenuation of alcohol reward. Collectively, the data reviewed herein may contribute to
further understanding the complex mechanisms involved in development of alcohol
dependence  and  we  suggest  that  the  newer  dopamine  agents  as  well  as  indirect
modulators of dopamine signalling deserve to be further evaluated for treatment of
alcohol dependence.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Alcohol dependence is a chronic relapsing psychiatric disorder significantly contributing to the
global burden of disease [1] and affects about four percent of the world's population over the
age of 15 (WHO). In the fifth edition of the diagnostic and statistical manual of mental disor‐
ders (DSM), the term alcohol use disorder was introduced and grossly defined as problem
drinking that has become severe. The characteristics of this disorder include loss of control over
alcohol intake, impaired cognitive functioning, negative social consequences, physical tolerance,
withdrawal and craving for alcohol. To date, there are three medications approved by both the
European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the
treatment of alcohol dependence; disulfiram, naltrexone and acamprosate. The FDA has also
approved the use of a long‐acting injectable naltrexone. More recently, the EMA granted
authorization also for nalmefene, a compound intended for the reduction of alcohol consump‐
tion in adults with alcohol dependence (EMA 2012). Details regarding the mechanism of action
of these compounds are outside the scope of this review. In brief, the pharmacological profile
is established for disulfiram (an aldehydedehydrogenase inhibitor), naltrexone (an opioid
receptor antagonist) and nalmefene (an opioid receptor modulator), whereas the mechanism of
action of the anti‐alcohol relapse drug acamprosate is not fully understood. An indirect activation
of  mesolimbic dopamine via  accumbal  glycine receptors  and ventral  tegmental  nicotinic
acetylcholine receptors (nAChRs) appears likely [2, 3], but additional targets has been suggest‐
ed (for review see [4]). Finally, the clinical efficacy of these agents is limited [5], possibly due to
the  heterogeneous  nature  of  the  disorder  and  the  complex  neurochemical  mechanisms
underlying alcohol dependence. Thus, the need for novel and efficacious medications remains.
The mesocorticolimbic dopamine system (or the so‐called brain reward system, Figure 1) is
one of the established neurobiological systems involved during the development and main‐
tenance of alcohol dependence and thus one potential treatment target. Here, we aim to review
the animal and human data describing the role of dopamine and the mesolimbic dopamine
system during acute and chronic alcohol exposure. Finally, preclinical and clinical studies
evaluating the potential of available dopaminergic agents as well as indirect dopamine
modulators as novel medications for alcohol dependence are discussed.
1.1. The brain reward system: the mesocorticolimbic dopamine system
The mesocorticolimbic dopamine system has an established role in driving the rewarding
sensations from natural rewards such as food, sex and exercise, which are important behav‐
iours to ensure our survival [6, 7] as well as among drugs of abuse, including alcohol (for
review see [8]). The physiological importance of the mesocorticolimbic dopamine system is
highlighted by its evolutionary stability and conservation in primitive invertebrates, such as,
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flatworms, all the way up to primates, including humans. It was identified serendipitously in
the 1950s when Olds and Milner found that rats self‐administer electrical currents into certain
specific brain regions [9]. These findings were later corroborated by studies showing that rats
favoured electrical stimulation in the same specific brain regions, over natural rewards [10].
The primary neurotransmitter regulating the rewarding sensation was determined to be
dopamine [11]. Furthermore, the specific neuronal circuitries were progressively mapped with
major projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc, i.e.
the ventral striatum), the prefrontal cortex (PFC) and amygdala. Collectively, this network of
neurons was denominated the mesocorticolimbic dopamine system [12, 13]. The system was
later divided into two distinct projections [12], modulating different dopamine‐mediated
behavioural effects; the mesolimbic pathway (from the VTA to the NAc) thought to be
responsible for the rewarding and pleasurable effects of natural as well as substances of abuse
including alcohol (e.g. [14–16]), and the mesocortical pathway (from the VTA to the PFC)
believed to be responsible for the motivational and emotional effects [15]. In addition, there
are dopamine projections from the VTA to the amygdala and the hippocampus, respectively,
involved in reward associative learning and declarative memory formation [15, 17].
In healthy controls, alcohol consumption stimulates dopamine release mediating its reinforc‐
ing effects. Repeated bouts of intoxications will overtime downregulate the dopamine activity
in the mesocorticolimbic pathway, leading to an increased risk of developing alcohol depend‐
ence and other impulse control disorders. [18, 13]. It has also been hypothesized that in
vulnerable individuals (e.g. those with a family history of alcohol dependence), the proneness
Figure 1. Representative illustration of the mesocorticolimbic dopamine system in rat brain.
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to develop an addiction is higher since they are born with a reduced number of dopamine D2
receptors in mesocorticolimbic pathway, leading to the alcohol dependence [18, 13]. Further,
it has been speculated that this dopamine deficiency is responsible for driving craving and
compulsive drinking and contributes to relapse even after a period of protracted abstinence
[18, 19]. The preclinical and clinical evidence of the underlying interaction between alcohol
and the dopamine D2 receptors within the mesocorticolimbic dopamine system during the
acute as well as during chronic intake is reviewed below. The involvement of the dopamine
D1, D3, D4 and D5 receptors falls outside the scope of the present review but has previously
been reviewed elsewhere [20].
1.2. Interaction between alcohol and the mesocorticolimbic dopamine system
1.2.1. Preclinical evidence: acute alcohol exposure and dopamine
Dopamine's importance for alcohol‐induced reward was first identified in studies showing
that the catecholamine‐synthesis inhibitor, α‐methyltyrosine (an agent with the ability to
inhibit the formation of dopamine in the cytosol of terminals of dopaminergic neurons [21])
blocked alcohol‐induced euphoria, social interaction and talkativeness in humans [22] as well
as attenuated alcohol‐induced locomotor activity in rats [23]. Ex vivo and in vivo voltammetry
studies in rats found that alcohol increases the dopamine levels in NAc [24]. In addition, in
vivo microdialysis studies have since shown that systemic administration of alcohol and other
drugs of abuse, including amphetamine, cocaine, opiate and nicotine, increases the accumbal
dopamine levels in freely moving rats [25–35], strengthening the hypothesis of an association
between the rewarding or euphoric sensation and dopamine release in the NAc. This hypoth‐
esis is further supported by studies showing that drugs that are not rewarding or abused by
humans do not modify synaptic accumbal dopamine levels in rat [27]. In addition, voluntary
alcohol consumption causes a dose‐dependent [36] release of dopamine in the NAc in rat [37–
39]. Finally, intravenous administration of alcohol, as well as other drugs of abuse, increases
the firing rate of dopamine neurons in the VTA in rats [40, 41]. Further support for the role of
dopamine D2 receptors in the reinforcing effects of alcohol is given by a study showing that
dopamine receptor D2 knockout mice self‐administer less alcohol than the wild‐type mice [42].
In addition to the extensive literature showing a link between accumbal dopamine and alcohol‐
induced reinforcement, it has been shown that the pure anticipation of alcohol (i.e. without
alcohol being present) increases the release of dopamine in NAc in rodents trained to self‐
administer alcohol [43–45, 36] and that accumbal dopamine release is associated with asso‐
ciative learning, rather than exposure to the reward itself [46]. Moreover, this anticipation effect
is more noticeable in high compared to low‐alcohol‐preferring rats [47]. Studies have also
shown that the anticipation of a reward increases the firing of accumbal dopamine neurons
[41]. It should, however, be mentioned that results from studies with lesion of the mesocorti‐
colimbic dopamine pathways have shown contradicting results with both decreased [48–50]
and unaltered alcohol intake [51–56]. These inconsistent results indicate that the role of
accumbal dopamine in reinforcement is complex and highlights that the rewarding properties
of alcohol may extend beyond direct or indirect effects on dopamine, involving interactions
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with several other neurotransmitters including acetylcholine, glutamate, GABA, serotonin
(5HT), noradrenaline, taurine and opioids, as well as hormones and peptides [24, 57, 58].
To further elucidate the role of the NAc and the VTA in alcohol‐mediated dopamine regulation,
extensive rodent studies, with for example intra‐cranial alcohol infusions and electrophysio‐
logical techniques, have been conducted. With regards to the NAc, rodent studies confirm that
intra‐NAc alcohol perfusions increase the release of dopamine in the same brain region (e.g.
[59, 38, 60–62]). An effect that is suggested to be regulated via a neuronal circuitry involving
glycine receptors in the NAc as well as anterior ventral tegmental nAChR [59, 63, 64]. Inter‐
estingly, the NAc is a heterogeneous region most often divided into two distinct anatomically
and functionally different regions, that is the central core and the surrounding shell compart‐
ment [65–69] and it has been suggested that dopaminergic innervation of the NAc core is
associated with the nigrostriatal system, while that of the NAc shell is related to the mesolimbic
system [70]. Alcohol has been shown to increase the release of dopamine in NAc shell, but not
in the core [71–73]. Studies are also emerging suggesting the need for further division of this
brain region since it was demonstrated that a borderline region between the core and shell of
the NAc is the region most responsive to alcohol [74].
With regards to the VTA, both in vitro and in vivo studies show that alcohol increases the firing
of dopamine neurons in the VTA projecting to NAc [75–79, 40]. Similarly, in a situation of
synaptic transmission blockade, alcohol has been found to increase the firing of dissociated
VTA dopamine neurons [76, 77] implying that alcohol activates ventral tegmental dopamine
neurons independent of afferent signalling. Furthermore, studies with intra‐VTA alcohol
infusions highlight that different subregions within the heterogeneous VTA might have
different ability to modulate the alcohol‐induced dopamine response. Specifically, rats
voluntarily self‐administer alcohol, as well as acetaldehyde (an alcohol metabolite) into the
posterior, but not anterior, part of the VTA [80–85], indicating that alcohol is reinforcing only
within the posterior VTA. The suggestion is further supported by a study showing that intra‐
cranial infusions into the posterior VTA of the D2 agonist quinpirole (in doses that activate
local D2 autoreceptors, thereby reducing the firing rate of VTA dopamine neurons [86, 87]),
attenuates alcohol self‐administration, which can be restored when the D2 agonist is removed
or blocked with administration of a D2 antagonist [84]. In corroboration are the findings that
the sensitivity of the posterior VTA to the reinforcing effects of alcohol is enhanced in alcohol‐
preferring rats [88]. There are, however, some contradicting results indicating that these
subregion‐specific effects might be related to the administered dose of alcohol, the use of
various methods, the rat strains across the studies as well as differences in coordinates used
for local injections (within the anterior VTA). For example, it has been demonstrated that
perfusion of a low, but not a high dose of alcohol into the anterior, but not posterior part of
the VTA increased accumbal dopamine in rats [89], and a recent study indicates that additional
VTA subregions might be involved as alcohol increases the firing frequency of a subset of
dopamine neurons in the medial, but not lateral, part of the VTA [90]. It should also be noted
that in both outbreed as well as alcohol‐preferring rats, there are studies showing no influence
on the accumbal dopamine levels regardless of dose of alcohol or location in the VTA [59, 91].
Collectively, these data suggest that VTA is a heterogeneous area that differs in morphology
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and topography (for review, see [92]), and the anterior/posterior and lateral/medial part have
different functions regarding alcohol and its activation of the mesolimbic dopamine system.
1.2.2. Clinical evidence: acute alcohol consumption and dopamine
The development of positron imaging technique (PET) and the radiotracer 11C‐raclopride in
the 1990s made it possible to study in vivo dopamine function in humans. A series of human
imaging studies over the last decade have demonstrated that alcohol [93, 94] as well as other
drugs of abuse [95] increase striatal dopamine release. This is further corroborated by the
findings that self‐reported behavioural measures of stimulation, euphoria or drug wanting by
alcohol correlates with the magnitude and rate of ventral striatum dopamine release [96–98,
94, 99, 100]. These studies clearly substantiated the involvement of dopamine in the reinforcing
effects of alcohol and closely mimicked the findings of the preclinical studies.
1.2.3. Preclinical evidence: chronic alcohol exposure and dopamine
As mentioned above, it has been hypothesized that the chronic intake of alcohol induces a
dopamine deficit state in the brain reward system and that this dysfunction may drive craving
and relapse to drinking [101, 18, 19]. In outbred rodents, however, the effects on the mesolimbic
dopamine system following chronic alcohol treatment are inconsistent [102]. One possible
explanation for these discrepancies may be that most preclinical studies to‐date have used
forced alcohol administration which introduces an element of stress and artefact into the
experiment, casting doubt on the applicability to our understanding of human alcohol
dependence. In this review, we will therefore focus on studies with clear face validity to the
human condition, that is those using voluntary self‐administration.
The dopamine deficiency hypothesis is supported by a study showing decreased dopamine
receptor gene expression after several months of voluntary alcohol drinking [103]. In addition,
microdialysis studies in freely moving outbred rats show a decreased dopamine output in the
NAc, compared to age‐matched alcohol‐naïve controls, following 7 weeks [104] and 10 months
[29] of voluntary alcohol consumption. Furthermore, after 10 months of drinking, a blunted
dopamine response following a systemic alcohol challenge has been found in long‐term
drinking, compared to alcohol‐naïve rats [29]. These results indicate that long‐term drinking
attenuates the responsiveness of the system to external dopamine stimulation, in addition to
decreasing baseline levels of dopamine. It should, however, be noted that acute administration
of alcohol induces a twofold increase in dopamine output in the NAc shell in high compared
to low‐alcohol‐preferring rats [105], indicating that there might be a difference in these aspects
between outbred standard laboratory rats and inbred alcohol‐preferring rats.
The selectively inbred alcohol‐preferring and non‐alcohol‐preferring rat strains have been
extensively used to investigate the neurochemical mechanisms underlying alcohol depend‐
ence. In line with the dopamine deficiency hypothesis, the baseline accumbal dopamine levels
appear to be lower [105] and the dopamine D2 receptors in NAc are fewer [106] in high‐
preferring compared to low‐preferring rats. In fact, neurochemical data show that high‐
alcohol‐seeking behaviour is associated with 10–15% lower accumbal dopamine content
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compared with low‐alcohol‐seeking rats [107]. In addition, overexpression of accumbal
dopamine D2 receptors reduces alcohol in non‐preferring as well as high‐preferring rats [108,
109]. These results highlight that not only chronic alcohol consumption, but also genetic
factors, influence the dopaminergic response to alcohol. Furthermore, it has been suggested
that more dorsal parts of the striatum is recruited once the dependence develops [110, 111]
although until now this has been investigated only in other drugs of abuse than alcohol.
1.2.4. Clinical evidence: alcohol dependence and dopamine
As mentioned earlier, in vulnerable individuals (related to genetic and environmental factors)
as well as healthy individuals, repeated administration of alcohol can lead to perturbations in
the dopamine‐regulated circuitry, leading to the development of alcohol dependence. For
instance, a human laboratory study has demonstrated that intravenous administration of
alcohol causes an increase in dopamine in the ventral striatum in non‐treatment‐seeking
alcohol‐dependent individuals [112]. Further, imaging studies have shown that the number of
dopamine D2 receptors is lower in individuals with alcohol or drug dependence, compared
to healthy controls [113, 114] and there is considerable evidence that the low levels of D2
receptors levels contribute to the excessive urges/craving for alcohol and subsequently to
relapse [115]. In addition, decreased dopamine transmission in the mesolimbic regions, such
as the ventral striatum, likely contributes to anhedonia and decreased reward sensitivity in
alcohol‐dependent individuals. Further, in abstinent high‐risk drinkers as well as alcohol‐
dependent individuals, alcohol‐associated cues activate the ventral striatum, which further
contribute to the high risk of relapse in these individuals [116, 117].
A recent PET study [118] demonstrated for the first time that, in addition to the ventral
striatum, the long‐term consumption of alcohol leads to lowered dopamine levels also in
prefrontal cortical structures. These findings support the extensive clinical findings demon‐
strating that alcohol‐dependent individuals have significant impairments in executive
functions such as working memory, impulsivity and decision‐making; functions governed by
the cortical brain structures. The fact that there is also less dopamine in the prefrontal cortex,
governing these executive functions, is of significance as it could impair the alcohol‐dependent
individual's capacity to utilize behavioural treatment strategies, which are critical to relapse
prevention.
Collectively, these data indicate that dopamine plays a central role in reward, motivation and
planning. Given the relevance of dopamine in the chronic phase of alcohol use and in the
development of alcohol dependence, there is considerable interest in evaluating medications
that can specifically modify dopamine, thereby serving as potential pharmacotherapies to treat
alcohol dependence.
1.2.5. Human genetic evidence: alcohol dependence and dopamine
The preclinical and clinical evidence presented above suggest that dopamine regulates alcohol‐
mediated behaviours. Numerous human genetic studies have therefore investigated associa‐
tions between alcohol dependence and genes related to dopamine function. As early as the
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1990s, a polymorphism in the dopamine D2 receptor gene was found to be associated with
alcohol dependence [119]. Several studies have since then tried to replicate this association,
but the outcome has been inconsistent (for review, see [120]). Although associations have been
found between polymorphism of the dopamine D4 gene and alcohol craving, binge drinking
as well as novelty seeking (which is a known personality trait important for drinking behaviour
in patients with alcohol dependence) [121–123], no positive associations between dopamine
D4 receptor genes and alcohol dependence per se have been established (for review, see [120]).
Released dopamine into the synaptic cleft is eliminated by catechol‐O‐methyltransferase
(COMT) metabolism as well as reuptake by dopamine transporter (DAT). Studies have shown
that DAT polymorphism is associated with alcohol withdrawal symptoms as well as with
paternal history of alcohol dependence rather than alcohol dependence per se [124, 125]. The
risk of developing late onset alcohol dependence (especially in males) as well as the co‐
dependence of alcohol and nicotine is associated with polymorphism in COMT [126–128].
Albeit cumulative evidence shows association between polymorphisms in various dopamine‐
related genes and behaviours associated with alcohol dependence, the findings are inconclu‐
sive and therefore, the conclusions from these human genetic studies are limited and remain
controversial.
2. The dopamine system: a potential treatment target for alcohol
dependence
2.1. Dopamine D2 receptor antagonists
Traditional dopamine D2 receptor antagonists (so‐called neuroleptics, first‐generation
antipsychotic drugs or typical antipsychotic drugs) are primary used for the treatment of
psychosis, schizophrenia and bipolar disorder [11] based on their ability to counteract a
heightened dopamine activity in the brain. It should also be mentioned that these typical
antipsychotic agents might have effects on other receptors including dopamine D1, 5HT2 and
alpha1 receptors. As reviewed above, the acute reinforcing effects of addictive drugs, including
alcohol, could be mediated by increased dopamine release in the NAc, activating dopamine
D2 receptors [71, 27, 30]. Thus, traditional dopamine D2 receptor antagonists have been
evaluated as potential treatment targets for alcohol dependence based on the hypothesis that
they are expected to block the rewarding effects of alcohol.
2.1.1. Preclinical evidence for the use of dopamine D2 receptor antagonists to attenuate alcohol‐mediated
behaviours
The hypothesis that dopamine D2 receptor antagonists have the ability to attenuate alcohol‐
mediated behaviours is supported by rodent studies showing that both haloperidol and
pimozide attenuate alcohol‐induced locomotor stimulation [129] and that these compounds
as well as fluphenazine, decrease alcohol‐seeking behaviour and operant self‐administration
[130–132]. These findings are further substantiated by the data showing that peripheral
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administration of the dopamine D2 receptor antagonist fluphenazine decreased responding
for alcohol, without affecting responses for water in rats [133]. In addition, haloperiodol dose‐
dependently reduced operant self‐administration of alcohol in rats [134] as well as decreased
alcohol presentations in the self‐administration model [132]. Supportively, low doses of
dopamine D2 receptor antagonists inhibit the rewarding properties of other drugs of abuse in
rats [135, 42, 136]. It should be noted that some studies have shown contradicting effects [137–
139], indicating that the role of dopamine in alcohol‐mediated behaviours in complex.
Studies elucidating the underlying mechanism of action of the complex dopamine–alcohol
interaction have been conducted. Experiments exploring the role of accumbal dopamine
receptors in alcohol‐mediated behaviours showed that intra‐NAc administration of first‐
generation antipsychotic drugs including fluphenazine or raclopride decreased alcohol self‐
administration in rats [133] as well as the total responding for alcohol [140] and reduced the
total responding by decreasing time course and response rate for alcohol self‐administration
in rats [141]. On the other hand, local administration of the dopamine D2 receptor antagonist,
sulpiride, into the anterior VTA did not alter alcohol nor sucrose intake in high‐alcohol‐
preferring rats [142]. It should also be mentioned that accumbal dopamine D1 receptor might
regulate alcohol‐induced reward. Indeed, intra‐NAc infusion of a dopamine D1 receptor
antagonist (SCH23390 or ecopipam) decreased alcohol‐mediated behaviours in rats [141, 143].
Collectively, these data indicate that the dopamine D2 as well as D1 receptors within the NAc
regulate alcohol reinforcement.
2.1.2. Clinical evidence for the use of dopamine D2 antagonists for the treatment of alcohol dependence
Based on the preclinical evidence of a reduction in alcohol consumption via blockade of
dopamine D2 receptors, the potential of dopamine D2 antagonists as a pharmacotherapy for
alcohol dependence has been investigated in clinical populations.
Dopamine D2 receptor antagonists have been studied in human laboratory studies involving
alcohol administration in dependent individuals and found to be effective in reducing craving.
In a laboratory study involving 16 individuals with alcohol abuse and/or dependence, the D2
antagonist haloperidol was compared to placebo. The results of this small study demonstrated
that haloperidol significantly decreased measures of craving, reduced impulsivity, and the
amounts of alcohol ingested [144]. The dopamine D2 antagonist flupenthixol has also been
evaluated in a clinical study of 281 recently detoxified alcohol‐dependent patients [145]. The
results demonstrated that treatment with the depot formulation of flupenthixol led to a
significant increase in rates of relapse (85.2% on active treatment compared with 62.5% on
placebo). A major concern with flupenthixol is results from studies demonstrating an increase
in the risk of relapse in rodents as well as humans [146], an effect preferentially observed in
males [147]. Overall, the clinical utility of atypical antipsychotics has shown to be of some
benefit in patients suffering from alcohol dependence and a concomitant psychiatric diagnosis
including schizophrenia [148, 149]. A major challenge, however, with the first‐generation
antipsychotic drugs is their severe side effect profile including extrapyramidal symptoms,
sedation, cognitive impairment, neuroleptic malignant syndrome, which have limited their
use in research and in turn its clinical utility in treating alcohol dependence [150, 151].
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2.2. Atypical dopamine D2 receptor antagonists
The newer generations of dopamine D2 receptor antagonists (so‐called atypical antipsychotics
or second generation antipsychotic drugs) have a broader pharmacological profile since they
target several dopamine receptors, including D1, D3, D4 and D5, as well as various other
neurotransmitter systems including 5‐HT, muscarinic acetylcholine and histamine receptors.
These atypical antipsychotics have a significantly improved side effect profile compared to the
traditional first generation of dopamine D2 antagonists. Thus, there has been a renewed
interest in evaluating these medications as potential treatment for alcohol dependence with
the assumption that the atypical antipsychotics might reduce craving and consumption of
alcohol without the substantial adverse effect profile [152]. Furthermore, they are clinically
used for alcohol‐dependent patients during the acute detoxification phase to prevent agitation,
hallucinations and delirium tremens [153].
2.2.1. Preclinical evidence for the use of atypical dopamine D2 receptor antagonists (i.e. atypical
antipsychotics) to attenuate alcohol‐mediated behaviours
The hypothesis that atypical antipsychotics may decrease alcohol intake are supported by two
separate studies with risperidone and olanzapine in high‐alcohol‐preferring rats [154, 155].
Furthermore, remoxipride decreases the number of alcohol presentations per session in rats
by inducing an early termination of the alcohol‐drinking bout during the self‐administration
session [132] and repeated systemic administration of paliperidone decreased the acquisition
of alcohol consumption in high‐alcohol‐preferring P rats [156]. In addition, a recent study,
comparing the effect of the atypical antipsychotic drug clozapine to that of the traditional
dopamine D2 receptor antagonist haloperidol, showed that clozapine but not haloperidol
attenuated the initiation of alcohol drinking and development of alcohol preference in high‐
alcohol‐preferring rats [157]. Neither compound had an effect on maintenance of chronic
alcohol drinking [157], which is in line with a study showing that clozapine did not reduce
alcohol consumption in alcohol‐preferring rats [155].
2.2.2. Clinical evidence for the use of atypical dopamine D2 antagonists for the treatment of alcohol
dependence
The atypical antipsychotic tiapride has been found to be efficacious in reducing alcohol
drinking two placebo‐controlled clinical trials [158, 159]. A small study in twenty alcohol‐
dependent individuals, with significant levels of anxiety or depression, showed that tiapride
treatment causes a reduced alcohol intake as well as prolonged periods of abstinence [158]. In
the largest of the studies [159], 100 recently abstinent alcohol‐dependent patients were
randomized to 300 mg of tiapride or placebo for a 3‐month treatment period. This study
showed that patients receiving medication had higher rates of abstinence and improved on an
array of health care outcomes.
Another atypical antipsychotic drug, quetiapine, has been evaluated in a case study [160] and
an open‐label study [161] in patients with alcohol dependence and comorbid psychiatric
diagnosis. Both studies demonstrated that quetiapine was well tolerated and in the latter study,
the medication not only reduced alcohol consumption and overall psychiatric symptom
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intensity but also significantly reduced craving. A double‐blind placebo‐controlled study by
Kampman and colleagues evaluated the effect of quetiapine and found that the medication
was well tolerated and clinically effective in reducing drinking [162]. The effect of medication
was found to be stronger in individuals with a more severe disease phenotype. It should,
however, be noted that more recent clinical trials using the extended release formulation of
quetiapine [163, 164] failed to replicate the clinical findings of the previous studies.
In a retrospective study of 151 schizophrenic patients with alcohol dependence, 36 patients
received the atypical antipsychotic medication clozapine. At the 6‐month follow‐up, 79% of
the patients on clozapine were in remission from a diagnosis of alcohol dependence, while
approximately 33% of those not taking clozapine were in remission [148].
Olanzapine, another example of a second generation of antipsychotics, has been evaluated in
a human cue‐craving study, where the compound reduced the urge to drink post‐exposure to
alcohol cues, without affecting the rewarding effects of alcohol following the consumption of
a priming dose of alcohol [152]. Based on this clinical finding and the knowledge that olanza‐
pine also has a high affinity for the D4 receptors, it was hypothesized whether the dopamine
receptor D4 gene maybe involved in meditating its clinical effects. In a subsequent pharma‐
cogenetic, 12‐weeks placebo‐controlled trial in heavy social drinker olanzapine was evaluated
in 67 individuals [165] showing that those individuals with the dopamine D4 receptor 7 repeat
allele (a polymorphism of the dopamine D4 receptor gene) reported a greater reduction in cue‐
induced craving and alcohol consumption compared to individuals with the short allele. These
data are supported by the findings that olanzapine reduces craving for alcohol at baseline for
both individuals with the DRD4 shorter and longer allele, but only reduces craving after
exposure to alcohol cues and after a priming dose of alcohol for individuals with the DRD4
longer allele [166]. Overall, the results from studies evaluating olanzapine as a potential
medication for alcohol dependence have provided evidence of a marginal effect restricted to
a sub population of patients (with the longer dopamine D4 receptor allele).
In conclusion, although some clinical trials with atypical antipsychotics in alcohol‐dependent
patients show promising results, a recent systemic review of atypical antipsychotics, a
heterogeneous class of drugs [167] has demonstrated inconsistent clinical response across
studies on these compounds effects on alcohol‐related parameters. The clinical use of atypical
antipyschotics for treatment of alcohol dependence might also be limited by their side effects
profile, even though it is substantially improved compared to the typical antipsychotics (for
review see [168]).
2.3. Dopamine D2 agonists
As described previously, in vivo microdialysis studies rodent and imaging studies in individ‐
uals with alcohol dependence have demonstrated that chronic exposure to alcohol induce a
dopamine deficit state. Thus, it is logical to hypothesize that a dopamine agonist would
substitute for this dopaminergic dysfunction during alcohol dependence and alleviate the
associated depression‐like symptoms and craving for alcohol.
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2.3.1. Preclinical evidence for the use of dopamine agonists to attenuate alcohol‐mediated behaviours
The potential of dopamine D2 agonists to regulate alcohol‐mediated behaviours is support‐
ed by a study showing that apomorphine, dose‐dependently reduces operant self‐adminis‐
tration as well as decreases momentary response rates for alcohol in rats [134] and that SDZ‐
205‐152, a synthetic‐mixed D1/D2 dopamine receptor agonist dose‐dependently reduces self‐
administration of alcohol, but not water, in rats [169]. Moreover, cabergoline, a dopamine D2
receptor agonist, decreased alcohol intake, relapse drinking as well as alcohol‐seeking
behaviour in rodents [170]. In addition, low doses of bromocriptine produced a significant,
dose‐dependent shift in decreasing the preference for alcohol while enhancing water
consumption [171], indicating that the compound at lower doses preferentially augment
autoreceptor function, leading to decreased dopamine turnover with a blunted response to
the rewarding effects of alcohol as a result. Studies with intra‐NAc administration of
quinpirole, further indicating that D2 receptors are involved in a biphasic effect on alcohol
self‐administration, by showing that low doses of the agonist increase, whereas higher doses
decrease, self‐administration of alcohol [141] (but see also [140]). A study has also investi‐
gated the effect of dopamine D2 receptor agonist administration into VTA on alcohol intake.
This study showed that microinjection of either quinpirole or quinelorane, into the anterior
part of the VTA dose‐dependently decreased alcohol, but not sucrose, intake in alcohol‐
preferring rats [142]. In support are the data showing that local administration of cabergo‐
line into the VTA reduced alcohol‐seeking behaviour in rats [170]. These data are
contradictory to the findings showing that the dopamine D2 receptor antagonist into the
anterior VTA did not alter alcohol intake in high‐alcohol‐preferring rats [142]. Therefore,
mechanisms regulating alcohol reinforcement might be different in selectively breed high
alcohol‐consuming rats compared to outbreed rats, and this should be investigated in more
detail. It should also be mentioned that infusion of the dopamine D1‐like agonist SKF 38393
into NAc had no effect on alcohol self‐administration in rats [141]. Albeit the data are
somewhat contradictory, it might be hypothesized that accumbal as well as ventral tegmen‐
tal dopamine D2 receptors may regulate alcohol reinforcement in rodents.
2.3.2. Clinical evidence for the use of dopamine agonists for the treatment of alcohol dependence
Bromocriptine, a dopamine agonist has been used clinically for Parkinson's disease. At low
doses, bromocriptine can reduce alcohol consumption in animals [171]; it is possible that low‐
dose dopamine agonists preferentially augment autoreceptor function, thereby decreasing
dopamine turnover and blunting the rewarding effects of alcohol. An early double‐blinded
study [172] reported that bromocriptine reduced alcohol craving in alcohol‐dependent patients
with a specific genotype of the dopamine D2 receptor gene (i.e. the A1/A1 and A1/A2 geno‐
types). However, subsequent double‐blind placebo‐controlled trials found no effect on relapse
or related behaviours [173, 174]. Currently, due to the knowledge of the addictive potential of
dopamine agonists, combined with the lack of consistent findings from clinical studies, it is
suggested that dopamine receptor agonists do not hold promise as a treatment for alcohol
dependence.
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2.3.1. Preclinical evidence for the use of dopamine agonists to attenuate alcohol‐mediated behaviours
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part of the VTA dose‐dependently decreased alcohol, but not sucrose, intake in alcohol‐
preferring rats [142]. In support are the data showing that local administration of cabergo‐
line into the VTA reduced alcohol‐seeking behaviour in rats [170]. These data are
contradictory to the findings showing that the dopamine D2 receptor antagonist into the
anterior VTA did not alter alcohol intake in high‐alcohol‐preferring rats [142]. Therefore,
mechanisms regulating alcohol reinforcement might be different in selectively breed high
alcohol‐consuming rats compared to outbreed rats, and this should be investigated in more
detail. It should also be mentioned that infusion of the dopamine D1‐like agonist SKF 38393
into NAc had no effect on alcohol self‐administration in rats [141]. Albeit the data are
somewhat contradictory, it might be hypothesized that accumbal as well as ventral tegmen‐
tal dopamine D2 receptors may regulate alcohol reinforcement in rodents.
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dopamine turnover and blunting the rewarding effects of alcohol. An early double‐blinded
study [172] reported that bromocriptine reduced alcohol craving in alcohol‐dependent patients
with a specific genotype of the dopamine D2 receptor gene (i.e. the A1/A1 and A1/A2 geno‐
types). However, subsequent double‐blind placebo‐controlled trials found no effect on relapse
or related behaviours [173, 174]. Currently, due to the knowledge of the addictive potential of
dopamine agonists, combined with the lack of consistent findings from clinical studies, it is
suggested that dopamine receptor agonists do not hold promise as a treatment for alcohol
dependence.
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2.4. Partial dopamine agonists
Based on the knowledge that alcohol can both stimulate dopamine activity as well as induce
a hypo‐dopaminergic state, it has been suggested that partial agonists might have potential as
novel medications for alcohol dependence. A partial agonist, such as aripiprazole, has a lower
intrinsic activity at the receptor than a full agonist (e.g. dopamine), meaning that when it binds
to the receptor, it will activate the receptor but produce a less potent biological response than
the full agonist [175–177]. In the presence of high levels of the full agonist, a partial agonist
will have functional antagonistic activity by binding to the receptor and preventing the
response from the full agonist. Partial dopamine D2 agonists, therefore, offer the opportunity
to treat the dysregulated dopamine activity during acute alcohol consumption as well as
alcohol dependence.
2.4.1. Preclinical evidence for the use of partial dopamine agonists to attenuate alcohol‐mediated
behaviours
In line with the hypothesis that a partial dopamine D2 agonist would block the reinforcing
effects of alcohol, aripiprazole attenuates alcohol's ability to increase the locomotor activity in
mice [178, 179](an indirect measure of activation of the mesolimbic dopamine system). On the
other hand, aripiprazole did not interfere with the alcohol‐induced impairment in motor
balance as measured by rotarod test [179]. Furthermore, repeated systemic aripiprazole
administration decreases alcohol intake in alcohol‐preferring rats [180], while single oral
administration dose‐dependently decreases alcohol self‐administration in outbred rats [181].
In addition, aripiprazole has been shown to reverse alcohol‐induced place preference and
anxiety‐like behaviour in mice [182].
2.4.2. Clinical evidence for the use of dopamine partial agonists for the treatment of alcohol dependence
Clinically, the partial dopamine D2 agonist aripiprazole has been evaluated in a few random‐
ized placebo‐controlled trials and human laboratory studies. A pilot study showed that
aripiprazole reduces the rate of relapse and craving in patients with alcohol dependence [183].
In a subsequent larger 12‐weeks, double‐blind, placebo‐controlled study of 295 alcohol‐
dependent patients aripiprazole was initiated at 2 mg/day, titrated to a maximum dose of 20 
mg/day [184]. This study showed that aripiprazole decreased heavy drinking days compared
to placebo during week four and eight; however, the effect was lost by the maximum dose at
week twelve [184]. The effects of aripiprazole were also evaluated in a human laboratory study
in non‐treatment seeking alcohol‐dependent individuals (n = 30), showing that the compound
was well‐tolerated and reduced drinking, especially in impulsive individuals [185]. Voronin
and colleagues also showed that aripiprazole decreased the number of drinks in a bar–lab
environment after consumption of a priming drink, as well as weakened the association
between the priming‐induced stimulation and further drinking. In another double‐blind
comparison trial, aripiprazole was shown to reduce craving [186] but to a lesser extent than
the FDA‐approved medication naltrexone [187]. Finally, a brain imaging study demonstrated
that aripiprazole attenuated cue‐induced activation as evidenced by a reduced activation of
the right ventral striatum with a corresponding reduction in drinking in individuals with
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alcohol dependence [188]. Thus far, early results with aripiprazole appear promising, although
whether this or similar compounds might be useful to treat alcohol dependence or be posi‐
tioned as a medication with a specific profile, that is as targeted intervention in more impulsive
alcohol‐dependent individuals needs to be evaluated further.
2.5. Dopamine stabilizers
As a further development of the partial agonist concept, Nobel Laureate Arvid Carlsson and
co‐workers, developed a novel family of compounds based on their ability to stabilize, that is
to stimulate, suppress or show no effect on the dopamine activity depending on the prevailing
dopaminergic tone [189]. This stabilizing concept was postulated based on a PET study in
rhesus monkeys where infusions with the compound (‐)‐OSU6162 (OSU6162) induced a
dopaminergic tone‐dependent effect with a reduction in the striatal L‐[11C]DOPA influx rate
in monkeys with high baseline values and an increased striatal L‐[11C]DOPA influx rate in
animals with low baseline values [190]. The mechanism of action is, however, not completely
understood, and although in vitro studies indicate that OSU6162, like aripiprazole, acts as a
partial agonist at D2 receptors [191, 192], behavioural studies have failed to demonstrate any
intrinsic activity of the compound ([195]). Instead it has been suggested that OSU6162 produces
functionally opposite effects by acting as an antagonist at both presynaptic autoreceptors and
postsynaptic D2 receptors [189, 193–195]. Based on the hypothesis that OSU6162 can counteract
both hyper‐ and hypo‐dopaminergic states, the compound has recently been evaluated in both
animal models modulating alcohol‐mediated behaviours as well as in a placebo‐controlled
human laboratory study in alcohol‐dependent patients.
2.5.1. Preclinical evidence for the use of dopamine stabilizers to attenuate alcohol‐mediated behaviours
A series of experiments in outbred rats show that the dopamine stabilizer OSU6162 attenuates
several alcohol‐mediated behaviours including voluntary alcohol intake, alcohol withdrawal
symptoms and cue/priming‐induced reinstatement of alcohol seeking in long‐term drinking
rats [196]. Furthermore, OSU6162 blunted alcohol‐induced dopamine output in the NAc of
alcohol‐naïve rats [196], indicating that OSU6162 has the ability to attenuate the rewarding
effects of alcohol. In contrast, a more recent microdialysis study conducted in long‐term
drinking rats, showed that OSU6162, compared to vehicle‐pretreatment, had no significant
effect on the alcohol‐induced dopamine peak [29]. The contrasting microdialysis results in
alcohol‐drinking versus alcohol‐naïve rats highlight OSU6162´s ability to modulate the
dopamine output dependent on the prevailing dopaminergic tone. Furthermore, these results
indicate that OSU6162 might have the ability to attenuate alcohol‐mediated behaviours by
counteracting the hypo‐dopaminergic state induced by long‐term drinking. Collectively,
together with the finding that OSU6162 did not induce conditioned place preference [29] (an
indication that the compound has no rewarding properties of its own), these results indicate
that OSU6162 has many of the favourable characteristics of a potential medication for alcohol
dependence.
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2.5.2. Clinical evidence for the use of a dopamine stabilizer for the treatment of alcohol dependence
The dopamine stabilizer OSU6162 was recently evaluated in a placebo‐controlled human
laboratory alcohol craving study in 56 alcohol dependent individuals [197]. Two weeks of
OSU6162 treatment significantly attenuated priming‐induced craving and induced signifi‐
cantly lower subjective “liking” of the consumed alcohol, compared to placebo. Interestingly,
the treatment effects of OSU6162 were driven by those individuals with high level of baseline
impulsivity, corroborating previous results with the partial dopamine D2 agonist aripiprazole
[185]. These results suggest that pharmacological stabilization of the dopamine system might
prove as an effective target for alleviating some of the reward driven behaviours during alcohol
dependence. Together with OSU6162's favourable side effect profile [198, 197, 199], these
results render support for a larger placebo‐controlled efficacy trial in alcohol‐dependent
patients to evaluate OSU6162's effect on drinking outcomes.
2.6. Pharmacological agents inducing indirect modulation of dopamine
As mentioned previously, in addition the affecting the dopamine system directly, alcohol
interacts with the mesolimbic dopamine system indirectly via several other neurotransmitters.
There is a wide range of such compounds, and here, we will only mention a few, specifically
targeting glycine receptors and nAChRs, with a clear interaction with dopamine transmission
in the mesolimbic dopamine system [64].
2.6.1. Preclinical evidence for the use of compounds that indirectly targets dopamine to attenuate alcohol‐
mediated behaviours
Rodent studies exploring the potential of targeting the glycine system as a medication for
alcohol dependence showed that systemic administration of the glycine transporter‐1 inhibitor
Org25935 increased extracellular glycine in the NAc, which prevented alcohol‐induced
dopamine release [200, 201] as well as decreased alcohol intake and prevented relapse drinking
[202, 203]. These results provided rational for a randomized placebo‐controlled clinical trial in
alcohol‐dependent individuals.
Emerging data suggests that the activity of dopamine neurons in the VTA projecting to the
NAc is regulated by several afferents, such as, for example the cholinergic neurons projecting
from the laterodorsal tegmental nucleus (LDTg) (for review see [204]). Although alcohol's
direct interaction with this cholinergic‐dopaminergic reward link remains to be fully eluci‐
dated, a study show that voluntary alcohol intake in high‐alcohol‐consuming rats causes a
concomitant release of ventral tegmental acetylcholine and accumbal dopamine [39]. Several
rodent studies with nAChR antagonists such as mecamylamine or selective nAChRs antago‐
nists such as alpha‐conotoxin MII highlight the potential of nAChRs as novel medications for
alcohol dependence by showing that these compounds prevent alcohol from increasing
dopamine and reduce alcohol consumption behaviour [28, 38, 32, 34, 35]. These nAChR
antagonists are limited in a clinical setting due to low blood–brain barrier permeability and
an unfavourable side effect profile. The potential of nAChR's as novel treatment target was
revived with the marketing of the partial nAChR agonist varenicline as a smoking cessation
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agent. It has been shown that varenicline reduce alcohol intake and alcohol‐seeking behaviour
in long‐term drinking rats [205] and modulate NAc dopamine after systemic administrations
of alcohol alone and in combination with nicotine [206].
2.6.2. Clinical evidence for the use of indirect modulation of dopamine for the treatment of alcohol
dependence
Albeit the preclinical data look promising regarding the glycine transporter‐1 inhibitor
Org25935, the multicenter randomized clinical trial produced a negative outcome on alcohol
intake, but did not discard the potential importance of the mechanism [207]. More promis‐
ing clinical studies with varenicline show that this agent decreased alcohol consumption and
craving in an experimental setting in heavy‐drinking smokers [208–210]. Moreover, data from
a randomized clinical trial in alcohol‐dependent individuals show that the smoking cessa‐
tion agent reduced the weekly percent heavy drinking days drinks, decreased the drinks per
drinking day as well as prevented alcohol craving [211]. It should, however, be noted that
recent clinical trials in alcohol‐dependent individuals were unable to find a beneficial effect
of varenicline based on self‐reported alcohol consumption [212, 213]. Nevertheless, when also
monitoring the selective alcohol biomarker phosphatidylethanol (PEth) in the blood of the
subjects in the above‐mentioned clinical trial [212], it was found that varenicline indeed had
effect on this objective measure of alcohol consumption [214] strengthening the potential of
varenicline as potential novel medication for alcohol dependence. Besides glycine receptors
and nAChR, there are various signalling systems indirectly targeting the mesolimbic
dopamine system with promising preclinical findings on alcohol‐mediated behaviours.
Collectively, these data indicate that indirect modulation of dopamine signalling might be a
potential target for novel treatment strategies for alcohol dependence and that these targets
should be investigated in more detail in human laboratory studies as well as randomized
clinical trials.
3. Conclusion
Extensive preclinical and clinical research support the hypothesis that alcohol's acute rein‐
forcing effects are mediated through a dopamine surge in the mesocorticolimbic dopamine
system and that the chronic and excessive alcohol consumption, in contrast, induces a
dopamine deficient state driving the processes of craving and relapse. In addition, it is well
substantiated that alcohol affects dopamine directly via the NAc and VTA as well as through
indirect activation of the mesolimbic pathway via interaction with other reward‐related brain
regions and neurotransmitters. These complex relationships need to be investigated further.
Given dopamine's pivotal role in the development and maintenance of alcohol dependence,
medications targeting dopamine does constitute an important area of research. Although
promising preclinical results, the majority of results from the clinical studies with dopamine‐
acting medications have thus far been discouraging. The side effects profile of many of the
evaluated compounds, including typical antipsychotic drugs, render them clinically unfav‐
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potential target for novel treatment strategies for alcohol dependence and that these targets
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3. Conclusion
Extensive preclinical and clinical research support the hypothesis that alcohol's acute rein‐
forcing effects are mediated through a dopamine surge in the mesocorticolimbic dopamine
system and that the chronic and excessive alcohol consumption, in contrast, induces a
dopamine deficient state driving the processes of craving and relapse. In addition, it is well
substantiated that alcohol affects dopamine directly via the NAc and VTA as well as through
indirect activation of the mesolimbic pathway via interaction with other reward‐related brain
regions and neurotransmitters. These complex relationships need to be investigated further.
Given dopamine's pivotal role in the development and maintenance of alcohol dependence,
medications targeting dopamine does constitute an important area of research. Although
promising preclinical results, the majority of results from the clinical studies with dopamine‐
acting medications have thus far been discouraging. The side effects profile of many of the
evaluated compounds, including typical antipsychotic drugs, render them clinically unfav‐
Recent Advances in Drug Addiction Research and Clinical Applications96
ourable. On the other hand, newer dopamine agents, without complete antagonism or
agonism, especially the dopamine stabilizers show promise and deserve further investigation
in alcohol‐dependent patients.
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Abstract
Alcohol use disorders (AUDs) constitute one of the 10 leading causes of preventable deaths
worldwide.  To date,  there  are  only  a  few Food and Drug Administration (FDA)‐
approved  medications  for  AUDs,  all  of  which  are  only  moderately  effective.  The
development of improved and effective strategies for the management of AUDs is greatly
needed. This review focuses on understanding the neurobiological basis of alcohol
addiction with a special emphasis on the role of serotonin (5‐hydroxytryptamine, 5‐HT)
and noradrenaline (NE) in AUDs and sheds light on their complex interplay in the
basolateral amygdala (BLA)––a brain region widely implicated in addiction. There is a
significant evidence to support the role of the amygdala in stress‐induced negative
emotional states resulting from withdrawal from alcohol; in fact, it has been hypothe‐
sized that this leads to craving and relapse. Dysregulation of 5‐HT and NE signaling in
the BLA have been proposed to alter affective behavior, memory consolidation, and most
importantly increase the propensity for addiction to alcohol and other common drugs of
abuse. Improving deficits in 5‐HT and NE receptor signaling may provide ideal targets
for the treatment of AUDs.
Keywords: Addiction, alcohol use disorders, noradrenaline, serotonin, basolateral
amygdala
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1. Introduction
1.1 Alcohol addiction: one drink too many
Alcohol dependence or alcohol abuse, now collectively known as alcohol use disorders (AUDs),
causes significant loss of productivity, health concerns, emotional instability, career‐oriented
failures, and socioeconomic problems [1]. It is estimated that AUDs amount to 3.8% of global
deaths and 4.6% of disability‐adjusted life years [2]. The Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM‐IV‐TR), defines AUDs on the persistence of dependence symp‐
toms like tolerance, withdrawal, increased amounts of alcohol consumed over time, ineffec‐
tive efforts to reduce use, interference with personal or professional life, significant amount of
time spent obtaining, using, and recovering from alcohol or continued use of alcohol despite
harmful consequences [3].  The U.S.  National  Institute of  Alcohol Abuse and Alcoholism
(NIAAA) defined men who consume more than 14 drinks per week and women having more
than 11 drinks per week belong to the “At Risk” category of alcohol consumers.
1.2 Neurobiology of alcohol addiction: a vicious cycle
Alcohol addiction like any other drug addiction is a chronic relapsing disorder characterized
by compulsive alcohol use and alcohol‐seeking behavior [4, 5]. The neurobiology of alcohol
addiction is increasingly complex; however, for the purpose of simplicity, it can be delineated
in three stages. The first phase of this cycle is the Binge and intoxication stage [5]. During this
phase, reward areas of the brain involving the mesocorticolimbic system like the dorsal
striatum and nucleus accumbens (NAc) are activated, which results in pleasurable and
rewarding feelings [5, 6]. Dopamine is a key neurotransmitter involved in this stage [7–9]. The
positive reinforcement is triggered by the pleasurable effects of alcohol where the user wants
“more” to experience the hedonic effects. This is then followed by the Withdrawal stage [5].
During this phase, brain regions that are associated with negative feelings and emotions are
activated, such as the amygdala and bed nucleus of stria terminalis (BNST) [4, 5]. Chronic
withdrawal‐induced stress blunts the activity of the stress–response system and sensitizes
extrahypothalamic structures of the extended amygdala [6, 10]. This stage marks a critical
phase in the addiction cycle where alcohol use is primarily motivated by the desire to avoid
negative feelings of stress, dysphoria, and negative emotional states of alcohol withdrawal.
The third phase is the Preoccupation and anticipation stage [5]. During this phase, brain regions
like the frontal cortex and hippocampus [11] that respond to previously paired alcohol cues
and contexts are activated, intensifying alcohol‐seeking behavior [12, 13]. Since the frontal
cortex is involved in decision‐making and higher executive functions, alcohol‐induced
neuroadaptations of the frontal cortex [14] impair higher cognitive and decision‐making
processes, increasing the rate of relapse in alcoholics.
Over time, as this cycle is repeated, alcohol‐induced neuroadaptations in the reward circuitry,
stress–response pathway, and brain regions involved in higher cognitive functions facilitate
the transition from nondependent to dependent alcohol consumption. These maladaptive
neuromodulations contribute to sensitization, tolerance, craving, and relapse to alcohol‐
seeking [4]. For instance, alcohol‐induced plasticity in glutamatergic signaling in the NAc may
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contribute to behavioral sensitization to the effects of alcohol [15], while changes in the synaptic
properties of NAc‐medium spiny neurons contribute to relapse during withdrawal [16].
Furthermore, chronic alcohol modulates presynaptic and postsynaptic functions on glutamate
neurons in the basolateral amygdala (BLA) [17]. Finally, alcohol impairs communication
between the amygdala and prefrontal cortex to disrupt cognitive and emotional responses that
lead to altered affective states that further contribute to the development of alcohol dependence
[18, 19].
1.3. Pharmacotherapy: available treatment options for AUDS
Bill Wilson and Bob Smith took early steps toward alcohol remediation in 1935 with the
introduction of Alcoholic Anonymous (AA) [20, 21]. This 12‐step approach toward rehabili‐
tation was built on the premise of acceptance of individual helplessness during addiction to
alcohol and other drugs of abuse [22]. This method was adopted by the “Minnesota model of
addiction treatment” in a 28‐day rehabilitation setting [23]. Parallel efforts to treat alcohol‐
ism by understanding the nature and cause of alcohol dependence were gaining momentum,
which led to the foundation of the National Institute of Alcohol Abuse and Alcoholism
(NIAAA) in 1970 [24].
Since then, several approaches to understand and treat alcoholism were designed that took
into consideration individual differences and susceptibility to AUDs. Cognitive behavioral
therapy or motivational therapy was adopted as the first line of treatment to match the needs
of the addict to help recuperate in a 12‐week therapy session called “Project MATCH” [25].
This project was successful in rehabilitation of patients that did not have any psychiatric
conditions. The next step was to combine behavioral and pharmacotherapy in the treatment
of alcoholism called “Project COMBINE” [26]. This study evaluated the efficacy of available
pharmacotherapies, namely acamprosate and naltrexone, in conjunction with or without
medical assistance and with or without cognitive–behavioral therapy [27].
Acamprosate (CampralTM), the calcium salt of N‐acetyl homotaurine, suppresses alcohol
consumption and relapse [28, 29]. Early reports delineating the mechanism of action of
acamprosate were unclear [30]; however, recent studies have shown that acamprosate works
through the calcium ion in its molecular structure [31]. This was supported with improved
results in patients that showed an increase in plasma calcium levels following acamprosate
treatment [31]. Acamprosate has been shown to have a good safety and a tolerability profile
and is highly effective in maintenance of abstinence in patients who are abstinent at treat‐
ment initiation [32].
In addition to acamprosate, the mu‐opioid receptor antagonist, naltrexone (Re ViaTM), was
found effective as a treatment for alcohol consumption and relapse [33]. However, studies have
shown that naltrexone is ineffective in achieving abstinence in alcoholic subjects; instead it is
more effective to reduce consumption [34, 35]. Also, recent research demonstrated that it acts
more specifically for a cohort with single nucleotide polymorphism (SNP) in exon 1 of the mu‐
opioid receptor gene (OPRM1) [36] limiting broader efficacy. Nevertheless, naltrexone reduces
alcohol consumption through a dopaminergic/opioidergic reinforcement system, causing
increased sedation and less arousal in patients consuming alcohol [35]. Both these drugs were




successful in reducing drinking in combination with behavioral therapy, as highlighted by the
COMBINE project [37].
In addition to acamprosate and naltrexone, disulfiram (Antabuse®) was approved as a
therapeutic treatment for alcoholism. The anti‐alcohol addiction properties of disulfiram were
serendipitously discovered, when a Danish physician Jacobsen accidentally ingested alcohol
over disulfiram and experienced its unpleasant and nauseous effects [38, 39]. Disulfiram
inhibits the enzyme aldehyde dehydrogenase (ALDH), which results in the accumulation of
acetaldehyde on alcohol ingestion [40]. This toxic metabolite produces aversive symptoms,
such as flushing, nausea, and vomiting, and a desire to avoid this reaction encourages
abstinence [41]. Disulfiram also inhibits dopamine‐β‐hydroxylase (DBH), the enzyme required
to synthesize noradrenaline (NE). It reduces NE concentrations and elevates dopamine (DA)
concentrations to facilitate normal DA functioning [40, 41], a pharmacotherapeutic feature of
the drug that makes it an excellent treatment option even for cocaine addicts.
In addition to this, our lab has investigated the role of neuronal nicotinic acetylcholine
receptors in alcohol addiction and came up with varenicline (ChampixTM) as a treatment option
for AUDs [42, 43]. Varenicline was found to be more efficacious in heavy‐drinking smokers
because of the comorbid nature of both the types of addiction involving the recruitment of
nicotinic acetylcholine receptors. Varenicline is now in its third stage of clinical trial as a
treatment option for AUDs [44, 45].
1.4. Shortcomings of available treatment options for AUDs: need for better pharmaceutical
alternatives
Acamprosate, naltrexone, and disulfiram are the only available medications for alcoholism
approved by the Food and Drug Administration (FDA), while nalmefene (SelincroTM), an
opioid receptor antagonist having a similar mechanism of action to naltrexone [46], is approved
as a medication for alcohol abstinence in Europe [47]. Most of these drugs treat one aspect of
alcoholism at best without significantly altering other parameters of alcohol addiction.
Drugs like acamprosate reduce consumption and are effective in motivating abstinence for a
certain period of time. However, acamprosate does not significantly affect abstinence‐induced
rebound consumption of alcohol [48]. Also, despite achieving an aversion for alcohol, the
likelihood of the addict returning to drinking with increased tolerance cannot be assured. A
case study also indicated the development of Parkinson's‐like syndrome with acamprosate
use [49].
Although naltrexone was shown to be very effective with and without cognitive behavioral
therapy, noncompliance with maintenance of drug regimen was shown to limit efficacy [50].
About 37% patients were reported to discontinue naltrexone therapy by 12 weeks and 80%
by 6 months [50]. It is possible that some of the severe complications involved with naltrex‐
one use, that is, renal failure and hepatitis, may have contributed to its early discontinuation
[51]. Furthermore, the efficacy of naltrexone appears to be related to alcohol abusers having
the mu‐opioid SNP [36].
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All the above drugs work best when combined with an individual's motivation to quit
drinking. Disulfiram works on this principle as it deters the positive reinforcing effects of
alcohol and masks them with aversive and negative feelings stimulated by the action of the
drug post‐alcohol consumption [52]. As a result, this drug is effective for alcoholics with a goal
to achieve complete abstinence, but has limited efficacy for alcoholics without these goals.
Noncompliance is one of the biggest challenges in the use of disulfiram, illustrated by the 20%
compliance measure in the largest controlled trial to date [53]. Also, disulfiram is contraindi‐
cated in patients with cardiac disease and on rare occasions may cause severe liver damage [54].
Despite the availability of these pharmacotherapies and behavioral therapy, AUDs are widely
prevalent. As illustrated by COMBINE, no single medication or treatment strategy is effec‐
tive in every case or in every person [37]. A detailed investigation of other neurobiological
factors that play a role in alcohol dependence is needed as are further strategies to treat
alcoholism.
The remainder of this chapter highlights the role of serotonin (5‐hydroxytryptamine, 5‐HT),
NE, and BLA in alcohol addiction with a view to improve current treatment strategies for
AUDs.
2. NE and serotonin: role in alcohol dependence
Prolonged alcohol exposure causes maladaptive changes in regions of the extended amygda‐
la that cause sensitization to negative emotional states and reinforcement of addictive
behaviors during withdrawal. These neuroadaptations alter the activity of important neuro‐
transmitters particularly involved in stress. Such changes are well documented for increas‐
ing the activity of the stress neurotransmitter corticotrophin‐releasing factor (CRF) in rodent
models of alcohol dependence [4]. Additionally, changes in the function and signaling of other
neurotransmitters including 5‐HT [55–57] and NE [55–61] have also been implicated in the
development of alcohol addiction.
NE and 5‐HT play a crucial role in regulating mood, emotions, and importantly, behavioral
adaptations to stress that include addictive phenotypes [57, 60]. As these neurochemicals
widely innervate the reward system [62–66] and extrahypothalamic regions involving the
amygdala [67–71], these are prime candidates to influence alcohol and even other drug‐seeking
behaviors.
Dysregulation of the 5‐HT pathway is implicated in AUDs and other affective states like
depression and anxiety disorders [57, 72, 73]. Recent studies have demonstrated an increase
in the immunoreactivity of tryptophan hydroxylase (TRH)––the rate‐limiting step in 5‐HT
synthesis, in the dorsal raphe nuclei (DRN) of alcohol‐dependent victims of depression and
suicide compared to normal psychiatric controls [74]. Such disruptions in brain serotonin levels
in these individuals have widespread implications in the role of 5‐HT to regulate emotional
and behavioral vulnerability to alcohol and other drugs of abuse. Alcohol increases 5‐HT levels
in the ventral tegmental area (VTA), NAc, and amygdala [75]. These brain regions play a




pivotal role in processing of information from emotional and rewarding stimuli. Chronic
alcohol abuse alters the activity of these brain areas, resulting in changes in motivational and
goal‐directed behaviors, which further drive alcohol‐seeking behavior [76, 77]. For instance,
studies have shown that behavioral sensitization to alcohol is mediated by accumbal 5‐HT2C
receptors [76], and blockade of 5‐HT3 receptors especially in the VTA attenuates alcohol
consumption [77]. The 5‐HT receptors, 5‐HT1A, 5‐HT1B, 5‐HT2A, and 5‐HT2C, [78–80] have been
widely implicated in alcohol consumption in animal models with new evidence also impli‐
cating 5‐HT3 and 5‐HT6 receptors in alcohol addiction [81, 82].
NE has been shown to play a significant role in negative emotional states which contribute to
alcohol consumption [60, 83, 84]. Acute alcohol decreases [85], while chronic alcohol and
withdrawal increases the activity of neurons in the locus coeruleus (LC), a region that provides
the majority of NE in the brain [86]. Activation of the α2‐adrenergic autoreceptors has been
shown to attenuate the overall negative effects of withdrawal [87], and blocking α1‐adrener‐
gic receptors (ARs) using prazosin reduced alcohol consumption in dependent rats [88] and
human alcoholics [89]. Likewise, treatment with the β‐AR antagonist, propranolol, reduced
drinking in dependent rats [60]. Evidence also suggests that β‐ARs may also contribute in
mediating the anxiolytic effects of alcohol [58].
Furthermore, CRF is a regulating factor in the activation of the hypothalamus–pituitary–
adrenal (HPA) axis to stress [90–94]. Chronic alcohol consumption affects CRF signaling in the
central nucleus of amygdala (CeA) and BNST, as evidenced by alterations in CRF transmis‐
sion during withdrawal [95]. Interestingly, NE and 5‐HT have been shown to interact with the
neurotransmitter CRF in neuroanatomical sites like the LC, DRN, CeA, and BNST [96–100] to
influence addictive behaviors. For instance, yohimbine, a pharmacological agent used to
promote stress in rats, has effects on NE, 5‐HT, and CRF signaling to potentiate alcohol
drinking and reinstatement [101, 102], suggesting possible mutual regulatory roles of these
neurotransmitters in alcohol dependence and relapse. This was further evidenced by CRF
antagonism in the DRN to attenuate yohimbine‐induced alcohol‐seeking behavior in rats [100].
Also, CRF and NE antagonism has been shown to be effective in reducing stress‐induced
reinstatement in human alcoholics [88, 103].
3. The BLA: role in alcohol addiction
The amygdaloid complex is made up 13 distinct nuclei which are divided in three groups: the
deep or basolateral group, the superficial or cortical‐like group, and the centromedial group
[104]. These nuclei have been proposed to be located in such a way to maximize the amygdala's
connections with other limbic, cortical, and subcortical regions of the brain to help facilitate
its function in emotional processing, learning, and fear memory [105–107]. The basolateral
amygdalar complex, comprising of lateral amygdala (LA), basal and basomedial nuclei [108,
109] controls behavioral expressions like emotional arousal, fear, and stress that are linked to
traumatic incidents, stressful environmental stimuli, or pharmacological stressors, and
consolidates them as memories [70]. The BLA communicates through excitatory efferents to
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the prefrontal cortex and structures of the limbic system involving the hippocampus, NAc,
dorsomedial striatum (DMS), and BNST [110–114], while it receives feedback from these
structures through glutamatergic afferents [115, 116], majority of which converge with the
cortical inputs [114] running toward the BLA.
The role of the BLA in fear, memory consolidation, and emotional learning along with its
contribution in associative learning for appetitive conditioning is well documented [70, 105,
117, 118]. Since the BLA can impart incentive salience to a previously neutral stimulus in
response to a motivational or a goal‐directed task [119], recent efforts have now focused on
the role of the BLA in drug‐seeking, including cocaine [120], morphine [121], and alcohol [122–
124].
Alcohol has been shown to increase neuronal activity and glucose utilization in the BLA [125].
Additionally, long‐term alcohol exposure alters glutamate transmission in the BLA [126] and
NAc [127], which is implicated in increased alcohol self‐administration in rodents [128].
Furthermore, alcohol‐induced withdrawal stress increases presynaptic glutamatergic func‐
tion in thalamic afferents to the BLA that may explain the increased emotional dysregulation
during withdrawal [129]. It has also been shown that altered neuropeptide S function in the
BLA following long‐term alcohol exposure may contribute to relapse [130]. Furthermore, a
recent study has shown that IL‐1 receptor signaling in the BLA contributes to binge‐like alcohol
consumption in mice [131].
There is growing body of evidence that supports the role of the BLA in conditioned–cued
relapse [132] and context‐induced reinstatement [133] for alcohol and a variety of other
drugs [134–137]. It was shown that the BLA may play a significant role in cue‐induced alcohol
reinstatement [138], following exposure to previously alcohol‐paired environmental cues
[123]. Research has also shown that BLA–glutamatergic signaling attributes salience to
conditioned cues that are related to alcohol‐seeking [132], while the opioidergic system of the
BLA may play a role in context‐induced alcohol‐seeking [140]. Indeed, since the BLA exten‐
sively communicates with the NAc, alcohol withdrawal‐induced changes in glutamatergic
function in the BLA get perpetuated in structures of the reward system that may contribute to
craving and relapse [141].
It is well documented that repeated and chronic stress leads to adverse behavioral outcomes,
and many studies support the reinforcing effects of chronic stress in drug addiction in animal
models [86, 142–144]. Stress alters the morphology of BLA principal cells and impairs fear
extinction memory [145] that may have implications in the development of affective disor‐
ders like PTSD and depression. It has been shown that the BLA modulates chronic stress‐
induced learning and memory deficits in the hippocampus, suggesting that dysregulation of
BLA–hippocampal signaling may affect memory storage, retrieval, and extinction of fear
memory that may contribute to emotional disorders and drug dependence [146]. Further‐
more, early life stress causes increased excitability of pyramidal cells in the BLA [147], while
chronic restraint stress in adolescent and adult rats increases BLA activity [148]. Increased BLA
excitability has been positively correlated with increased anxiety and increased alcohol‐
seeking behavior [141, 147, 149, 150].




Long‐term exposure to alcohol simulates chronic stress‐like conditions [130] that have a
profound effect on fear memory consolidation [151]. Alcohol withdrawal‐induced stress has
been shown to increase conditioned fear [152] and impair extinction of fear memory [153]. A
recent study also showed that repeated alcohol exposures enhance retrieval of previously
consolidated fear memories and augments activity in BLA and other brain regions involved
in fear memory retrieval [154].
4. Role of 5‐HT and NE in the BLA in alcohol addiction
There is significant evidence that supports the role of NE and 5‐HT in drug dependence and
alcohol addiction [87, 155–157]. Moreover, the BLA which is highly implicated in depend‐
ence to alcohol‐seeking [17, 123, 131, 132] is densely innervated by these neurotransmitters [58,
71, 158, 159]. Since chronic alcohol exposure causes neuroadaptations that affect the signal‐
ing and receptor subtypes of these neurotransmitters, dysregulation of NE and 5‐HT trans‐
mission in the BLA may lead to a constellation of aversive outcomes including altered
consolidation of alcohol‐related memories, anxiety disorders, and eventually higher rates of
relapse [132, 138].
NE plays a vital role in facilitating the function of the BLA in fear memory consolidation [70].
It has been shown that intra‐BLA infusions of β‐AR agonists enhance retention of inhibitory
avoidance [160], while β‐AR antagonists block fear memory enhancement [69]. Also, α1‐AR
activation in the BLA enhances fear memory consolidation through an interaction with β‐
ARs [161]. This evidence suggests that noradrenergic receptors strongly contribute to BLA
function. It is possible that alteration in NE activity in the BLA may lead to altered memory
consolidation and stress‐coping mechanism that may enhance alcohol‐seeking and relapse
[162]. Indeed, antagonism of α1‐ARs reduced dependence‐induced increase in alcohol
consumption in rats [88]. Furthermore, recent evidence supports the role of β‐ARs in alcohol‐
induced enhancement of GABA synapses in the BLA, suggesting a possible noradrenergic
mechanism mediating the anxiolytic effects of alcohol [58] (Figure 1). This was further
evidenced by intra‐BLA infusions of a β3‐AR agonist that enhanced inhibitory GABA signaling
on BLA pyramidal cells to reduce anxiety‐like and alcohol‐seeking behavior [163].
Furthermore, the neuroadaptive changes associated with chronic alcohol consumption
including desensitization of β‐ARs in the BLA have been shown to modulate its activity [164]
(Figure 1).
In contrast to excitatory dopaminergic/glutamatergic signaling in the BLA that increases its
activity, serotonergic transmission in the BLA is inhibitory [165]. The serotonergic innerva‐
tions on principal glutamate cells in the BLA decrease the overall excitatory activity of these
cells [166] through 5‐HT1A receptors [167] and modulate BLA output (Figure 2). This is
supported by a recent study where depletion of serotonin in the BLA increased glutamate
receptor density and fear‐potentiated startle in mice, indicating that serotonergic inhibition
regulates excitatory signaling in the BLA to modulate affective behaviors like anxiety [68].
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tions on principal glutamate cells in the BLA decrease the overall excitatory activity of these
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Chronic alcohol‐induced neuroadaptations change 5‐HT receptor expression and function in
the brain [168] that alters the regulatory control of serotonin over BLA principal cells. Loss of
inhibition on BLA principal neurons increases BLA output, increasing anxiety [169, 170] and
other symptoms of withdrawal. In support of this, chronic alcohol or withdrawal stress
increases the expression of 5‐HT1A autoreceptors in the raphe nucleus [168] which causes a
reduction in 5‐HT levels in the BLA. This increases BLA activity, which contributes to anxiety‐
like behaviors following withdrawal from chronic alcohol (Figure 2). Furthermore, 5‐HT2A/2C
receptors have been suggested to potentiate inhibitory GABAergic tone on principal BLA
glutamatergic cells to decrease excitability [67]. Chronic alcohol causes adaptive changes that
lower the expression levels of these receptors, reducing inhibition over BLA principal
neurons [67]. This augments BLA output and increases the possibility of anxiety‐induced
relapse following a period of chronic alcohol exposure [141] (Figure 2). In addition to this,
Figure 1. Changes in NE signaling and BLA output following acute and chronic alcohol exposure or withdrawal.
Acute alcohol decreases NE signaling in the BLA, which is regulated by a feedback loop through presynaptic α2‐adre‐
nergic autoreceptors expressed on NE fibers in the LC. Decreased BLA‐NE levels decrease the excitation of BLA princi‐
pal cells through postsynaptic α1‐ARs. Acute alcohol further enhances the inhibition of BLA principal cells by NE‐
mediated enhancement of GABA synapses through β‐ARs expressed on GABAergic LPSCs. The net result of this
inhibition is decreased BLA principal neuron excitability and BLA activity which has been suggested to reduce anxiety
and may explain the anxiolytic effect of acute alcohol. Chronic alcohol/withdrawal increases NE levels that enhance α1‐
AR mediated excitation of BLA principal cells. Chronic ethanol has been shown to desensitize β‐ARs in the brain
which leads to a reduction in NE's effects on GABA‐LPSCs causing a decrease in the inhibitory tone over BLA princi‐
pal cells, increasing excitability. This increases the net excitability of BLA principal cells and increases BLA activity
causing anxiety during withdrawal and may contribute to alcohol‐seeking and relapse.




chronic alcohol‐induced neuroadaptations in other receptor subtypes like the GABA‐A
receptors facilitate the anxiolytic effects of alcohol [171]. Increasing the activity of 5‐HT on
GABA‐A receptors on BLA principal cells may contribute in reducing withdrawal‐induced
anxiety and alcohol‐seeking.
Figure 2. Changes in 5‐HT signaling and BLA output following acute and chronic alcohol exposure or withdrawal.
Acute alcohol increases 5‐HT release in the BLA which is regulated by a feedback loop through 5‐HT1A autoreceptors
expressed on 5‐HT neurons in the DRN. Increased BLA‐5‐HT levels enhance the inhibition of BLA activity through
postsynaptic 5‐HT1A receptors expressed on principal neurons. Increased 5‐HT signaling also activates 5‐HT2A/2C recep‐
tors expressed on GABAergic interneurons in the BLA that further increase the inhibition on BLA principal cells
through increased GABAergic tone. The net result of this inhibition is decreased BLA principal neuron excitability and
BLA activity, which has been shown to reduce anxiety and may explain the anxiolytic effect of acute alcohol. Chronic
alcohol/withdrawal increases the expression of 5‐HT1A autoreceptors in the DRN which decreases 5‐HT levels in the
BLA. This reduces 5‐HT1A‐mediated inhibition on BLA principal cells. Chronic alcohol‐induced withdrawal downregu‐
lates the expression of 5‐HT2A/2C receptors on GABAergic interneurons to further decrease the inhibitory GABA tone on
BLA principal cells, increasing excitability. Chronic alcohol also upregulates GABA receptors on principal cells. This
results in a net increase in BLA activity causing anxiety that may contribute to alcohol‐seeking and relapse.
Furthermore, cross‐modulation of synaptic transmission in the BLA by 5‐HT1A/1B receptors and
β‐ARs dictates BLA output [159] that may affect behavioral outcomes like stress, anxiety, and
drug dependence. In support of this, we have shown that pindolol, a drug having dual
pharmacological activity on 5‐HT1A/1B receptors and β1/β2 ARs, decreases alcohol consump‐
tion in mice following long‐term alcohol exposure. Our electrophysiological experiments also
indicate that the BLA may mediate the effects of pindolol on alcohol consumption [172].
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5. Conclusion
Research in the past few decades has significantly increased our understanding of the
neurobiological basis of alcohol dependence. Recent research has targeted pathways that
mediate more than just the reinforcing properties of alcohol. However, despite these concert‐
ed efforts, effective pharmacological interventions for the management of AUDs remain
elusive.
Chronic alcohol consumption causes maladaptive changes in brain regions like the extended
amygdala that cause sensitization to negative emotional states of withdrawal. These changes
disrupt the signaling of many neurotransmitters including those involved in stress. Dysregu‐
lation of NE and 5‐HT signaling has been widely implicated in the development of affective
disorders and alcohol addiction. Specifically, NE and/or 5‐HT impairments in the BLA, a region
involved in stress, emotional processing, and reward‐seeking have been suggested to play a
major role in the development of alcohol dependence (Figures 1 and 2).
In addition to the growing evidence in animal models of alcohol addiction, pharmacological
compounds that target NE and 5‐HT receptors have also shown promise as potential treat‐
ment strategies for AUDs in human patients [173, 174]. Noradrenergic compounds like
propranolol [175, 176] and atenolol [174] have been shown to attenuate alcohol‐seeking
behavior and reduce craving in human alcoholics. Similarly, serotonergic compounds like
buspirone show efficacy to reduce anxiety‐induced consumption in alcoholics [177, 178].
Moreover, our research indicates that pindolol, the FDA‐approved antihypertensive drug
having activity on both 5‐HT and NE receptors, may have a similar mechanism of action to
more effectively reduce alcohol consumption following chronic intake [172].
Since the BLA plays a vital role in affective disorders and stress‐induced maladaptive
behavioral conditioning, drugs that selectively modulate NE and 5‐HT signaling in the BLA
offer great promise in the treatment of AUDs. With the increasing need for improved
pharmacotherapeutic strategies for the management of AUDs combined with the modest
efficacy of current treatments, putative compounds that target 5‐HT and NE receptors may
prove useful for the development of more effective treatment strategies for alcohol depend‐
ence.
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Abstract
This  chapter  provides  a  broad  overview  of  therapies  for  substance  abuse.  These
therapies are understood in the context of the history of drug use in the United States
and factors that influenced the expansion and regulation of substance use.  This is
followed by a discussion of how the complexity of these factors was associated with
difficulties in understanding substance misuse and created challenges to the creation of
effective treatment systems.  The chapter reviews the moral  and disease models of
addiction before discussing the diagnosis of substance-related disorders. The chapter
describes major treatment approaches and their efficacy.
Keywords: Substance abuse, Treatment
1. Introduction
This chapter will provide a brief overview of the history of substance abuse therapeutics and
survey of approaches to the treatment of substance use disorders. To fit the history of, and
approaches to, substance abuse therapeutics into a chapter of this type, great simplification is
required; at the same time, the entire enterprise bears much resemblance to the well-worn parable
of the group of blind men attempting to describe an elephant. The elephant parable illustrates
beautifully that reasonable people may disagree vigorously about the essence of something by
virtue of how they encounter it. This array of views has been likened to metaphors [1], but the
significance of each metaphor has profound implications. So, while the parable of the men and
the elephant does highlight the potential validity of differing perspectives on substance use, the
parable does not do enough to consider the implications and consequences of substance abuse.
Community and professional responses to substance use have reflected the untold conflict and
enormous consequences that have still  not yielded widely agreed upon responses to the
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destructive effects of substance use. The vast social issues include, but are certainly not limited
to moral, legal, ethical, economic, political, sociological, and psychological considerations. So,
it is virtually impossible to be exhaustive in one’s review of these issues, and this chapter will
focus only on the highlights of treatment of substance use conditions.
Modern data indicate that substance use and misuse continue to be widespread [2]. For 2014,
nearly 140 million people over the age of 12 used alcohol, more than 60 million reported some
binge drinking, and more than 16 million people reported heavy binge drinking in the United
States. Estimates for the use of illicit drugs overall appear to be overshadowed by data
pertaining specifically to marijuana use. More than 22 million people reported use of mari‐
juana, nearly 67 million reported use of tobacco, and more than 4 million persons reported
misuse of prescription medication. Perhaps of greater concern than the reported patterns of
use overall is the reported 17 million people whose self-reported use is consistent with a
diagnosis of an alcohol use disorder and more than 21 million people whose self-reported use
is consistent with a diagnosis of a substance use disorder. Clearly, misuse of psychoactive
substances remains a significant problem.
2. Early roots of treatment in the United States
The treatment of substance-related problems in the United States came from the intersection
of various forces in the middle of the nineteenth century. Patterns of alcohol and other
substance use, social reform movements, regulatory efforts, and the dynamics of professio‐
nal guilds all combined to shape the beginning of attempts to intervene with these problems.
Both the Europeans on the North American continent and the Africans who were brought as
slaves were users of alcohol, but the Native Americans were mostly not users of alcohol.
Cultural factors were significant and patterns of usage and resulting problems, including the
catastrophic effect of alcohol on Native American tribes [3]. As colonization progressed, public
drunkenness may have been the most significant problem that was explicitly identified [4].
Benjamin Rush (1746–1913) was an influential writer on a number of subjects, having been a
member of the Continental Congress, a signer of the Declaration of Independence, and notable
hospital reformer of the eighteenth century. Rush’s work was rich with descriptions of alcohol
use as a progressive medical condition that required abstinence as a method of invention. Until
the influence of his writings, alcohol had previously been seen as a moral problem or a
manifestation of mental illness [4].
2.1. Temperance
The American temperance movement emerged as alcohol-related problems became more
salient. As one might discern from the name of the organizations (“Temperance”), the initial
goals were to promote moderate use. However, the goals of the temperance movement
changed to a perspective that emphasized abstinence [5]. While modern abusers of substan‐
ces must battle for recovery in the context of a variety of possible interventions, substance
abusers in the nineteenth century had far fewer alternatives. There is evidence that these
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persons turned to a variety of social change movements and were met with various attitudes.
For example, the political attitudes of temperance movement participants could sometimes be
confused with other political stances (e.g., slavery). Thus, factors that were associated with the
rise and fall of various social movements were also critical to attempts to establish programs
to assist substance users (primarily alcoholics at that time).
2.2. Institutional treatment
Because of the difficulties associated with substance misuse, attempts have been made to
provide shelter for persons who needed some form of assistance. These efforts to provide
residential care have been referenced in writings as long as 5000 years ago [6]. By the early
1800s in the United States, the physical effects of alcohol were becoming clearer, and there was
a significant increase in the number of institutions that emphasized the treatment of alcohol
and other addictions [7].
Just as the public response to substance abuse was a product of complex forces, complex forces
were also significant to treating institutions. Economic forces, primitive clinical methods,
conflict within the field, and problems associated with individual behavior all contributed to
a decline in the institutional treatment movement. It was clear by the mid-1800s that the search
was on for more effective approaches to treating addictions. Not surprisingly, miracle cures
were suggested in the context of entrepreneurialism. Innumerable chemical preparations and
marketing techniques were seen [8]. The first “inebriate asylum” was called for by Dr. Samuel
B. Woodward, whose efforts led to the establishment of the first real institutional treatment in
the form of the New York State Inebriate Asylum, established in 1864. The first facility for
women was the Martha Washington Home in Chicago that was established in 1867. Further
progression in institutional care as part of the moral treatment that Dr. Woodward espoused
was slow to grow.
2.3. The increase in legal controls
The sentiment of many Americans seemed to have been critical of the non-medical use of any
drug, including alcohol and tobacco. From colonial times through the Civil War, these attitudes
were associated with abstentionist outcries against alcohol and tobacco and calls for regula‐
tion. The regulation of substance use has been increasingly relevant to treatment since the
proliferation of public regulations in the early 1900s. However, the energy expended to stem
the availability and use of psychoactive substances has met with controversy. The specific
consequences of both direct and indirect action included the intention to eliminate use,
pressure to make the price of substances rise, and efforts to reduce social costs of use [9].
History has been clear that race, ethnicity, and social class have been highly tied to efforts to
control substance use and that legal controls frequently represented bigotry and oppression
that served the aims of dominant groups.
The path to regulation began with registration and taxation mandates. The first significant step
in this regard was the Pure Food and Drug Act of 1906. At time in which there had been decades




Drug Act established the requirement that medications with opiates and other drugs must
provide a list of ingredients. This made opium and cocaine were early casualties of regula‐
tion attempts [10].
The Harrison Narcotic Act was passed in 1914 by the United States government. The origi‐
nal intention of the bill was to place a special tax on opium and coca, but the effect was to
eliminate legal opiates. Alcohol and tobacco were also soon to be subject to growing legal
pressure. Tobacco was not traditionally used in the form of modern cigarettes, but tobacco
habits were fostered by the development of modern cigarettes, leading to large increases in
tobacco use between 1900 and 1910.
The battle over alcohol was even to be more visible and controversial. Andrew Volstead of
Minnesota saw his name attached to the Eighteenth Amendment to the United States
Constitution. The result of the “Volstead Act” (H.R. 6810) was that from 1920 until 1933, and
the manufacture, sale, and consumption of alcohol were prohibited in the United States. The
failure of prohibition leads to the Twentieth Amendment that repealed federal prohibition
in 1933. The states gradually repealed their own legislation ending with Mississippi in 1966.
As one alternative to the futility of broad prohibition, legally mandated treatment for substance
abusers is now widely practiced [11], and legally mandated treatment is seen as a sensible
approach for persons whose criminal offense is substance related. The intention is to direct the
convicted individual to a system in which treatment is a more central focus then would be
expected in a traditional correctional context. Critics of the approach question the propriety
and efficacy of this strategy.
2.4. Spiritual traditions and intervention
Another common perspective on treatment of substance-related problems emerged from
spiritual traditions. Spiritual traditions provided the foundation for a variety of approaches to
substance-related problems. Some of this influence has been direct and some indirect. For
example, a movement as broad as the American temperance movement was substantially
derived from the evangelical movement. The Benjamin Rush speculated that religion by itself
could “carry the day” with substance abusers [12]. The early view that religious experiences
were an important path to recovery was bolstered by the perspectives of some early mental
health professionals. Some professionals in health care were skeptical of religious ap‐
proaches and others opined that religious approaches were only good for certain patients. Even
within psychology, there were advocates for spiritually based intervention. The prominent
work of George Cutton’s The Psychology of Alcoholism (1907) and the broad work of the
pragmatist William James (non-practicing M.D. and Harvard psychologist) went far to
legitimize the spiritual view. James was well known because of the variety of his contribu‐
tions related to psychology. James operationalized the center of religious conversion as anti-
Christian by referring to it as “the hot place in a person’s consciousness … The habitual center
of one’s personal energy ([13], p. 196).” Despite knowing that reports of religious conversion
experiences would be met with skepticism in a professional community of materialists, James
felt that the results or specific components of spiritual interventions should be considered
independent of the underlying assumptions of a particular spiritual perspective. The contin‐
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ued significance of the spiritual contribution to substance abuse therapeutics is reflected in a
number of contemporary realities. The United States Congress passed a measure in 1996 that
allowed states to contract with faith-based programs in substance abuse treatment. This led to
an increase in emphasis on such programs and associated research into the effectiveness of
such approaches [14, 15]. Typically, such programs include Bible study, church services,
spiritually based therapy, in addition to a strict regimen of activities. There are continued
efforts to clarify the precise nature of treatment that is based on Christian principles [16].
3. Models of misuse and methods of treatment
3.1. The diversification of substances
Many types of substances have been used throughout history for a host of purposes. Early
North American settlers used a variety of preparations for a variety of medicinal and recrea‐
tional purposes. Until the late 1800s, it was easy for opponents of substance use to locate their
targets. Many substances began as legitimate medications and became used outside the clinic.
Despite the widespread use of a variety of substances, it was not until the Controlled Substance
Act of 1970 that anti-substance law began to keep up with the great variety of substances that
are used. The proliferation and diversification of substance use, the variety of substance
pharmacologic action, the impact of route of administration, and the host of socio-cultural
factors have all been significant in the development of effective treatment methods [17].
Tobacco was first introduced to Europeans by Native Americans. Sailors adopted tobacco, both
smoking the leaf and chewing it and brought tobacco home to Europe. By the time of the Civil
War, alcohol and tobacco were established and clearly the most common American substan‐
ces associated with problematic use.
Marijuana use has a long and complex history. Varied types of cannabis existed long before
its appearance in the United States. Cannabis sativa was available in the early days of the new
world, first appearing in South America in the 1500s [16]. Varieties of cannabis were both a
medicinal/recreational substance and a critical crop for the American colonies in the 1700s.
Hemp was grown for its fiber, and it was a major export for farmers as well as a source of rope
and sail material. In the 1800s, hemp plantations thrived in Staten Island, New York, as well
as in Mississippi, Georgia, California, South Carolina, and Nebraska [17].
At the same time that Hemp was so commercially and strategically significant, cannabis sativa
was becoming better known. Cannabis was known to have been used for thousands of years
in China, and “marijuana” became a widely accepted medication in the nineteenth century.
Limited non-medical use of cannabis began to appear and the allegedly scandalous behavior
of cannabis users was a featured item in the popular press in the early decades of the 1900s [17].
Publicity associated with anti-cannabis sentiments demonized the substance and patterns of
its use and manifest subtle themes of bigotry against Mexican people.
Opium was a new entry to the American scene in the 1800s. Railroad laborers from China




expensive labor than Americans. The connection between opium and the displacement of
American workers was not to be forgotten and became a part of legislation that emerged later.
However, the use of opium was not regulated by the mid-1800s, so opium and its extrac‐
tions were readily available. For medical purposes, morphine had been derived from opium
in the early 1800s and became an ingredient in some patent medicines (discussed below) in
the United States. A vibrant patent medicine industry developed in the United States, with
widespread marketing and distribution of a many products that contained large quantities of
opium. These “medicines” claimed to cure just about anything, but they were really a vehicle
for opium at an inexpensive price [17]. Perhaps, the most commercially dramatic develop‐
ment among the opioids was heroin. The Bayer Company first marketed heroin in 1898 as
an (allegedly) addiction-free pain medication as well as a curative for abuse of other opioids.
Cocaine has a long history that first appeared in accounts of the chewing of coca leaves by the
native populations of South America [17]. By 1844, cocaine had been isolated in pure form,
though little use of it was made until later in the century. In the late 1870s, cocaine was used
for the treatment of alcoholism and morphine addiction. In the 1880s, Sigmund Freud became
aware of the use of cocaine to sustain Bavarian soldiers and started to experiment himself. He
published his exuberance quickly, but he came to see cocaine as more problematic than he
originally reported. Other distinguished medical professionals saw cocaine’s beneficial
potential. William Stewart Halstead found the mood enhancing and anesthetic properties of
cocaine in the mid-1880s.
Amphetamines were first created in the laboratory in 1887, but it took 40 years for clinical
applications to be realized. Military physicians used these stimulants for various purposes in
the combat theater as well as in clinics. Illicit use increased in the military in the 1950s [17],
and the use was also seen in truck drivers and students for a variety of medical conditions.
By the 1870s, Native Americans had begun ritual use of peyote, as had the Aztecs before them.
For the Comanches, Cheyennes, Arapahoes, and other tribes, peyote rituals were a complete‐
ly religious practice, requiring total abstinence from alcohol. Among these tribes, alcohol was
considered to be a substance of considerable abuse. White land speculators sought to have
peyote outlawed as a way to join with Christian missionaries and secure the Indian land. Much
like other pursuits of criminalization of substances, there was a powerful motive that was
different than the overt motivation [17].
As existing medications took more complex and pure forms, there was an increase in the
promotion of “patent medicines.” These preparations were promoted with great vigor, so had
creative names and claims of effectiveness that were more associated with marketing than
clinical effect. These preparations that were not actually patented were produced in England
and began to appear in the colonies in the 1700s. The production of patent medications grew
independently in the United States in the nineteenth century and was available through a wide
range of vendors. Alcohol, cocaine, and morphine were common ingredients [18, 19]. These
products included Laudanum (an alcohol preparation that originally included all of the opium
alkaloids), Vin Mariani (a wine with coca leaves), and Coca-Cola (with cocaine as an ingredi‐
ent).
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In 1943, Dr. Albert Hofmann discovered what came to be a popular and widely used halluci‐
nogen, lysergic acid diethylamide (LSD). Working with the fungus ergot to isolate compo‐
nents for pharmaceuticals, he accidentally ingested a small amount of the substance and had
what has been described as the “first acid trip.” Despite his careful account of the experience
in a professional publication [20], his serendipitous discovery has been widely repeated and
distorted. Hofmann went on to do further research in several areas and was persistent
throughout his career in his criticisms of public claims of the great dangers of LSD.
3.2. Expanding treatment in the early twentieth century
Before the Second World War, there were relatively few treatment alternatives for a person in
trouble with substance use. Concerned persons and some healthcare professionals com‐
plained about the limited treatment options, but most addiction treatment centered on the
management of withdrawal symptoms (now known as detoxification). The result of the lack
of treatment was increased the expansion of where addicts would seek mood-altering
substances. The lack of treatment and expanding drug seeking combined with advancing
criminalization led to the evolution of a new category of criminal. In addition, the United States
Public Health Service became involved in the problem of addiction in the 1920s. State facilities
for psychiatric patients and prisons were being overcrowded because of the arrests follow‐
ing the Harrison Narcotic Act [17]. In 1929, the Porter Act was passed, allocating funds to
develop to rehabilitation facilities. The first results of this legislation were the new facilities in
Lexington, Kentucky (1935) and Forth Worth Texas (1938). Treatment consisted primarily of
withdrawal, convalescence, and rehabilitation. Outcome studies yielded disappointing
results.
Three groups were critical to the development of what has become known as the “modern
alcoholism movement.” The Research Council on Problems of Alcohol, the Yale Center of
Alcohol Studies, and the National Committee for Education on Alcoholism combined to
promote a host of initiatives aimed at promoting treatment [21]. Following the Second World
War, there was increasing understanding about substance abuse disorders and the need to
organize public health efforts. The “disease model” (discussed below) was instrumental in
promoting significant discussions about substance-related problems. Most treatment still
occurred in general hospitals, state psychiatric hospitals, and private sanitariums. It is also
significant that freestanding treatment programs began to appear. Many of the early free‐
standing programs became well known because of the unique ways in which they were
developed. What came to be important to all of the treatment efforts that began to emerge was
the nature of each facility’s connection to alcoholics anonymous.
3.3. Alcoholics and narcotics anonymous
Alcoholics anonymous was established in 1935, and the eponymously named book of the
central tenets of AA was published in 1939. AA is based on 12 “steps” that are central to the
process of recovery and are considered to be indispensable to success. These steps are part of
a program that is codified in the “Big Book” and is very specific about being effective for 75%




that a Power greater than ourselves could restore us to sanity” and Step 5: “Admitted to God,
to ourselves, and to another human being the exact nature of our wrongs”), AA developed a
strong following and claimed considerable success. When AA was established, the treat‐
ment industry and the understanding of addiction could reasonably describe as being in its
infancy. Despite claims made in the Big Book, the efficacy of AA is very difficult to submit to
rigorous empirical evaluation due to the structure and procedures of the organization [22].
As noted above, the range of substances used and the associated problems expanded in the
early twentieth century. Efforts to assist users of substances other than alcohol gradually
expanded. By the mid-1940s, AA’s co-founder Bill Wilson discussed the possibility of a group
for a drug addicts that was separate from AA.
The first realization of Wilson’s idea was called NARCO; it first appeared in 1947 and met
weekly at the United States Public Health Service’s treatment center in the Lexington,
Kentucky federal prison. By the end of the 1940s, a NARCO member started a short-lived group
called “Narcotics Anonymous” in the New York Prison System. By 1953, Narcotics Anony‐
mous was clearly established in California [17]. Early members, many of whom were from AA,
worked out the 12 Traditions for the new organization. Within a year, the first NA publica‐
tion was printed, called the “Little Brown Book.” There was controversy in AA and NA
regarding Bill Wilson’s experimentation with LSD. While he experimented under the super‐
vision of a psychiatrist and a psychologist, the use of another drug (in addition to alcohol) was
seen as antithetical to the letter and spirit of “Anonymous” teachings.
AA continues to foster a spiritual foundation and works to alter the thinking of alcoholics
through “spiritual awakening.” Studies of the effectiveness of AA have not produced clear
results. AA is supported primarily by voluntary donations, and meetings are held in a vast
array of facilities, including prisons, treatment facilities, hospitals, and churches. AA groups
are available in most towns in the United States. Despite the relative paucity of efficacy studies,
AA has been recognized by professional groups [21]. In addition, despite initial scorn by much
of the medical profession, the American Medical Society recommended use of such self-help
groups in 1979.
3.4. The moral and disease models
3.4.1. The moral model
Modern medical views of substance misuse claim to view the problem as a medical, rather
than moral, problem. This appears to refrain from giving serious consideration to morality or
values as the foundation for the problem. However, there is considerable evidence, in public
opinion and its reflection in political discourse and the law, that substance misuse continues
to be viewed as a moral problem. Consistent with current views, there is extensive history of
morality as a dominant component of the views of substance abuse by many [23]. The moral
view was, in part, a part of an absence of other useful perspectives. However, there is also
substantial evidence for social control exerted from class and culture-related factors [24, 25].
Social groups who were so oriented would promote public campaigns in which misinforma‐
tion and inflammatory information were promoted related to the types of substances used, the
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that a Power greater than ourselves could restore us to sanity” and Step 5: “Admitted to God,
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nature of substance use, and other conduct associated with substance use. Substance use and
certainly misuse was proclaimed to be a manifestation of misplaced values and lack of moral
standing. Today, criminal penalty remains a dominant approach to substance-related
problems, despite considerable evidence that argues against the practical value of such an
approach. Some elements of faith-related perspectives, while offering assistance to some users,
continue to communicate judgment of these problems.
3.4.2. The disease model
One of the most significant developments in the intellectual representation of substance use
disorders was the “Disease Model” of addiction. The first major proponent of this approach
was Morton Jellenik [26]. Jellinek had witnessed the massive failure of the Volstead Act to stem
the use of alcohol and began to write from the Yale Summer School of Alcohol Studies. The
Disease model posits that certain individuals are vulnerable to substance use disorders as a
result of (inferred) neurochemical dysfunction. This “disease” is characterized by, in part, an
inability to control/inhibit behavior, loss of control, a failure to recognize the syndrome in one’s
self, and predictable decline. The disease model also suggests that the substance abuse
vulnerability can/does occur independent of other problems and is chronic. Thus, the
enlightened practitioner refrains from judgment of the abuser, and problems with substance
use should be permitted to mitigate criminal punishment when crimes are committed [27].
The disease model is not always described in the same way, and it may be seen as having
evolved since its first description. For example, despite the focus on factors internal to the
substance abuser in the disease model, [28] characterized the disease model as being
“multidimensional” and including psychological and sociocultural factors.
The later diversification of the disease model has done little to mute its detractors. Major
objections to the disease model appear to be linked to the basic assumptions of any disease-
related approach. For example, Wallace [29] called for a move beyond the disease model in
the context of Native North Americans, suggesting that the disease model is particularly toxic
in its neglect of context and culture in evaluating and intervening with substance-related
problems. Feminist theorists have highlighted the construction of gender in the context of
research and treatment approaches in general [30]. A behaviorist approach has also made
cogent arguments against the disease model [31].
Recognizing the actual physical destruction that is a possible result of substance use, some
behaviorists argue that a disease model is not needed at all for there to be adequate rationale
for effective treatment. Consistent with general behavioral principles, the behavioral ap‐
proach finds it more useful and even humane to view the problematic use of substances is a
by-product of the interaction between unique features of virtual and reinforcement contin‐
gencies within their environment. That is, what is rewarding about the context in which a
person has learned to use the substance? The behaviorist perspective also gives careful
consideration to the nature of motivation, since the nature of motivation, or drive states, is




3.5. Diagnosis of the substance-related disorders
The history of psychology and psychiatry includes a legacy of efforts to develop the most
elegant and powerful nosology of disorders of psychological adaptation. There is evidence of
attempts to categorize disorders as far back as the ancients, but increased focus emerged
around 1900 and has accelerated since. The first comprehensive modern work was the
Diagnostic and Statistical Manual (DSM) in 1952 [32]. Given that psychoanalysis still en‐
joyed hegemony in the clinical world of the late 1940s, the original DSM was relatively brief
and grounded in clinical lore and psychoanalytic theory. The DSM subsequently evolved from
a primarily psychoanalytic work to an atheoretical compendium that is designed to reflect the
highest levels of clinical and empirical science. By the time of DSM-II (1968 [33]), the role of
theory was substantially reduced and increasing specificity in diagnostic criteria was realized.
The introduction of the Diagnostic and Statistical Manual of Mental Disorders (Fifth edition:
DSM-V [34]) brought revisions to previous diagnostic criteria in the DSM tradition. Most
recently, the DSM-IV [35] used two main categories of substance misuse conditions, sub‐
stance abuse and substance dependence. The DSM-IV criteria were considered to be inade‐
quately descriptive of what was seen clinically, and the new criteria are claimed to be a
substantial improvement. These two categories from DSM-IV were combined into one
disorder in DSM-V that is diagnosed in conjunction with a rating from mild to severe. This
also eliminates the “substance dependence” category, which was widely seen as easily
confused with “addiction.” While using the same underlying criteria, each substance is
indicated as a distinct use disorder, including alcohol, cannabis, hallucinogens, inhalants,
opioids, sedatives, hypnotics or anxiolytics, stimulants, and tobacco. Caffeine-related syn‐
dromes are not included.
It is important to review the DSM-V criteria for substance use disorder. It is important to bear
in mind that each of these eleven criteria may be manifest in different ways and will be
influenced heavily by the pharmacology of the specific substance. For each of the substances,
the following are the eleven possible symptoms:
1. Taking the substance in larger amounts and for longer than intended
2. Wanting to cut down or quit but not being able to do it
3. Spending a lot of time obtaining the substance
4. Craving or a strong desire to use the substance
5. Repeatedly unable to carry out major obligations at work, school, or home due to
substance use
6. Continued use despite persistent or recurring social or interpersonal problems caused or
made worse by substance use
7. Stopping or reducing important social, occupational, or recreational activities due to
substance use
8. Recurrent use of substance in physically hazardous situations
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9. Consistent use of opioids despite acknowledgment of persistent or recurrent physical or
psychological difficulties from using substance
10. *Tolerance as defined by either a need for markedly increased amounts to achieve
intoxication or desired effect or markedly diminished effect with continued use of the
same amount (does not apply for diminished effect when used appropriately under
medical supervision).
11. *Withdrawal manifesting as either characteristic syndrome or the substance is used to
avoid withdrawal (does not apply when used appropriately under medical supervision).
The DSM-V section with substance-related disorders includes gambling, which was not in the
same section as substances in prior versions of DSM. The task force members for the sub‐
stance and other addictive disorders section gathered findings that suggest that gambling
disorder is similar in a number of respects to substance-related disorders. It is also thought
that this development will make the accessing of treatment more likely. Other disorders that
may be considered relevant (e.g., Internet, social media) have not yet been seen as having the
empirical support needed for inclusion in this section.
4. Treatment approaches
There have been a staggering number of treatment approaches substance-related problems
over the centuries [17]. It is virtually impossible to organize and categorize all treatment
approaches, and the intersection of treatment method and type of professional further
complicates the picture. The difficulties of professional domains and perspectives are further
exacerbated by the relative lack of evidence for the effectiveness for different interventions
[36]. In fact, there is some evidence to suggest that the specific treatment approach or techni‐
que is not as important to outcome as are factors associated with intervention relationships
such as empathy [37]. Garner [38] issued a clear call for greater methodological rigor in studies
of treatment efficacy to ensure development of treatment approaches that are grounded in
empirical support. Recent suggestions have begun to clarify how this research might be
conducted. DuPont et al. [39] suggested that addiction should be considered separate from
other forms of health care because of the complexity and need for better kinds of research. In
addition, they highlighted the high level of investment required in successful treatment, the
variety of substances associated with disorders, and the varieties of organizational struc‐
tures present in the treatment community. They also highlighted the severity, complexity, and
chronicity of these disorders as important guideposts for the development of outcome
measures. In light of the complexity of the treatment factors just noted, the final section of this
chapter will highlight a few of the major treatment perspectives.
4.1. Detoxification
The critical role of detoxification in substance abuse treatment has continued since its central




impact of substance use, addictive processes, and treatment, there was obvious emphasis
detoxification as an essential step in recovery. In addition, there was considerable emphasis
on physical dependence as a central element of addiction. So, work with a patient began with
simply clearing the body of the toxic substances, often with inpatient medical supervision and
sometimes medications such as benzodiazepines. Today, detoxification is not technically
considered to be actual treatment for a substance use disorder, though it is widely seen as a
fundamental first step for treatment. However, contemporary perspectives on treatment
manifest great variability in the rate of movement from detoxification to longer forms of
intervention. The relative merits of gradual versus sudden withdrawal quickly became a
matter of intense dispute in the medical community [1,42–44]. Modern research has identi‐
fied factors that make detoxification a more effective part of a treatment system in which
approximately one-fifth of annual admissions include detoxification [40]. The availability of
intervention beyond detoxification is greatly influenced by healthcare economics. Despite
efforts associated with the Affordable Care Act, many persons with substance use disorders
are uninsured or underinsured. It is clear that finances are associated with the quality of
intervention as well as limitations on the quantity and nature of service modalities. The
Wellstone and Domenici move in 2008 to bring parity to mental health care did attempt to
reduce barriers to treatment utilization, reduce financial burdens, and decrease stigma, though
the success of those efforts is a matter of debate [41].
4.2. Harm reduction
“Harm reduction” is a relatively recent approach that functions in contrast to abstinence-only
models. There have been several major contributors who have influenced this approach,
though their assumptions and strategies are similar (in particular [1, 42–44]. With a pragmat‐
ic perspective that is theoretically inclusive, the harm reduction approach considers psycho‐
active substance use to be a part of the human experience and works to minimize damage
resulting from use. The harm reduction approach, like many other approaches, considers
substance use (and misuse) to be a complex result of many forces and maintains the view that
there are constructive and destructive ways to use many substances. Without minimizing the
real destruction from use, this perspective emphasizes the participation of substance users in
reducing harm as well as the great significance of poverty, class, racism, social isolation, past
trauma, sex-based discrimination and other social inequalities as vulnerability factors. With
this broad emphasis, intervention is associated with the unique realities of the person who is
struggling with substances and predetermined treatments are not embraced. Proponents of
harm reduction thus characterize it as a public health alternative to moral, criminal, or disease
models. From this point of view, it is appropriate to adopt a “whatever it takes” perspective
on intervention with persons who abuse substances.
Peele, in particular, supports harm reduction and speaks in contrast to the AA tradition,
promoting natural solutions in the context of careful goal-setting and the making of person‐
al meaning in recovery. His writing includes specific arguments about the perils of the disease
model. Peele argues that addicts are not different from other people in respects other than the
addiction. In addition, Peele disputes a number of long-standing assumptions of the AA
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tradition. He does not agree that recovery depends on forces outside the individual or that
substance abusers are unable to control themselves in any situation. Since Jellenik’s seminal
contributions to the disease model, “addiction” has been perceived as a predictable, progres‐
sive, and fatal disease. Peele argues that this is not the standard progression through which
an addict must inexorably pass, and recovery does not consist of a lifelong conscription to
absence and twelve-step methods. In fact, Peele argues that the pessimism and determinism
that are intrinsic to the disease model actually contribute to the likelihood of relapse and
continued harm.
Some harm reduction techniques include methadone maintenance, which serves as a safer
alternative to heroin use because of the longer half-life of methadone and the safer route of
administration. Other approaches may include over the counter medications or even care in
maintaining hydration with club drugs [45]. Needle exchange programs have been a highly
visible and controversial approach to harm reduction that targets the high levels of risk
associated with sharing intravenous drug administration supplies [46].
The harm reduction approach has been bolstered by the addition of mindfulness techniques
[47]. Grounded in Buddhist tradition, mindfulness is considered to be the cultivation of
awareness in the present moment. Mindfulness practices have been integrated into many of
the therapeutic approaches since it began to appear in Western teachings in the 1950s.
Mindfulness began to appear into the scientific literature associated with substance abuse
treatment relatively recently [48].
4.3. Relapse prevention
“Relapse” refers to a return of problem behavior following an interval during which an
individual has been relatively problem free. The study of relapse has been motivated by the
prevalence of relapse, by attempts to bolster treatment effectiveness as well as to understand
the persistence of substance-related problems. The practice of relapse prevention is an eclectic
blend of a variety of approaches that have mixed empirical support. Many of these ap‐
proaches are rooted in clinician beliefs and experience as well as guidance from recovering
users. For example, “booster sessions” may follow the termination of regular treatment contact.
Relapse prevention strategies are likely to be a part of a final phase of treatment and at‐
tempts to solidify relapse prevention may be a routine protocol during a termination phase.
Recovering users are called upon to identify high risk situations and develop a range of robust
coping mechanisms. Similar to this evaluation of the environment, persons in the treatment
are encouraged to identify warning signs within him or herself as well as overall factors of
vulnerability that may increase the risk of relapse. Attempts to generalize training experien‐
ces that are cultivated in treatment include exercises to bring lessons from treatment to real-
life situations.
4.4. Interpersonal therapies
Since the inception of psychoanalysis in the late 1800s, the relationship between a would-be




tions. As the understanding of the fundamental conditions of therapeutic relationships
advanced in the twentieth century, so did empirical support for the essential quality of certain
therapeutic conditions. Interpersonal therapies were not initially designed for substance
abusing persons, and the psychopharmacology of substances was recognized early in the
history of psychotherapy as a complicating factor in treatment. Freud’s exaltation of and
subsequent struggle with cocaine is a well-known example of this uncomfortable reality. Early
psychoanalytic theories of substance misuse were provocative and controversial [49–52]. In
general, however, themes emerged that suggested that substance use problems developed in
association with the person’s inability to meet their inner needs in more adaptive ways [53].
Interpersonal approaches to substance use disorders are optimized when recognizing and
incorporating psychopharmacological and substance use realities. In addition to the realities
of substance misuse, patients are encouraged to confront issues that emerge in the absence of
the substances. For example, a recovering user may be encouraged to grieve the “lost friend”
of the substance. Shame is frequently identified and challenged as a factor in the inevitable
frustration of needs. Defense mechanisms, originally couched in psychoanalytic language as
negative factors, became seen as essential elements of psychic life and forces which need to be
improved and not eliminated. For persons who use substances in problematic ways, defense
mechanisms are identified as adaptive or maladaptive and modified accordingly. In general,
the enhancement of self-expression and the relative satisfaction associated with human
connections are bolstered in this approach.
4.5. Cognitive behavior therapy
Cognitive behavior therapy (CBT) may reasonably consider one of the dominant perspec‐
tives in mental health and substance abuse therapeutics today [54]. CBT is a blend of behav‐
ior therapy (BT) and cognitive therapy (CT). BT was originally introduced as an attempt to
apply laboratory-based behaviorism to human change processes. BT was, in part, a reaction
to psychoanalysis that was seen as pessimistic, deterministic, and nearly impossible to
investigate empirically. An example of a behavioral approach to substance abuse therapeu‐
tics is contingency management (CM[55, 56]). CM uses the principles of operant condition‐
ing and provides established reinforcers for drug abstinence or other objective measures of
drug abstinence. The rewards may be a coupon for goods and services, a verbal reward, or
small monetary tokens. This approach includes escalating rewards with rules for resetting the
reward when there has been a relapse. Another example of a behavioral approach illustrates
the role of contingencies on task participation (in contrast to abstinence as in the previous
example). Spohr et al. [57] reported the results of behavioral approach in which rewards were
established related to participation in probation and treatment of tasks.
Cognitive therapy has a broad history, in as much as there is evidence of some of the central
tenets of the approach in the writings of the ancients [54]. While there are an increasing number
of variants, cognitive therapy addresses thinking patterns that contribute to problems in
adaptation.
Another approach that some consider to be within the cognitive behavioral tradition is
dialectical behavior therapy (DBT [58]). DBT is an empirically supported therapy approach
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that was designed originally to assist persons who are struggling with symptoms of border‐
line personality disorder. Since its original development, it has been adapted for the treat‐
ment of substance use disorders [59]. DBT prioritizes risky behaviors (self-injury) and then
works directly with substance use issues. Next, the approach attends to effects of substance
use, such as legal jeopardy and vocational difficulties. Finally, DBT builds skills for broad
psychological adaptation and relapse prevention.
4.6. Contributions from contemporary pharmacology and neuroscience
With the rise of neuroscience and a deeper understanding of cognitive processes, contempo‐
rary neuroscience has begun to offer evidence holds some promise of informing clinical efforts.
It has been suggested [60] that mechanisms associated with motivation and control elements
of addictive processes are better illuminated by advances in the neurocognitive laboratory than
prior models. In particular, attentional bias, reward processing, and cognitive control are
important areas of research that are soon to make direct contributions to treatment. These
findings are consistent with early findings related in impulse control that indicate that impulse
control problems is a likely culprit in at least the exacerbation if not a cause of substance abuse
problems [61]. EEG study has suggested that patterns of substance misuse may be associat‐
ed with detectable deflections in brain activity as assessed via quantitative electroencepha‐
lography (qEEG) methods [62]. The decade of the 2000s reflected increased interest in the role
of executive function in a number of human problems in adaptation including substance abuse
patterns. An essential element of executive function is the capacity to postpone, prevent, and/
or arrest a behavioral response to permit time for the development of more constructive paths
of behavior [63].
Some facets of substance misuse phenomena are being treated with repetitive transcranial
magnetic stimulation (rTMS [64]). This non-invasive method uses an electromagnetic field that
changes rapidly and induces electrical currents in the brain. rTMS has been found to have
promising effects on some aspects of addiction-related cognitions. While there is continued
investigation into the exact mechanism of effect of rTMS, craving has been seen as an area of
patient difficulty that responds to rTMS [65].
The role of dopamine represents another avenue of research/treatment progress. While the
direct treatment implications are not clear, it is important to note that the emerging work in
physiology indicates that substance abuse and disinhibition are different [66]. Prominent
striatal dopamine has an important influence on externalizing proneness (disinhibition) and
on reward-based decision-making. Using eyeblink rate as estimator of dopamine level
associated with disinhibition, investigators have found that dopamine is more strongly
associated how much an individual “wants” (motivation) to learn about making decisions
associated with tangible rewards. This orientation to learning about decision-making is then
accompanied by working with an individual’s broader substance use patterns that are
associated with learning of action-reward contingencies [67].
For a number of reasons consistent with the approaches just noted, psychotropic medica‐
tions have been used with some success to reduce vulnerabilities associated with substance




cravings (agonists or partial agonists), interfere with the pleasurable sensations that come from
use (antagonists), or create negative feelings with a substance is taken. Methadone, buprenor‐
phine (opioid partial agonist-antagonist), and naltrexone (antagonist) have been used for
opioid addiction. Antabuse has been used for alcohol since tire manufacturers noticed that
workers could not drink alcohol after the vapors of the precursor of antabuse was inhaled
during the vulcanization of rubber [17]. In the wake of problems associated with methadone
maintenance, buprenorphine has become an effective alternative in reducing withdrawal
symptoms and cravings associated with opioid dependence. For nicotine, there are three FDA-
approved approaches to nicotine replacement. The FDA first approved nicotine gum
(approved in 1984 and available over the counter in 1996) and the transdermal nicotine
patch (approved in 1992 and over the counter in 1996) for smoking cessation. Finally, nicotine
sprays (1996) and inhalers (1998) were approved for dispensing by prescription. Other
psychotropic medications have been used in an off-label fashion to reduce depression and
anxiety associated with recovery.
4.7. Motivational interviewing
Motivational interviewing (MI) is defined by its originators as a directive, client-centered
counseling style for eliciting behavior change by helping clients to explore and resolve
ambivalence [68]. The developers of MI affirm that MI is primarily a style of relating to service
recipients rather than a specific set of techniques [69]. The originators of MI explicitly described
borrowing many ideas from the interpersonal therapy tradition, and MI has become a “Gold
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and appreciating the variability in change readiness. In addition, empathy is emphasized and
therapeutic resistance is a force with which one collaborates, and client inconsistencies are
challenged. Further, MI emphasizes engagement with clients in empathic and collaborative
communication, attention to established behavior change goals, and the initiation of change
planning when the client is ready. There is a growing body of empirical work that supports
the efficacy of MI for substance abuse disorders [70, 71].
Despite the fact that MI is touted primarily as a style of relating to patients, literature that
followed its introduction highlighted specific techniques. These techniques were not forward‐
ed as specifically essential to the approach but rather were considered to be naturally emerging
and optimal examples of how the perspective might appear in practice.
4.8. Efficacy of treatment approaches
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substance-related disorders. In the interest of brevity, Table 1 is presented with references
pertaining to the nature of the treatment approaches and their efficacy. There are some
important observations that are worth noting beyond the specifics of the table. Evidence
continues to accumulate for the effectiveness of a variety of treatment approaches as well as
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for “translational research” that takes findings from the laboratory and cultivates enhanced
clinical practice [73]. New methods of assessing efficacy have been proposed that are more





[77] Argues for more specific targets in treatment and reviews difficulties in
empirical support for empirically supported treatments
[78] Examines issues associated with the development and use of evidence-
based treatment research
Detoxification [40] An evaluation of the factors that are associated with successful detox
completion
[79] Examined the impact of medically assisted detoxification on subsequent
outcomes
Harm reduction [80] Reviews approaches to and perspectives on the harm reduction approach
[81] Evaluation of syringe dispensing machines and public impact – example of
harm reduction strategy
Relapse prevention [82] Reviews three main approaches to pharmacological intervention for relapse
prevention
[83] Review of the effectiveness of relapse prevention with substance abuse
disorders
Interpersonal therapies [84] Description of practical elements of family therapy approaches to substance
abuse treatment
[85] Review of six articles that considered creative writing as a facilitator of the
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[87] Brief discussion of elements of interpersonal intervention with substance
abusers
[37] A discussion of relationship factors in treatment of substance use disorders
Cognitive behavioral and
behavioral therapy
[88] Examined the impact of adding a trauma component to group-based
cognitive behavioral therapy
[57] Outcome study of electronic reminders of goals for group of drug-involved
offenders.
[89] Review of the effectiveness of mindfulness interventions with substance use
disorders







[90] Report of a review of studies of transcranial magnetic stimulation on
addiction
[62] A review outcome studies of the effectiveness of EEG Biofeedback for
treatment of substance use disorder
[65] Evaluated the use of transcranial magnetic stimulation on smoking cue-
induced craving




[92] Discusses the combination of MI with cognitive behavioral
technique
[93] Considered the connection between therapist attitude toward MI and
impact on client interpersonal functioning
Drug court [94] Evaluated drug courts as a promoter of “turning points” for offenders
in areas of self-esteem, relationship, educational development,
employment
[95] Examination of the value of compulsory treatment of addiction in
Australia and the United States
Alcoholics anonymous [96] Considers the value of the “therapeutic alliance” that develops in
AA as a significant curative factor
[97] Examines the effectiveness of AA in a research method that reduces
previous method problems. Support for the effectiveness of AA
is reported.
Table 1. Representative literature of efficacy and application of treatment approaches.
5. Conclusion
The history of use of mood-altering substances is complex and controversial. For centuries, the
conflict between the benefits of varied substances and the massive societal costs of the misuse
of substances has been confused by political and economic motivations for action related to
substance users. A contemporary response to the complexity and cost of substance-related
disorders is the development of the drug court. The first drug court was created in Florida
in 1989 [75] as there was growing awareness of the widespread presence of substance abusing
offenders in the criminal justice system. As testimony to the appeal of the drug court con‐
cept, one may note that National institute of Justice reported that there were more than 3400
drug courts in the United States by the middle of 2014. Drug court programs consider an
individual’s unique patterns of use and associated consequences with a graduated series of
rewards for the attainment of target behaviors. Early evidence suggests that drug courts are
associated with lower recidivism [76]. Drug court may reflect the type of approach that fits the
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complex and destructive influence of substance misuse. Drug court is a program that offers
many services to legally mandated individuals, and it represents an intersection between
several models of addiction, most notably the moral and medical models. Following a legal
adjudication, a treatment and follow-up plan is created that involves the judgment and
leverage intrinsic to the criminal justice system. Thus, the moral dimension of drug court serves
as the “teeth” for the accountability built into the program. At the same time, the nature of the
substance use problem is assessed and diagnosed by treatment facilities that work in concert
with the court. Treatment is based on the prevailing diagnostic system (DSM, ICD) that reflects
the specific diagnostic criteria and decision rules that characterize the medical model. With
this combination of perspectives, the drug court concept may represent the interdisciplinary
future of substance abuse therapeutics.
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Abstract
Dual diagnosis (DD) is the coexistence of severe mental illness (SMI) and substance
use  disorder  (SUD).  The  increase  of  DD  observed  in  recent  years  has  important
implications for mental health services organization. The aim of this study is to assess
the prevalence and features of DD over a decade, comparing the periods 2003–2004
and 2013–2014. We performed a retrospective study retrieving sociodemographic and
clinical  data  from  the  medical  records  of  patients  at  their  first  admission  to  the
Psychiatric  Ward of  University Hospital  “Maggiore della  Carità” in Novara,  Italy.
Patients  with  SMI  and comorbid  SUD (SMI-SUD) and patients  with  SMI  without
comorbidity (SMI) were compared in the two periods, 2003–2004 versus 2013–2014.
SMI-SUD  patients  in  both  2-year  periods  were  more  likely  to  be  male,  younger,
unemployed, living with parents (or alone, for the 2013–2014 period) rather than with
a family of their own, and single (or divorced, in 2003–2004). The 2003–2004 patients
were  more  frequently  diagnosed  with  a  personality  disorder,  whereas  the  2013–
2014  patients  had  mixed  diagnoses.  We  have  found  differences  in  the  possible
predictors of substance abuse in the two periods as well: in both periods, male gender
was associated with an increased risk of DD, whereas age >61 years was associated
with decreased risk.  Only in  the  first  period (2003–2004)  was having a  university
degree associated with a decreased risk of DD, whereas the diagnosis of a personal‐
ity  disorder  was associated with an increased risk of  DD;  on the contrary,  in  the
second period (2013–2014), living in a protective environment was associated with a
decreased  risk  of  DD.  The  identification  of  changes  in  the  prevalence  of  first
admission DD patients and their clinical and sociodemographic features may help to
highlight an evolving pattern of substance use and to identify possible risk factors
that may be the target of prevention and treatment approaches.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.




The pathway that leads to addiction is characterized by specific steps: the initiation of sub‐
stance use, the established use, and, finally, the development of addiction. Several factors are
involved in this process, including genetic and environmental ones. The availability of the
substance may play a role in each stage in the development of addiction, whereas the accessi‐
bility of a substance seems relatively more important in the initiation of substance use [1].
Evidence from family, adoption, and twin studies converges on the relevance of genetic factors
in the development of addiction according to a complex model of inheritance and clinical and
genetic heterogeneity [2–10]. The role of genetic, sociocultural, biological, and other factors,
including drug availability, peer influence, social support, and type and psychoactive proper‐
ties of the drug, varies across the lifespan and in different stages of the addiction process. Briefly,
it seems that environmental factors (such as peer influences and family environment) have a
stronger effect on exposure and initial pattern of use, whereas genetic factors play a major role
in the transition from regular use to the development of addiction [11,12]. Moreover, it should
not be overlooked that genetic factors underlying addiction may overlap to various degrees
with those underlying other psychiatric disorders. For instance, studies focusing on the role of
the COMT gene polymorphism in the genetic predisposition to mental disorders [including
severe mental illness (SMI), such as schizophrenia, bipolar disorder, obsessive-compulsive
disorder, anorexia nervosa, and attention-deficit hyperactivity disorder] have found that the
same polymorphism may be involved in the pathogenesis of addiction and substance use
disorder (SUD). Probably COMT increases susceptibility to mental disorders in general, whereas
other genetic or environmental factors may influence the development of specific disorders,
including SUD [13].
1.2. Dual diagnosis (DD)
The World Health Organization defines DD as the co-occurrence, in the same person, of a
severe mental health condition (SMI) with a drug abuse or dependence disorder (SUD).
In 1993, First and Gladis [14] proposed to classify DD patients as follows: (1) main psychiat‐
ric disorder and secondary drug dependence, (2) main SUD and secondary psychiatric
disorder, and (3) main psychiatric disorder and drug dependence. Discriminating among these
three options may be particularly challenging in clinical settings, where it can be hard to
understand whether it is the SMI that induced drug consumption or the drug consumption
that induced or worsened the SMI.
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Consistent with the first class proposed by First and Gladis (psychiatric disorder first and
subsequent drug dependence), the study of the psychological attitudes in addiction disor‐
ders has lead to the self-medication hypothesis (SMH) proposed by Khantzian [15]. The SMH
primarily derives from clinical observations and posits substance dependence as a compen‐
satory means to modulate emotions and aimed at self-soothing in response to distressing
psychological states. According to this hypothesis, drugs would become addicting because of
their power to alleviate, counteract, or modulate psychological suffering; there would also be
a considerable degree of specificity in a person’s choice of drugs because of unique psycho‐
logical and physiological effects [15]. Hence, emotional states and distress, as well as expect‐
ancy of positive affective modifications, would be associated with substance use or relapse in
people with SUD [16]. The SMH has received a variable empirical support, particularly as far
as drug specificity is concerned [17]. The choice of type of drug according to the SMH is
sometimes counterintuitive. For instance, while DD bipolar patients seem to use substances to
maintain a euphoric state or soothe a depressive suffering, depressed patients, who might be
expected to choose stimulants as well, often turn to depressants such as alcohol. Schizophren‐
ic patients are often strongly nicotine addicted, and their heavy smoking may be an attempt
to alleviate cognitive deficits and to reduce extrapyramidal side effects induced by antipsy‐
chotic medication, through the effect of nicotine on dopaminergic activity [18]. Briefly, the
choice of a particular type of substance could depend on the symptoms that patients wish to
relieve, as well as on substance availability, and on patients’ basic personality traits [19].
Moreover, clinical experience in the last years has highlighted clear and ongoing changes in
the choice of type of drug [from heroin and lysergic acid diethylamide (LSD) to the current so-
called “smart drugs”, vegetable or synthetic origin compounds with psychoactive effects that
are not yet considered illegal]. For instance, changes in the prevalence of commonly used
substances in people with DD have been discussed in two studies that estimated the preva‐
lence of SUD in patients with SMI in Philadelphia [20,21]. These studies found a shift from
cannabis being the most commonly used drug to cocaine and associated changes in demo‐
graphic correlates. Although these data date back to more than 20 years ago, they highlight
the changing pattern of SUD [22,23].
Consistent with these results, in Italy, in the last two decades, significant changes in the main
drug used by patients attending addiction services have been noticed. Although the use of
alcohol has remained relatively stable, there has been a significant decrease in the use of heroin
and an opposite tendency regarding the use of cocaine; moreover, the use of “smart drugs”
and polyabuse (i.e., the abuse of several substances simultaneously) has increased in an
alarming way. The reasons underlying the use of new drugs may be different from those
guiding the first heroin addicts. For instance, ecstasy has been generally chosen by adoles‐
cents and young adults for its entactogenic properties (the stimulation and enhancement of
feelings of empathy, love, and presumed emotional closeness to others) [24,25].
As already suggested, personality may play a relevant role in the choice of the drug and
expectations concerning the desired effect of the drug itself. The motivation leading to drug
abuse may span from alleviating boredom and active search for pleasure, improvement of
attention and performance, to reducing tension and decreasing mental illness symptoms.




Hence, personality traits should be assessed to improve the understanding of the complex
relation between patients, drugs, and environment [26].
According to Cloninger’s model [27,28], personality consists of temperament and character
traits. Temperament is defined as a biological disposition reflected by relatively stable features
related to mood, attitudes towards the environment, and reactivity to external and internal
stimuli, including variability and intensity in emotional dispositions [29,30], whereas charac‐
ter is based on mechanisms that are developed through life experience. Although only a few
studies have investigated personality dimensions in DD patients with the model developed
by Cloninger, most of these found an association with high scores on the temperamental
dimension of “novelty seeking” [31,32] as well as with high scores on “harm avoidance” [31].
According to Cloninger’s descriptions of these temperament dimensions, we may expect
patients with high scores on “novelty seeking” using drugs to search pleasure and to escape
boredom and patients with high scores on “harm avoidance” using substances to achieve relief
from tension and unpleasant or painful emotional states [33].
1.3. Epidemiology and clinical features of DD patients
Comorbidity between drug and/or alcohol dependence and a SMI is highly prevalent, and
clinicians should be aware that patients asking for a psychiatric advice are likely to conceal
their problems related to use and/or abuse of substances, unless specifically asked about
them [34,35], possibly leading to an underestimation of DD. Recent studies report that the
prevalence of DD in patients attending mental health service and substance misuse services
ranges between 55% and 85% [36,37], and an association between SUD and mood and anxiety
disorders has been supported by epidemiological and clinical studies [38–41]. In 2014, in the
United States, among adults with a past year SUD, 39.1% had a comorbid psychiatric disor‐
der, whereas, among adults without a past year SUD, only 16.2% had a SMI [42]. Moreover,
epidemiological studies consistently describe a gender difference in DD patients as far as
diagnosis is concerned; overall, DD is more common in males, and male patients usually suffer
from psychotic and bipolar disorders, whereas depression and anxiety are more represented
in women who, on the contrary, represent a smaller percentage of DD samples [43,44].
Many longitudinal or cross-sectional studies tried to identify recurrent and significant
sociodemographic features and pattern/type of abuse typical of DD patients. The literature
suggests that DD patients, compared to those with SMI but no comorbidity with SUD, are
usually younger, males, with a lower level of education, often unemployed, still living with
parents rather than with a family of their own, and with an overall lower social functioning
[45–47]. DD is related to worst compliance to treatments, higher relapse rates and health
services usage, more functional disability, and cognitive as well as psychological, physical,
and social impairment [37,43,47,48]. Overall, DD patients show a poorer quality of life and
reduced life expectancy [49] compared with patients with SMI or patients with SUD with no
other comorbid psychiatric disorder.
The treatment of DD patients is particularly challenging because of the poor compliance and
significant deterioration in social functioning that often occurs in these patients. They are more
likely to suffer from comorbid medical conditions; as described above, they may experience
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more difficulties in family relationships and troubles maintaining a stable job and financial
situation; moreover, they may have legal problems related to the behavioral consequences of
substance use and/or to the illegal attempts to obtain the substance. Compared to schizophre‐
nia patients who do not use alcohol and drugs, patients with DD tend to have an earlier age
of onset, more frequent and sometimes longer periods of hospitalization, more severe
depressive and psychotic symptoms, more episodes of suicidal and violent behavior, more
legal and financial problems, and higher mortality risk [50–56]. Likewise, bipolar patients with
DD have 6.4-fold risk for violent crime compared with bipolar patients without comorbidity
[57,58]. Overall, because they are less likely to adhere to their medication regimen, patients
with DD also are at an increased risk of relapse and re-hospitalization [59,60]. However, even
in those who do adhere to their medication, commonly abused substances can trigger or
exacerbate psychiatric symptoms, eventually leading to relapse and need for inpatient
treatment.
Although, in the last years, several studies have been performed about early detection and
treatment of DD [59–64], there is a dearth of studies focused on the changes in the preva‐
lence of DD in psychiatric inpatients [65]. A study about comorbidity with SUD in psychiat‐
ric inpatients performed in Spain [66] found 24.9% of inpatients having a SUD as well as
another psychiatric disorder. Consistent with the literature about DD, a statistically signifi‐
cant predominance of men was found in the DD group together with younger age at the time
of their first psychiatric admission; the most common diagnoses in this group were schizo‐
phrenia or related psychoses, although patients with SMI only had mostly affective disor‐
ders. As described above for preferred substance of abuse, the most used was alcohol followed
by cannabis and cocaine.
Another interesting study assessing the trends in the incidence and demographic and clinical
correlates of DD among patients whose first psychiatric hospitalization occurred between 1996
and 2010 was performed in Israel by Ponizovsky et al. in 2015 [67]. Based on the literature and
their clinical experience, they hypothesized an increase of the proportion of DD among all first
psychiatric hospitalizations during the study period due to the increasing prevalence of
substance-related disorders in the general population, an increased vulnerability to DD on
behalf of specific population groups (e.g., new immigrants) [68–70], and, lastly, higher DD
rates in involuntarily hospitalized patients because they may be more likely to show epi‐
sodes of suicidal and violent behavior [52] compared to voluntarily admitted patients. Over
the study period, DD with drugs decreased from 1996 to 2010, whereas DD with alcohol and
DD with both drugs and alcohol increased. The changing pattern of DD over time was
supported as well as most findings concerning the sociodemographic features of DD pa‐
tients reported in the literature. The positive predictors of DD with alcohol were male gender,
previous suicide attempt, compulsory hospitalizations, and marital status. DD with alcohol
was found mainly in immigrants, whereas DD with drugs was more common in the native
population.




1.4. Challenges and perspectives in research
Treatment of DD patients requires a thorough understanding of both mental illness and
addiction and the consequent integration of the traditional treatment approaches in both the
mental health and addiction treatment fields [71].
In the research field, a complicating issue for DD studies is that they may focus on different
populations: the general public, the population of subjects referring to psychiatric services,
and the population of people currently treated by addiction services [72]. This diversity
affecting the research field may be a concrete, challenging reality from a clinical standpoint.
In Italy, this is particularly important because the standard practice for patients with comor‐
bid psychiatric disorders and SUD is a parallel treatment. In our country, mental health and
addiction facilities have different institutional cultures, etiological concepts, administrative
arrangements, screening, and treatment approaches [73]. The problematic issues of such
treatment approach include possible flaws in communication, collaboration, and linkage,
which might significantly hinder or complicate comorbidity service delivery [74,75].
Even if it is clearly a changing and growing problem, the number of studies on DD preva‐
lence in patients admitted to psychiatric wards in general hospitals in Italy is still scant. A
recent study [76] has focused on differences in the length of stay in first-hospitalization
schizophrenic patients with and without comorbid SUD and found that the first showed poorer
symptom improvement and required longer stays than the latter. The flaws of communica‐
tion and linkage between psychiatric and addiction services emerged from the study by Preti
et al. [77], who reported that only approximately 30% of patients with SUD discharged from
acute psychiatric inpatient facilities were referred to drug addiction services. Other issues that
have been investigated in this field include SUD in emergency room settings [78], gender
differences in DD patients [65], and attempts to understand whether SUD follows or pre‐
dates the psychiatric diagnosis [79,80].
Considering these premises, the aim of our study was to describe the sociodemographic and
clinical features of DD patients at their first admission to the Psychiatric Ward of University
Hospital “Maggiore della Carità” in Novara, Italy. With more detail, we collected data about
all patients admitted for the first time during the 2-year periods 2003–2004 and 2013–2014 to
(1) assess the extent of comorbidity with drug abuse in a sample of patients at their first
admission to a psychiatric ward in a general hospital in Italy; (2) investigate whether there are
differences between inpatients with and without comorbid SUD, focusing on sociodemo‐
graphic, clinical, and other background variables in both periods; (3) investigate the possible
differences between patients with comorbid SUD in the two 2-year periods; and (4) identify
the possible predictors of comorbidity with SUD and their changes over a decade.
2. Methods
We performed a retrospective study reviewing the clinical charts of patients at their first
admission to the Psychiatric Ward of University Hospital “Maggiore della Carità” in Novara,
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(1) assess the extent of comorbidity with drug abuse in a sample of patients at their first
admission to a psychiatric ward in a general hospital in Italy; (2) investigate whether there are
differences between inpatients with and without comorbid SUD, focusing on sociodemo‐
graphic, clinical, and other background variables in both periods; (3) investigate the possible
differences between patients with comorbid SUD in the two 2-year periods; and (4) identify
the possible predictors of comorbidity with SUD and their changes over a decade.
2. Methods
We performed a retrospective study reviewing the clinical charts of patients at their first
admission to the Psychiatric Ward of University Hospital “Maggiore della Carità” in Novara,
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Italy. We assessed two 2-year periods: 2003–2004 and 2013–2014. We excluded the records of
patients with a diagnosis at discharge of SUD with no comorbid psychiatric disorder. Because
our interest was to focus on DD, we collected data about patients with comorbid psychiatric
and SUD diagnosis (later on described as SMI-SUD) and about psychiatric patients without
comorbid SUD (SMI).
The following information was retrieved from the clinical charts: (1) sociodemographic data,
including age, sex, education, occupational status, living accommodation, marital status, and
legal problems and (2) clinical and psychopathological history, information concerning drug
use, history of self-harm (including suicidal and parasuicidal behaviors), and history of
aggressive behaviors and acting out.
Psychiatric diagnoses were made during the hospital stay by experienced psychiatrists with
the aid of the Structured Clinical Interview I [81] and II [82] for Axis I and Axis II disorders,
respectively. According to the International Classification of Diseases [83], diagnoses were the
following: schizophrenia and other psychoses, affective disorders, anxiety disorders, and
personality disorders; disturbance of conduct, mental retardation, eating disorders, acute
stress reaction, and adaptation reaction were grouped as “other diagnoses”.
Information about the use of psychotropic drugs was collected by the treating psychiatrist
during inpatient treatment, including age at first use and type of substance (alcohol, psychi‐
atric drugs, cannabis, heroin, and cocaine; methamphetamine, ketamine, phencyclidine, LSD,
butyl nitrite, amyl nitrite, and γ-hydroxybutyric acid were grouped together as “other drugs”).
As for diagnosis, these data were then gathered for research purposes from clinical charts. The
research project was approved by the Institutional Review Board of Università del Piemonte
Orientale.
Statistical analyses were performed using STATA 11 (Stata Corp., College Station, TX, 2011).
Initial descriptive statistics included the χ2 test to evaluate the differences in proportions
between groups (SMI-SUD vs SMI patients in the two periods). Then, a multivariate analysis
was performed using a logistic regression to assess the potential predictors of substance abuse.
The covariates included in the final model were selected using a stepwise forward selection
process, with a univariate p<0.25 as the main criterion [84]. Results are expressed as odds
ratio (OR) with 95% confidence interval (CI). A two-tailed p<0.05 was considered significant
for all analyses.
3. Results
Patients first admitted to our psychiatric ward and matching the inclusion criteria described
above were 227 in 2003–2004 and 257 in 2013–2014, respectively. The percentage of SMI-SUD
patients was 25.1% in 2003–2004 and 32.7% in 2013–2014.
We divided patients in the following age categories: <18, 19–40, 41–60, and ≥61 years. In 2003–
2004, SMI and SMI-SUD patients were 1.8% and 3.5% for <18 years, 42.9% and 56.1% for 19–
40 years, 31.2% and 36.8% for 41–60 years, and 24.1% and 3.5% for ≥61 years, respectively. In




2013–2014, SMI and SMI-SUD patients were 2.9% and 7.1% for <18 years, 31.8% and 54.8%
for 19–40 years, 38.7% and 33.3% for 41–60 years, and 26.6% and 4.8% for ≥61 years, respec‐
tively. Differences between SMI-SUD and SMI patients in age distribution were statistically
significant in both 2-year periods, and patients in the SMI-SUD group were more frequently
in the age category 19–40 years; moreover, in 2013–2014, this difference was found also in the
age category <18 years.
Table 1 reports data about sociodemographic features in the 2003–2004 and 2013–2014 groups,
further subdivided according to the presence or absence of comorbid SUD. The main statisti‐
cally significant differences between SMI and SMI-SUD patients included gender, occupa‐
tional status, and educational level. SMI-SUD patients compared to SMI patients were more
frequently males (70.2% vs 39.4% in 2003–2004 and 70.2% vs 36.6% in 2013–2014) and
unemployed (33.3% vs 15.0% in 2003–2004 and 41.3% vs 22.5% in 2013–2014) in both 2-year
periods. Furthermore, in 2013–2014, a higher percentage of students (10.0% vs 6.5%) and lower
educational level (junior high school; 63.0% vs 37.3%) were found in SMI-SUD patients
compared to SMI.
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Gender ≤0.05 ≤0.05
Male 39.4 (67) 70.2 (40) 36.6 (63) 70.2 (59)
Female 60.6 (103) 29.8 (17) 63.4 (109) 29.8 (25)
Nationality 0.209 0.334
Italian 94.1 (160) 98.3 (56) 86.7 (150) 82.1 (69)
Foreign 5.9 (10) 1.8 (1) 13.3 (23) 17.9 (15)
Educational level 0.179 ≤0.05
Primary school 28.8 (49) 28.1 (16) 16.9 (28) 13.6 (11)
Junior high school 38.2 (65) 50.9 (29) 37.3 (62) 63.0 (51)
High school 24.7 (42) 19.3 (11) 37.9 (63) 18.5 (15)
University degree 8.2 (14) 1.8 (1) 7.8 (13) 4.9 (4)
Occupational status ≤0.05 ≤0.05
Employed 38.1 (61) 48.1 (26) 31.4 (53) 33.7 (27)
Unemployed 15.0 (24) 33.3 (18) 22.5 (38) 41.3 (33)
Student 0.0 (0) 0.0 (0) 6.5 (11) 10.0 (8)
Disabled/retired 25.6 (41) 7.4 (4) 29.6 (50) 10.0 (8)
Other 21.3 (34) 11.1 (6) 10. 1(17) 5.0 (4)
Table 1. Sociodemographic features of patients in 2003–2004 and 2013–2014. A comparison of the subgroups of
patients, subdivided according to the presence or absence of comorbid SUD.
Recent Advances in Drug Addiction Research and Clinical Applications176
2013–2014, SMI and SMI-SUD patients were 2.9% and 7.1% for <18 years, 31.8% and 54.8%
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Foreign 5.9 (10) 1.8 (1) 13.3 (23) 17.9 (15)
Educational level 0.179 ≤0.05
Primary school 28.8 (49) 28.1 (16) 16.9 (28) 13.6 (11)
Junior high school 38.2 (65) 50.9 (29) 37.3 (62) 63.0 (51)
High school 24.7 (42) 19.3 (11) 37.9 (63) 18.5 (15)
University degree 8.2 (14) 1.8 (1) 7.8 (13) 4.9 (4)
Occupational status ≤0.05 ≤0.05
Employed 38.1 (61) 48.1 (26) 31.4 (53) 33.7 (27)
Unemployed 15.0 (24) 33.3 (18) 22.5 (38) 41.3 (33)
Student 0.0 (0) 0.0 (0) 6.5 (11) 10.0 (8)
Disabled/retired 25.6 (41) 7.4 (4) 29.6 (50) 10.0 (8)
Other 21.3 (34) 11.1 (6) 10. 1(17) 5.0 (4)
Table 1. Sociodemographic features of patients in 2003–2004 and 2013–2014. A comparison of the subgroups of
patients, subdivided according to the presence or absence of comorbid SUD.
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Table 2 describes the living accommodation and family features of patients in 2003–2004
and 2013–2014 and the comparison of the subgroups of patients, subdivided according to the
presence or absence of comorbid SUD. The main statistically significant differences between
SMI and SMI-SUD patients included living accommodation and marital status in both 2-year
periods and having kids in 2013–2014. SMI-SUD patients compared to SMI patients lived more
frequently with their family of origin (33.9% vs 19.2% in 2003–2004 and 33.8% vs 21.2% in 2013–
2014) rather than with a family of their own, and they were more frequently single (48.2% vs
41.3% in 2003–2004 and 60.2% vs 33.5% in 2013–2014) or divorced in 2003–2004 (28.6% vs 12%).
Moreover, in 2013–2014, SMI-SUD patients more frequently had no kids compared to SMI
patients.
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Accommodation ≤0.05 ≤0.05
Alone 25.8 (43) 23.2 (13) 18.6 (30) 27.3 (21)
With parents 19.2 (32) 33.9 (19) 21.1 (34) 33.8 (26)
Own family 49.1 (82) 28.6 (16) 49.1 (79) 29.9 (19)
Therapeutic community 3.0 (5) 3.6 (2) 7.5 (12) 6.5 (5)
Other 3.0 (5) 10.7 (6) 3.7 (6) 2.6 (2)
Marital status ≤0.05 ≤0.05
Married 38.3 (64) 21.4 (12) 44.1 (75) 22.9 (19)
Single 41.3 (69) 48.2 (27) 33.5 (57) 60.2 (50)
Widowed 8.4 (14) 1.8 (1) 6.5 (11) 3.6 (3)
Divorced 12.0 (20) 28.6 (16) 15.9 (27) 13.2 (11)
Siblings 0.412 0.112
No 22.9 (39) 31.6 (18) 20.0 (31) 29.9 (23)
1 33.5 (57) 31.6 (18) 38.1 (59) 28.2 (22)
≥2 43.5 (74) 36.8 (21) 41.9 (65) 56.4 (44)
Children 0.277 ≤0.05
No 47.1 (80) 50.9 (29) 35.6 (58) 63.3 (50)
1–2 40.0 (68) 43.9 (25) 57.7 (4) 32.9 (26)
≥3 12.9 (22) 5.3 (3) 6.8 (11) 3.8 (3)
Table 2. Living accommodation and family features of patients in 2003–2004 and 2013–2014. A comparison of the
subgroups of patients subdivided according to the presence or absence of comorbid SUD.




Family problems were reported as significantly more common by SMI-SUD patients in the
years 2003–2004 than in SMI patients (21.1% vs 8.2 %, p=0.009), although no statistically
significant difference was found between the two groups in the years 2013–2014 (47.9% vs
44.0%, p=0.588). Similarly, patients’ parents were divorced in a significantly higher percentage
of SMI-SUD patients than in SMI patients in the years 2003–2004 (7.0% vs 1.8%, p=0.047),
although no significant difference was found in the two groups for this variable in the years
2013–2014 (84.2% vs 76.9%, p=0.604).
2003–2004 (n = 227) 2013–2014 (n = 257)
SMI, % (n) SMI-SUD, % (n) p* SMI, % (n) SMI-SUD, % (n) p*
Diagnosis ≤0.05 ≤0.05
Affective disorders 24.1 (41) 10.5 (6) 17.9 (31) 4.8 (4)
Schizophrenia/psychosis 25.3 (43) 7.0 (4) 22.5 (39) 26.2 (22)
Personality disorders 23.5 (40) 52.6 (30) 19.1 (33) 23.8 (20)
Anxiety disorders 7.6 (13) 0.0 (0) 30.1 (52) 22.6 (19)
Other 19.4 (33) 29.8 (17) 10.4 (18) 22.6 (19)
Self-injury behaviors 32.9 (56) 26.3 (15) 0.350 35.3 (60) 30.0 (24) 0.408
Acts of harm 4.7 (8) 12.3 (7) ≤0.05 11.8 (20) 26.3 (21) ≤0.05
Imprisonment 1.8 (3) 8.8 (5) ≤0.05 2.9 (5) 7.4 (6) 0.104
Table 3. Clinical features of patients in 2003–2004 and 2013–2014. Comparison of the subgroups of patients subdivided
according to the presence or absence of comorbid SUD.
Table 3 reports the clinical and legal features of patients in 2003–2004 and 2013–2014, and the
results of the comparison of the subgroups of patients, subdivided according to the presence
or absence of comorbid SUD. The main statistically significant differences between SMI and
SMI-SUD patients included diagnosis and acts of harm in both 2-year periods and imprison‐
ment in 2003–2004. In 2003–2004, SMI-SUD patients compared to SMI patients were more
frequently diagnosed with a personality disorder (52.6% vs 23.5%). In 2013–2014, the same
difference was found, albeit less striking (23.8% vs 19.1%), together with a higher percentage
of schizophrenia and psychosis in SMI-SUD patients compared to SMI patients (26.2% vs
22.5%). Acts of harm were more common in SMI-SUD patients than in SMI ones in both
periods (12.3% vs 4.7% in 2003–2004 and 26.3% vs 11.8% in 2013–2014), whereas imprison‐
ment was significantly more common in SMI-SUD patients only in 2003–2004 (8.8% vs 1.8%).
The following variables were included in the multivariate analysis: gender, nationality,
educational level, occupation, marital status, living accommodation, family problems, acts of
harm, imprisonment, age at admission, and diagnosis. The statistically significant results of
the multivariate analysis performed to investigate the possible predictors of comorbidity with
SUD are described in Table 4.
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In both 2-year periods, female gender and age >61 years were associated with comorbidity
with SUD with an OR <1 (adjusted OR 0.24, 95% CI 0.09–0.64, p=0.004 vs adjusted OR 0.15,
95% CI 0.06–0.39, p<0.001; adjusted OR 0.92, 95% CI 0.01–0.81, p=0.031 vs adjusted OR 0.03,
95% CI 0.01–0.31, p=0.003).
In 2003–2004, having a university degree was associated with a decreased risk of comorbid
SUD (adjusted OR 0.04, 95% CI 0.01–0.64, p=0.023), whereas having a diagnosis of personali‐
ty disorder was associated with an increased risk of SMI-SUD comorbidity (adjusted OR 3.51,
95% CI 1.05–11.77, p=0.042).
In 2013–2014, living in therapeutic rehabilitation center (compared to living alone) was
associated with a decreased risk of SMI-SUD comorbidity (adjusted OR 0.02, 95% CI 0.01–0.41,
p=0.011).
2003–2004 2013–2014
OR (95% CI) p OR (95% CI) p
Gender 0.24 (0.09–0.64) ≤0.05 0.15 (0.06–0.39) ≤0.05
Education level
Primary school Ref. – Ref. –
Junior high school 0.46 (0.12–1.69) 0.239 0.63 (0.14–2.81) 0.546
High school 0.40 (0.10–1.64) 0.205 0.19 (0.04–1.03) 0.054
University degree 0.04 (0.01–0.64) ≤0.05 0.65 (0.08–5.02) 0.675
Accommodation status
Alone Ref. – Ref. –
With parents 3.63 (0.92–14.27) 0.065 0.87 (0.23–3.26) 0.837
Own family 1.11 (0.17–7.14) 0.916 0.49 (0.12–1.98) 0.318
Therapeutic community 0.45 (0.04–5.84) 0.544 0.02 (0.01–0.41) ≤0.05
Other 5.40 (0.56–52.40) 0.146 0.63 (0.07–5.91) 0.691
Age at admission
19–40 years old Ref. – Ref. –
<18 years old 1.39 (0.15–12.88) 0.771 0.60 (0.07–5.16) 0.644
41–60 years old 0.90 (0.30–2.74) 0.851 0.66 (0.23–1.87) 0.437
≥61 years old 0.92 (0.01–0.81) ≤0.05 0.03 (0.01–0.31) ≤0.05
Disease
Affective disorders Ref. – Ref. –
Psychosis/schizophrenia 0.29 (0.06–1.38) 0.120 0.77 (0.16–3.68) 0.739
Personality disorders 3.51 (1.05–11.77) ≤0.05 2.21 (0.44–11.01) 0.334
Anxiety disorders – – 0.96 (0.22–4.18) 0.961





OR (95% CI) p OR (95% CI) p
Other 3.94 (0.99–15.69) 0.052 3.11 (0.56–17.11) 0.192
Table 4. Multivariate analysis for the assessment of potential predictors of comorbid SUD in psychiatric patients in
2003–2004 and 2013–2014.
As far as substance used is concerned, the assessment of the SMI-SUD sample in 2003–2004
and 2013–2014 highlighted a decrease of alcohol (78.9% of SMI-SUD patients in 2003–2004 vs
64.6% of SMI-SUD patients in 2013–2014) and heroin consumption (19.2% of SMI-SUD patients
in 2003–2004 vs 14.6% of SMI-SUD patients in 2013–2014). Polyabuse did not seem to change
after 10 years (42.1% vs 42.6%). On the contrary, we found an increase of the use of medica‐
tion, cannabinoids, cocaine, and other drugs (0.05% vs 17.0%, 33.3% vs 57.3%, 28.0% vs 36.5%,
and 0.05% vs 17.0%, respectively).
4. Discussion
The percentage of first admissions for SMI-SUD increased from the first to the second 2-year
period considered (2003–2004 vs 2013–2014), being 25.1% and 32.7%, respectively. Accord‐
ing to the existing literature, DD is a growing phenomenon. Studies performed in similar
settings report a percentage of DD patients ranging from 24% to 51% [85,86]. In Italy, data from
mental health departments and from addiction services describe a prevalence of psychiatric
disorders with comorbid SUD ranging from 4% to 42%, respectively [87–91].
4.1. Sociodemographic and family features
Statistically significant differences were found in both periods between SMI and SMI-SUD
patients as far as gender, age at admission, occupational status, marital status, and living
accommodation are concerned. With more detail, SMI-SUD patients in both 2-year periods
were more likely to be male, younger, unemployed, living with parents (or alone, for the 2013–
2014 period) rather than with a family of their own, and single (or divorced, in 2003–2004). All
these results are in line with similar reports from most other studies in this field. Regarding
marital status and living accommodation, DD patients seem to experience relational prob‐
lems in their families and have difficulties either creating or maintaining lasting relation‐
ships. Besides, comorbidity of psychiatric disorders and SUD may impact on relationships in
and of itself. In a previous study [65], we found that this impact was particularly meaningful
in female patients. Some differences between SMI and SMI-SUD patients were not shared
between the two 2-year periods. For instance, in the 2-year period 2013–2014, SMI-SUD
patients were more likely than SMI ones to have a junior high school degree rather than a high
school one or a university degree and to have no kids [92]. On the contrary, family problems
and parents’ divorce were reported as significantly more common by SMI-SUD patients in the
years 2003–2004 than in SMI patients. We may suppose an evolving pattern of substance
seeking through the years; it may be that the motivation leading to addiction is shifting in most
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cases from relief of psychological and emotional distress to active search for pleasure and
entactogenic effects. This hypothesis is consistent with the widespread changes in the choice
of the main substance of abuse.
Overall, consistent with the literature [91,93], what emerges from these data is that SMI-SUD
patients are more likely to have a poorer sociorelational functioning and achievement, albeit
our results do not allow to discriminate which came first, whether comorbidity or a poorer
performance, which are likely to be strictly intertwined.
4.2. Clinical features
In both 2-year periods examined, psychiatric diagnosis was significantly different between
SMI-SUD and SMI patients. This difference is striking in 2003–2004 patients: SMI-SUD patients
are more frequently affected by personality disorders and “other” diagnoses (including
disturbance of conduct, mental retardation, eating disorders, acute stress reaction, and
adaptation reaction), whereas, in 2013–2014, there is still a difference as far as personality
disorders is concerned, albeit less striking, together with differences in “other” diagnoses and
schizophrenia, which is more frequent in SMI-SUD than in SMI patients. These results are
partially consistent with the existing literature [37,94–97] especially because of the under-
representation of mood disorders in the SMI-SUD group of patients. On the contrary, this
change in diagnosis is interesting, as it may suggest a different pattern of substance use after
10 years. It seems that schizophrenic and psychotic patients are more likely, in recent years, to
use substances, but it is not clear whether this change suggests a trend towards more self-
medication seeking on behalf of these patients or rather a greater potential of substances to
induce long-lasting psychotic symptoms. It should be considered that the type of substances
used have changed a lot over a decade; cannabinoid, ecstasy, and new drugs are studied for
their potential of inducing psychosis, and in clinical settings, it is quite common to observe
long-lasting, medication-resistant psychotic symptoms in young patients who have taken one
of the several new synthetic drugs. Besides, these are difficult or impossible to identify and
detect with standard laboratory methods.
As far as acts of harm are concerned, these were significantly more common in SMI-SUD
patients than in SMI ones, in both 2-year periods, and overall, the percentage of acts of harm
was higher in 2013–2014. Several studies have focused on the relation between substance abuse
and aggressive behaviors; the use of substances may result in poor insight, neurocognitive
impairments, hallucinations, impulsivity, as well as other emotional or physiological prob‐
lems that may underlie aggressiveness. Moreover, some studies report that SMI-SUD patients
are more likely to have a criminal history and legal problems than SMI ones [36]. Violent
behaviors and substance abuse may be entangled because of the close relationship between
drug distribution and the criminal system; moreover, the constant need of money to get the
drug may lead patients to aggressive acts to obtain it [98]. Despite the almost 2-fold increase
in the percentage of acts of harm from 2003–2004 to 2013–2014, only in 2003–2004 was the
frequency of imprisonment significantly different in SMI-SUD and SMI patients, being higher
in the first.




As far as substance used is concerned, our findings are consistent with the literature and with
clinical observations, especially regarding the increased use of cannabinoids, cocaine, and
“other” drugs on the one hand and the decreased consumption of heroin on the other.
Surprisingly, we found polyabuse to be relatively stable even after 10 years.
4.3. Multivariate analysis
In both 2-year periods, female gender and being ≥61 years old appear to be associated with a
decreased risk of SMI-SUD comorbidity. Both results are consistent with the existing litera‐
ture and could be expected according to clinical experience [66,85–87,91].
In the 2-year period 2003–2004, having a university degree was associated with a decreased
risk of comorbid SMI-SUD, whereas having a diagnosis of personality disorder was associat‐
ed with an increased risk of comorbid SMI-SUD, but 10 years later we found educational level
and diagnosis having no impact on comorbidity. As already described above, this may suggest
possible changes in the pattern of SUD as far as problematic family issues are concerned;
notwithstanding the fact that, in 2013–2014, educational level and diagnosis no longer
represented risk factors, it would have been interesting to assess whether individuals with
different cultural levels as assessed by schooling of with different diagnosis share the same
pathways towards SUD and similar choices regarding type of substance and use. As far as
educational level is concerned, in a recent study, we found that, although having a universi‐
ty degree was associated with a decreased risk of DD for males, it was associated with an
increased risk of DD in females [65]. We hypothesized a different pattern of social function‐
ing and performance in male and female SMI-SUD patients [44] and that males and females
may access substances via different pathways and choose different types of substances as
well [99–102], with a variable impact on their lives.
As far as diagnosis is concerned, the same study mentioned above, which assessed the
period 2003–2012, found affective and “other” disorders associated with an increased risk of
comorbid SUD, compared to personality disorders, which according to Baigent [94] would be
more likely than Axis I disorders to be associated with chronic SUD. On the contrary, reports
from the literature show mixed results about this issue, and recent studies suggest that the
frequency of comorbid SUD is similar in schizophrenic psychoses and in personality disor‐
ders [37] and that primary mood and/or anxiety disorders are at high risk for comorbid SUD
as well [96,97].
Last, in the 2-year period 2013–2014, we found that living in therapeutic rehabilitation centers
was associated with a decreased risk (compared to living alone) of comorbidity with SUD. This
result is encouraging and may support the effectiveness of such therapeutic settings in
protecting patients from exposition and/or relapse into SUD.
5. Limitations
Some limitations should be underscored. The retrospective design and data gathering through
clinical charts entail some limitations. Some information could not be retrieved, for example,
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detailed descriptions of type of self-harm or aggressive behavior. Psychiatric diagnoses were
grouped into broad categories (affective disorders, schizophrenia and other psychosis,
personality disorders, anxiety disorders, and others), and we did not discriminate between
bipolar and unipolar affective disorders. We did not include data about laboratory tests
objectively detecting drugs; nonetheless, it has been suggested that a urine drug screening can
only identify a small additional rate (5%) of substance users [52]. Although it would have been
interesting to assess details about reason for “acute” inpatient psychiatric admission, in this
study, we focused specifically on a “snapshot” of comorbidity in a psychiatric ward over a 10-
year period. Last, we cannot exclude that our results might have been influenced by broader
systemic differences in the treatment of the DD population across time. Anyway, in our
country, in the study period, there have neither been relevant changes in treatment options
available for DD patients, not in the legal policies about drugs.
6. Conclusions
This study adds to the scant literature about this issue in our country, and the large sample
size is a strength of this research. Both SMI and SUD are predictors of underachievement and
failure in educational and occupational settings, difficulty facing family responsibilities,
violent and abusing behaviors, poverty, legal problems, and scarce compliance to treatment
[103]. Acute settings may be particularly appropriate for the development of targeted
interventions [104], and the treatment of patients with comorbid psychiatric disorders and
SUD should begin early during hospitalization [105].
Changes in the pathways leading to drug abuse and in the patterns of addiction should not be
overlooked.
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Abstract
Neuroimaging tools have provided novel methods for understanding the impact of
prenatal drug exposure on brain structure and function and its relation to develop‐
ment and behavior.  Information gained from neuroimaging studies  allows for  the
investigation of how prenatal drug exposure alters the typical developmental trajecto‐
ry.  The  current  prevalence  and  characteristics  of  prenatal  drug  exposure  and  its
implications for vulnerable periods of brain development are reviewed. Structural and
functional neuroimaging methods are introduced with examples of how study results
from prenatal alcohol, cocaine, marijuana, and tobacco exposure further our under‐
standing of the neurodevelopment impact of prenatal drug exposure. Prenatal drug
neuroimaging studies have advanced our understanding of mechanisms and function‐
al deficits associated with prenatal drug exposure. Studies have identified brain circuits
associated with the default mode network, inhibitory control, and working memory
that show differences in function as a result of prenatal drug exposure. The informa‐
tion gained from studies of prenatal drug exposure on brain structure and function can
be used to make connections between animal models and human studies of prenatal
drug exposure, identify biomarkers of documented effects of prenatal drug exposure
on behavior, and inform prevention and intervention programs for young children.
Keywords: fMRI, prenatal substance exposure, alcohol, cocaine, marijuana, tobacco
1. Introduction
This chapter begins with a review of issues surrounding the assessment of the impact of
prenatal drug exposure on developmental outcomes in children followed by a brief update of
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
current trends in prenatal drug exposure including the prevalence, patterns, and characteris‐
tics of prenatal drug use, including alcohol, tobacco, marijuana, and other illicit drugs. Then,
the impact of current neuroimaging methodology on our understanding of the effects of
prenatal drug exposure is explored. The review considers examples of how neuroimaging
tools have increased our understanding of the often subtle and complex impact of prenatal
substance exposure on child brain development and behavior. The impact of prenatal drug
exposure is challenging to assess due to characteristics of maternal drug use such as poly‐
drug exposure and differences in the purity and legality of drugs. Developmental outcomes
associated with prenatal drug exposure will also be affected by the timing, dose, and pat‐
tern of drug use during pregnancy, and the varying impact of other environmental factors
such as maternal health and nutrition, access to prenatal care, and the home environment [1,
2]. For over 40 years, the impact of prenatal drug exposure has been studied in relation to
growth,  behavior,  and  cognitive  outcomes  using  both  longitudinal  and  cross-sectional
designs, which have provided a depth of understanding. Overall, the most important outcome
of decades of research has been that no safe levels of any type of prenatal drug use during
pregnancy have been identified. Furthermore, the impact of prenatal drug exposure is often
subtle and combined with other environmental risk factors, contributes to poor developmen‐
tal outcomes for young children and adolescents.
2. Methodological Issues and Current Trends in Prevalence and
Characteristics of Prenatal Drug Exposure
Prenatal drug exposure is a major public health concern for mothers and their children. In
addition, society bears significant financial costs associated with social and child welfare
services utilization [3, 4], neonatal intensive care unit costs, and longer hospital stays after
delivery [3–8]. Children with prenatal drug exposure are also more likely to need interven‐
tion services to address medical, developmental, behavioral, academic, and socio-emotional
issues [9]. Decades of research have documented the negative impact of prenatal drug
exposure on child developmental outcomes including growth, emotion and behavior regula‐
tion, and cognitive function. The impact of prenatal drug exposure on the developing child
has also been shown to interact with the quality of the child’s environment. Given the
complexities related to prenatal drug exposure and the influence of many potential external
factors, the prevalence, characteristics, and effects on developmental outcomes can be difficult
to assess. Difficulties arise from the dose, timing, and duration of prenatal drug exposure, the
use of multiple drugs during pregnancy, methodology limitations in the ability to document
prenatal drug exposure, differentiating between delayed and longer-term effects, genetic
factors, and variability introduced by environmental experiences including the quality of
relationships and the home environment [10]. In addition, methods used to measure prena‐
tal drug exposure are varied, ranging from survey methods (e.g., national surveys) to prenatal
interviewing (e.g., longitudinal cohort studies).
The main strategy for dealing with the complexities of research aimed at elucidating the impact
and mechanisms of prenatal drug exposure on child development is to use longitudinal
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current trends in prenatal drug exposure including the prevalence, patterns, and characteris‐
tics of prenatal drug use, including alcohol, tobacco, marijuana, and other illicit drugs. Then,
the impact of current neuroimaging methodology on our understanding of the effects of
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substance exposure on child brain development and behavior. The impact of prenatal drug
exposure is challenging to assess due to characteristics of maternal drug use such as poly‐
drug exposure and differences in the purity and legality of drugs. Developmental outcomes
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tern of drug use during pregnancy, and the varying impact of other environmental factors
such as maternal health and nutrition, access to prenatal care, and the home environment [1,
2]. For over 40 years, the impact of prenatal drug exposure has been studied in relation to
growth,  behavior,  and  cognitive  outcomes  using  both  longitudinal  and  cross-sectional
designs, which have provided a depth of understanding. Overall, the most important outcome
of decades of research has been that no safe levels of any type of prenatal drug use during
pregnancy have been identified. Furthermore, the impact of prenatal drug exposure is often
subtle and combined with other environmental risk factors, contributes to poor developmen‐
tal outcomes for young children and adolescents.
2. Methodological Issues and Current Trends in Prevalence and
Characteristics of Prenatal Drug Exposure
Prenatal drug exposure is a major public health concern for mothers and their children. In
addition, society bears significant financial costs associated with social and child welfare
services utilization [3, 4], neonatal intensive care unit costs, and longer hospital stays after
delivery [3–8]. Children with prenatal drug exposure are also more likely to need interven‐
tion services to address medical, developmental, behavioral, academic, and socio-emotional
issues [9]. Decades of research have documented the negative impact of prenatal drug
exposure on child developmental outcomes including growth, emotion and behavior regula‐
tion, and cognitive function. The impact of prenatal drug exposure on the developing child
has also been shown to interact with the quality of the child’s environment. Given the
complexities related to prenatal drug exposure and the influence of many potential external
factors, the prevalence, characteristics, and effects on developmental outcomes can be difficult
to assess. Difficulties arise from the dose, timing, and duration of prenatal drug exposure, the
use of multiple drugs during pregnancy, methodology limitations in the ability to document
prenatal drug exposure, differentiating between delayed and longer-term effects, genetic
factors, and variability introduced by environmental experiences including the quality of
relationships and the home environment [10]. In addition, methods used to measure prena‐
tal drug exposure are varied, ranging from survey methods (e.g., national surveys) to prenatal
interviewing (e.g., longitudinal cohort studies).
The main strategy for dealing with the complexities of research aimed at elucidating the impact
and mechanisms of prenatal drug exposure on child development is to use longitudinal
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research designs that incorporate measurement of explanatory variables. Pregnant sub‐
stance abusers are not studied based on whether they classify as “recreational” users or addicts.
Rather, the timing (first, second, third trimester), dose, and pattern of drug use (continuous
vs. binge exposure) are key variables. Among cohort studies, there are differences in sample
characteristics that are important for the interpretation of any study results that suggest
negative developmental outcomes associated with prenatal drug exposure. For example, some
studies focus on “high- dose” exposure (e.g., Seattle Longitudinal Study of Fetal Alcohol
Syndrome), whereas other studies focus on the full spectrum of exposures ranging from light-,
moderate-, to high-dose exposure (e.g., Pittsburgh Maternal Health Practices and Child
Development Project). Most studies have attempted to quantify the pattern of drug expo‐
sure as either continuous (e.g., average number of drinks/day) or binge (e.g., ≥4 drinks/
occasion). Cross-sectional study designs are also used to study clinical populations, captur‐
ing the important characteristics of young children who have been referred for assessment and
services.
Current trends suggest that while the prevalence of women using drugs during pregnancy is
relatively low, maternal substance use has an impact on many children. Approximately
400,000–440,000 infants, 10–11% of all births, are prenatally exposed to alcohol, tobacco, or
illicit drugs [11]. In addition, current trends in prenatal drug exposure suggest shifts in both
the prevalence and patterns of maternal substance use that reflect both wide spread knowl‐
edge and perceptions of the impact of drugs of abuse in general, and prenatal drug exposure
more specifically. Alcohol and tobacco are the most commonly used drugs during pregnan‐
cy, followed by marijuana, cocaine, and opioids [12]. For all types of prenatal drug exposure,
the data show that reported use in pregnant women is lower compared to nonpregnant women
in the same age category and that more pregnant women report use in the first trimester
compared to second and third trimesters [12]. In general, a greater number of younger
pregnant women (ages 18–25) report use compared to older women (ages 26–44) [12].
2.1. Current prevalence estimates of prenatal drug exposure
Recent estimates [12] show that the rates of prenatal alcohol use are approximately 9.4%, of
which 2.3% of women report binge drinking and 0.4% report heavy drinking. Higher levels of
drinking are reported in the first trimester compared to second and third trimesters. Patterns
of alcohol use among pregnant women have changed over time. More recently, pregnant
women are reported to drink more heavily and are more likely to develop an alcohol use
disorder compared to earlier studies [13]. In addition, women of childbearing age have shown
an increase in binge drinking, a trend that has decreased in males over time [14, 15]. Women
who binge drink during pregnancy report, on average, 4.6 binge drinking episodes (nonpreg‐
nant women report 3.1 episodes) and the number of drinks consumed, while binge drinking
does not differ from nonpregnant drinkers [2]. The Centers for Disease Control reports that
medical record analysis shows a rate of 0.3 out of 1000 children ages 7–9 are diagnosed with
fetal alcohol syndrome (FAS), while in-person assessments find higher rates (6–9 per 1000
children). Rates of fetal alcohol spectrum disorders are more difficult to ascertain, but
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community based studies in both the United State and Western Europe suggest that 24–48
per 1000 school children are affected by prenatal alcohol exposure [16, 17].
Reflecting national trends, the NSDUH [12] reports that cigarette use among women has been
steadily decreasing from a rate of 30.7% in 2002–2003 to 24.0% in 2012–2013. However, during
the same time period, the prevalence rate of cigarette use among pregnant women did not
show a similar significant reduction. Eighteen percent of pregnant women reported cigarette
use during pregnancy in 2002–2003 compared to 15.4% in 2012–2013. Other studies have shown
that efforts to reduce smoking prevalence among female smokers before pregnancy have not
been effective; however, efforts targeting pregnant women have met some success as rates
have declined during pregnancy and after delivery [18,19].
The most commonly used illicit drug is marijuana, but illicit drug use also includes cocaine,
opioids, and amphetamines. Among pregnant women, the rate of any illicit drug use is 5.4%
and has not changed significantly since 2010–2011 [12]. Use remains higher in younger
women (14.6%, ages 18–25) compared to older women (3.2%, ages 26–44). A high proportion
of women are using marijuana illegally and fail to disclose their use to their providers. A recent
study showed 81 percent of providers in urban outpatient clinics are asking their pregnant
patients about illicit drug use and; of the women surveyed, 11% of women disclosed current
use of marijuana, while 34% tested positive for one or more substances with marijuana being
the most commonly detected (27%) [20]. Women who use methamphetamine during preg‐
nancy show decreased prevalence and frequency of use from first to third trimester and women
who decreased their use were more likely to seek prenatal care during pregnancy [21].
2.2. Maternal and environmental variables
There are a number of maternal and environmental characteristics that are associated with
substance use during pregnancy [22]. Prenatal substance use is associated with younger
maternal age [12] and socioeconomic factors such as lower level of education, unemploy‐
ment, and higher levels of poverty [1]. Physical and mental health factors such as the uti‐
lization of health care during pregnancy [23, 24], fear of criminalization and/or stigma [25],
higher rates of affective disorders including depression [1], and poly-substance exposure [1]
are highly prevalent in pregnant substance users. Women using drugs during pregnancy
are also more likely to have had either current and/or childhood exposure to violence and/
or abuse [24]. Domestic violence is also associated with a higher proportion of substance
use in women [24, 26].
The complex interactions of social, psychological, and physical variables that are at play in
pregnant substance abusers also have an impact on the stability and quality of the child–parent
relationship, a significant factor in healthy child development. The care that infants receive
from their primary caretaker lays the foundation for the development of behavior and emotion
regulation, social skills, and cognitive ability [18, 19, 27, 28], as well as physical and mental
health [29, 30]. Substance abusing mothers show decreased responsivity to their infants. For
example, opioid abusing mothers show a decreased ability to identify their infant’s cues and
to respond appropriately to them [31]. Addiction and mental illness, two factors associated
with prenatal substance exposure are also associated with difficulty in forming healthy
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community based studies in both the United State and Western Europe suggest that 24–48
per 1000 school children are affected by prenatal alcohol exposure [16, 17].
Reflecting national trends, the NSDUH [12] reports that cigarette use among women has been
steadily decreasing from a rate of 30.7% in 2002–2003 to 24.0% in 2012–2013. However, during
the same time period, the prevalence rate of cigarette use among pregnant women did not
show a similar significant reduction. Eighteen percent of pregnant women reported cigarette
use during pregnancy in 2002–2003 compared to 15.4% in 2012–2013. Other studies have shown
that efforts to reduce smoking prevalence among female smokers before pregnancy have not
been effective; however, efforts targeting pregnant women have met some success as rates
have declined during pregnancy and after delivery [18,19].
The most commonly used illicit drug is marijuana, but illicit drug use also includes cocaine,
opioids, and amphetamines. Among pregnant women, the rate of any illicit drug use is 5.4%
and has not changed significantly since 2010–2011 [12]. Use remains higher in younger
women (14.6%, ages 18–25) compared to older women (3.2%, ages 26–44). A high proportion
of women are using marijuana illegally and fail to disclose their use to their providers. A recent
study showed 81 percent of providers in urban outpatient clinics are asking their pregnant
patients about illicit drug use and; of the women surveyed, 11% of women disclosed current
use of marijuana, while 34% tested positive for one or more substances with marijuana being
the most commonly detected (27%) [20]. Women who use methamphetamine during preg‐
nancy show decreased prevalence and frequency of use from first to third trimester and women
who decreased their use were more likely to seek prenatal care during pregnancy [21].
2.2. Maternal and environmental variables
There are a number of maternal and environmental characteristics that are associated with
substance use during pregnancy [22]. Prenatal substance use is associated with younger
maternal age [12] and socioeconomic factors such as lower level of education, unemploy‐
ment, and higher levels of poverty [1]. Physical and mental health factors such as the uti‐
lization of health care during pregnancy [23, 24], fear of criminalization and/or stigma [25],
higher rates of affective disorders including depression [1], and poly-substance exposure [1]
are highly prevalent in pregnant substance users. Women using drugs during pregnancy
are also more likely to have had either current and/or childhood exposure to violence and/
or abuse [24]. Domestic violence is also associated with a higher proportion of substance
use in women [24, 26].
The complex interactions of social, psychological, and physical variables that are at play in
pregnant substance abusers also have an impact on the stability and quality of the child–parent
relationship, a significant factor in healthy child development. The care that infants receive
from their primary caretaker lays the foundation for the development of behavior and emotion
regulation, social skills, and cognitive ability [18, 19, 27, 28], as well as physical and mental
health [29, 30]. Substance abusing mothers show decreased responsivity to their infants. For
example, opioid abusing mothers show a decreased ability to identify their infant’s cues and
to respond appropriately to them [31]. Addiction and mental illness, two factors associated
with prenatal substance exposure are also associated with difficulty in forming healthy
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attachments [32]. The complex interactions of variables associated with prenatal substance
exposure is important because the events that occur early in life, both in terms of the quality
of relationships and environment, play a significant role in brain development. The impor‐
tant neural connections that support the brain circuitry that underlies emotional, social, and
cognitive behavior are established early in life [33].
Prenatal drug exposures, the timing, and quality of other early experiences have a profound
impact on child development because of their influence on early brain development. Early life
experiences have an impact on the development of brain structure by influencing the timing
and pattern of gene expression and the refinement of neural circuitry [34]. Neuroimaging
methods that examine the structure and function of the brain have provided access to study
the impact of prenatal drug exposure on the developing brain. Methods such as magnetic
resonance imaging (MRI), diffusion tensor imaging (DTI), and functional magnetic reso‐
nance imaging (fMRI) are noninvasive allowing for their use in children. Neuroimaging tools
have been used to better understand typical patterns of structural and functional develop‐
ment in the brain. This information can be used to examine how prenatal drug exposure affects
normal brain development and how it relates to physical and behavioral outcomes.
3. Prenatal drug exposure and brain structure
3.1. Volume, symmetry, and cortical thickness
MRI uses the inherent magnetic properties of the body to create detailed images. Short
radiofrequency pulses inside a strong magnetic field create patterns of excited molecules that
can be used to create an image of the structure [35]. Offering detailed structural images of the
brain, MRI is an essential tool for assessing structural characteristics including global and
regional brain volumes, symmetry, and cortical thickness. Structural brain differences serve
as biomarkers of the impact of the prenatal drug exposure and, eventually, may aid in
identification and intervention. Overall, studies of prenatal drug exposure show consistent
reductions in head circumference, overall and regional reductions in brain volumes, and
differential reduction in gray and white matter volumes, results which are dependent on the
accumulation of polydrug exposures [36].
Recent reports are consistent with previously documented widespread changes in brain
structure in children and adolescents with moderate to heavy prenatal alcohol exposure [37].
Prenatal alcohol is associated with overall reductions in global [38, 39] and regional brain
volume including the hippocampus, basal ganglia, cingulate cortex, and corpus callosum [37,
40–43]. Several studies indicate that reductions in brain volume linked to prenatal alcohol
exposure were associated with deficits in cognitive function and facial dsymorphology. For
example, prenatal alcohol exposed is linked to reductions in caudate volume which are also
associated with deficits in cognitive control and verbal learning and memory [44] as well as
palpebral fissure length [45]. Moreover, reductions in brain volume increase as a function of
the amount of alcohol consumed during pregnancy and the severity of diagnosis [38, 46] and
were reported from early childhood through young adulthood, suggesting long-term and
persistent alterations in brain structure.
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Prenatal alcohol exposure was also associated with increased asymmetry in the caudate
nucleus, cingulate cortex, and corpus callosum. Specific to the caudate nucleus, moderate
alcohol exposure was associated with increased volume in the left caudate compared to the
right [43, 47]. Asymmetry in the cingulate cortex was due to reduced volume localized to the
right caudal region of the cingulate [48], which may be related to differential loss of white
matter compared to gray matter in this brain region [49].
Studies have evaluated the effects of prenatal alcohol on cortical morphology by examining
cortical thickness. Several studies have reported increased cortical thickness in diffuse regions
across the frontal, temporal, and parietal lobes [50–52] while another study reported cortical
thinning [53]. Longitudinally, children with prenatal alcohol exposure show less develop‐
mentally appropriate cortical thinning across time compared to controls [54]. When cortical
thickness is examined in contrast to surface area, prenatal alcohol exposure affects global
surface area to a greater degree than cortical thickness especially in the right temporal gyrus
[55].
Past neuroimaging studies show that prenatal cocaine exposure was also associated with long-
term changes in brain structure. Recent studies confirm overall reductions in global brain
volume as well as in the caudate, corpus callosum, and right cerebellum [56–58] differences in
shape and volume characteristics of the striatum [45], and cortical thickness and volume of the
right prefrontal cortex [59]. In adolescence, prenatal cocaine exposure was associated with
specific reductions in gray matter volumes in frontal cortical and posterior regions [60]. In one
study, the structural changes were correlated with impulsivity [59]. However, the prenatal
cocaine exposure-related structural changes were subtle and may lose significance when
covariates including other prenatal exposures are properly controlled [36].
Prenatal tobacco exposure was linked to overall reductions in intrauterine growth [61], which
is also reflected in the brain. Prenatal tobacco exposure was associated with reductions in fetal
head growth, reduced volume of the frontal lobes and cerebellum, and smaller width of the
lateral ventricles [62, 63]. During childhood, prenatal tobacco exposure is associated with
additional changes in brain structure including smaller total brain volume and smaller cortical
gray matter volume [36, 64], cortical thinning in superior frontal and parietal cortices [64] and
reduced gray matter volume in subcortical regions including the amygdala, thalamus, and
pallidum [59, 65]. Increased volume in the frontal cortex with corresponding decreases in the
anterior cingulate cortex was also observed [66]. Regional brain volume changes persisted into
adolescence but may be explained by current adolescent tobacco use because children with
prenatal tobacco exposure are at increased risk for early initiation and smoking behavior [67].
Fewer recent studies have been conducted on the impact of prenatal marijuana, methamphet‐
amine, and opioid exposure on global and regional brain volume. But, some initial research
indicates that prenatal exposure to these drugs is also associated with difference in brain
structure. In contrast to other types of prenatal drug exposure, prenatal marijuana exposure
was not related to reductions in global brain volume [36]. A small sample of children with
prenatal opioid exposure showed reduced global brain volume as well as regional differen‐
ces including reduced volume in the cerebral cortex, amygdala, nucleus accumbens, puta‐
men, pallidum, brainstem, cerebellar cortex, cerebellar white matter, and inferior lateral
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Prenatal alcohol exposure was also associated with increased asymmetry in the caudate
nucleus, cingulate cortex, and corpus callosum. Specific to the caudate nucleus, moderate
alcohol exposure was associated with increased volume in the left caudate compared to the
right [43, 47]. Asymmetry in the cingulate cortex was due to reduced volume localized to the
right caudal region of the cingulate [48], which may be related to differential loss of white
matter compared to gray matter in this brain region [49].
Studies have evaluated the effects of prenatal alcohol on cortical morphology by examining
cortical thickness. Several studies have reported increased cortical thickness in diffuse regions
across the frontal, temporal, and parietal lobes [50–52] while another study reported cortical
thinning [53]. Longitudinally, children with prenatal alcohol exposure show less develop‐
mentally appropriate cortical thinning across time compared to controls [54]. When cortical
thickness is examined in contrast to surface area, prenatal alcohol exposure affects global
surface area to a greater degree than cortical thickness especially in the right temporal gyrus
[55].
Past neuroimaging studies show that prenatal cocaine exposure was also associated with long-
term changes in brain structure. Recent studies confirm overall reductions in global brain
volume as well as in the caudate, corpus callosum, and right cerebellum [56–58] differences in
shape and volume characteristics of the striatum [45], and cortical thickness and volume of the
right prefrontal cortex [59]. In adolescence, prenatal cocaine exposure was associated with
specific reductions in gray matter volumes in frontal cortical and posterior regions [60]. In one
study, the structural changes were correlated with impulsivity [59]. However, the prenatal
cocaine exposure-related structural changes were subtle and may lose significance when
covariates including other prenatal exposures are properly controlled [36].
Prenatal tobacco exposure was linked to overall reductions in intrauterine growth [61], which
is also reflected in the brain. Prenatal tobacco exposure was associated with reductions in fetal
head growth, reduced volume of the frontal lobes and cerebellum, and smaller width of the
lateral ventricles [62, 63]. During childhood, prenatal tobacco exposure is associated with
additional changes in brain structure including smaller total brain volume and smaller cortical
gray matter volume [36, 64], cortical thinning in superior frontal and parietal cortices [64] and
reduced gray matter volume in subcortical regions including the amygdala, thalamus, and
pallidum [59, 65]. Increased volume in the frontal cortex with corresponding decreases in the
anterior cingulate cortex was also observed [66]. Regional brain volume changes persisted into
adolescence but may be explained by current adolescent tobacco use because children with
prenatal tobacco exposure are at increased risk for early initiation and smoking behavior [67].
Fewer recent studies have been conducted on the impact of prenatal marijuana, methamphet‐
amine, and opioid exposure on global and regional brain volume. But, some initial research
indicates that prenatal exposure to these drugs is also associated with difference in brain
structure. In contrast to other types of prenatal drug exposure, prenatal marijuana exposure
was not related to reductions in global brain volume [36]. A small sample of children with
prenatal opioid exposure showed reduced global brain volume as well as regional differen‐
ces including reduced volume in the cerebral cortex, amygdala, nucleus accumbens, puta‐
men, pallidum, brainstem, cerebellar cortex, cerebellar white matter, and inferior lateral
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ventricles [68]. Prenatal methamphetamine exposure was linked to regional volume reduc‐
tions in both striatal and limbic structures including the caudate, anterior and posterior
cingulate, inferior frontal gyrus, and ventral and lateral temporal lobes; regions that are
vulnerable to the neurotoxic effects of methamphetamine in adult abusers [69]. Another study
showed similar results, as well as sex-specific effects of prenatal methamphetamine expo‐
sure on brain structure, including increased volume in the striatum in males and increased
cortical thickness in females [70].
3.2. Integrity of white matter tracts
DTI uses MRI to examine white matter microstructure by measuring the diffusion of water
molecules in tissue and the integrity of water diffusion in one direction across a membrane.
Unrestricted water molecules are capable of diffusing in any direction, however; in the
presence of structural barriers such as cell membranes and myelin, water tends to diffuse in
an increasingly directional manner. The degree to which water molecules are isotropic
(directionally independent) versus anisotropic (directionally dependent) is determined using
DTI. Anisotropy occurs in white matter tract fibers, particularly in myelinated axons [35, 71].
Functional anisotropy (FA) is used as a quantitative measure of diffusion and ranges in value
from 0 (isotropic) to 1 (anisotropic) [72]. FA is highly sensitive to microstructural changes in
white matter, but not to the type of change (radial or axial) [71]. Developmentally, FA
undergoes the greatest amount of change during early childhood (through 5 years) [73, 74]
and can be used to distinguish between stages of brain development [75]. In general, abnor‐
mal brain development or brain damage is associated with lower FA values in white matter
[76]. Abnormalities in white matter that leads to decreases in FA may result from either
increased radial (perpendicular and associated with changes in myelination) diffusivity and/or
reduced axial (parallel and associated with axonal integrity) diffusivity [77]. Prenatal sub‐
stance exposure is linked to lower FA and alterations in the structural integrity of myelin [78].
White matter microstructure, however, has been most widely studied in children with prenatal
alcohol or cocaine exposure.
The impact of prenatal alcohol exposure on measures of white matter microstructure shows
that effects can be detected at multiple stages of development, are associated with behavior,
and fall on a continuum ranging from mild to severe Abnormalities in the corpus callosum are
frequently reported, but also in anterior–posterior fiber bundles, corticospinal tracts, and the
cerebellum [79–82]. Effects of prenatal alcohol exposure are linked to reduced white matter
structural integrity in the cerebellum [83] and abnormalities in axial diffusivity [84] as early as
infancy. In addition, subtle changes in FA have been associated with deficits in cognitive
function including processing speed, math ability, executive function, and eye-blink condi‐
tioning [50, 81, 85–92] A recent study was also able to demonstrate that structural white matter
changes are linked to disturbances in functional connectivity while at rest [83].
In contrast, DTI studies of the impact of prenatal cocaine or methamphetamine exposure on
white matter integrity are mixed. Cocaine exposure has been associated with increased
diffusion in left frontal callosal and right frontal fibers [93], but do not appear to remain
significant after controlling for other prenatal drug exposures [36]. Another study that
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controlled carefully for other prenatal drug exposures showed that prenatal cocaine-related
FA differences in fiber pathways including right cingulum, right arcuate fasciculus, left inferior
longitudinal fasciculus, and splenium of the corpus callosum were associated with deficits in
attention and response inhibition [94]. Only one study has reported a trend for higher FA
associated with prenatal methamphetamine exposure [95]. These early studies and the lack of
research on the impact of prenatal tobacco and marijuana exposure on white matter integri‐
ty indicate the need for additional research to better understand the impact of prenatal drug
exposure on DTI measures.
4. Prenatal drug exposure and brain function
Neural circuits that control brain function have different patterns of activity that can be
measured using fMRI. fMRI provides an indirect measure of brain function by quantifying the
blood oxygen level-dependent (BOLD) response, which reflects changes in blood oxygen
utilization throughout the brain. When neural circuits become active, MR signals will increase
by a small amount, reflecting a signal change of approximately one percent. The ability to
detect a change in MR signal depends on the different magnetic properties of oxygenated vs.
deoxygenated blood and that blood flow to areas of the brain that are working are very
sensitive. Different types of experimental designs are used in conjunction with fMRI meth‐
ods to determine the location of brain activity. In the simplest type of experiment, patterns of
brain activity are examined as a subject alternates between an experimental and control
condition. The signal will increase and decrease as a function of the experimental conditions
after adjusting for time. Functional neuroimaging studies produce group-averaged maps that
show the level of brain activation that is associated with a specific task or in response to a
specific stimulus. The group maps are then compared between conditions and/or between
groups to examine the magnitude and extent of brain activation for a given response [96].
fMRI research has been used to determine if prenatal drug exposure has an impact on areas
of the brain that receive more or less oxygenated blood in response to performing a cogni‐
tive task. The method has been used to demonstrate the effect of prenatal drug exposure on
brain activation during a variety of cognitive behaviors. Recent work converges on three
domains, the default mode network, inhibitory control, and working memory; all of which
illustrate how fMRI methods can be used to better understand the impact of prenatal drug
exposure on brain function. In addition, innovative functional connectivity studies have
combined information from structural (MRI and DTI) with functional (fMRI) methods to
understand the temporal relations between spatially distinct brain regions.
4.1. Default mode network
The default mode network (DMN) is comprised of a set of brain regions including ventral
medial prefrontal cortex, posterior cingulate, inferior parietal lobe, lateral temporal cortex,
dorsal medial prefrontal cortex, and the hippocampus (see Figure 1) [97]. This network is active
when one appears to be at rest but is actually engaged in spontaneous and goal-directed mental
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controlled carefully for other prenatal drug exposures showed that prenatal cocaine-related
FA differences in fiber pathways including right cingulum, right arcuate fasciculus, left inferior
longitudinal fasciculus, and splenium of the corpus callosum were associated with deficits in
attention and response inhibition [94]. Only one study has reported a trend for higher FA
associated with prenatal methamphetamine exposure [95]. These early studies and the lack of
research on the impact of prenatal tobacco and marijuana exposure on white matter integri‐
ty indicate the need for additional research to better understand the impact of prenatal drug
exposure on DTI measures.
4. Prenatal drug exposure and brain function
Neural circuits that control brain function have different patterns of activity that can be
measured using fMRI. fMRI provides an indirect measure of brain function by quantifying the
blood oxygen level-dependent (BOLD) response, which reflects changes in blood oxygen
utilization throughout the brain. When neural circuits become active, MR signals will increase
by a small amount, reflecting a signal change of approximately one percent. The ability to
detect a change in MR signal depends on the different magnetic properties of oxygenated vs.
deoxygenated blood and that blood flow to areas of the brain that are working are very
sensitive. Different types of experimental designs are used in conjunction with fMRI meth‐
ods to determine the location of brain activity. In the simplest type of experiment, patterns of
brain activity are examined as a subject alternates between an experimental and control
condition. The signal will increase and decrease as a function of the experimental conditions
after adjusting for time. Functional neuroimaging studies produce group-averaged maps that
show the level of brain activation that is associated with a specific task or in response to a
specific stimulus. The group maps are then compared between conditions and/or between
groups to examine the magnitude and extent of brain activation for a given response [96].
fMRI research has been used to determine if prenatal drug exposure has an impact on areas
of the brain that receive more or less oxygenated blood in response to performing a cogni‐
tive task. The method has been used to demonstrate the effect of prenatal drug exposure on
brain activation during a variety of cognitive behaviors. Recent work converges on three
domains, the default mode network, inhibitory control, and working memory; all of which
illustrate how fMRI methods can be used to better understand the impact of prenatal drug
exposure on brain function. In addition, innovative functional connectivity studies have
combined information from structural (MRI and DTI) with functional (fMRI) methods to
understand the temporal relations between spatially distinct brain regions.
4.1. Default mode network
The default mode network (DMN) is comprised of a set of brain regions including ventral
medial prefrontal cortex, posterior cingulate, inferior parietal lobe, lateral temporal cortex,
dorsal medial prefrontal cortex, and the hippocampus (see Figure 1) [97]. This network is active
when one appears to be at rest but is actually engaged in spontaneous and goal-directed mental
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tasks such as free-thinking, remembering, and making future plans [98]. In contrast, the
network is inhibited while performing tasks with high-cognitive demand and increased task
difficulty [99, 100]. Behaviorally, both prenatal cocaine and alcohol exposure are associated
with early and persistent deficits in arousal regulation and attention deficits [101–105] and an
increased risk for a diagnosis of attention-deficit/hyperactivity disorder [106, 107]. One
interpretation of the results of these studies is that the dysregulation of arousal and attention,
in part, explains other observable deficits in higher-cognitive function.
Figure 1. Key regions associated with the default mode brain network.
Current neuroimaging research suggests, however; that the underlying impact of prenatal
cocaine or alcohol exposure on arousal and attention reflects changes in function of the DMN
network. Results are summarized in Table 1(A). Using resting-state fMRI, a recent large-scale
study of neonates with prenatal cocaine exposure or polydrug exposure showed polydrug-
related connectivity disruptions within frontal-amygdala, frontal-insula, and insula-sensori‐
motor circuits; and specific effects of prenatal cocaine exposure on the frontal-amygdala
network [108]. Results showed that polydrug exposure was associated with negative connec‐
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tivity within these networks. Negative connectivity is interpreted as a dysregulation in
excitatory and inhibitory inputs [109–111], and in this case, a failure to inhibit the amygdala
response from prefrontal cortex inputs.
A number of studies indicate that the effect of prenatal cocaine exposure on functional
differences within the DMN persist into childhood and adolescence. Adolescents with prenatal
cocaine exposure show overall reductions in regional cerebral blood flow at rest with
compensatory, relative increases in anterior and superior brain regions [112]. Additionally,
while in the resting state, adolescents with prenatal cocaine exposure show increased
functional connectivity in the DMN compared to controls [113], and less deactivation of the
network in the DMN, while performing a working memory task with emotional distracters.
Furthermore, the effects of prenatal cocaine and alcohol exposure on the DMN can be
dissociated. Similar to prenatal cocaine exposure, prenatal alcohol exposure is associated with
less deactivation in the DMN while performing a cognitive task [114]. In contrast to prenatal
cocaine exposure, prenatal alcohol exposure is associated with decreased functional connec‐
tivity within the DMN at rest [114]. These results suggests that the underlying mechanism for
prenatal cocaine or alcohol exposure effects on cognitive ability are due, in part, to changes in
baseline levels of arousal and dysregulation of excitatory and inhibitory control of neural
resources allocated to perform cognitive tasks.
4.2. Inhibitory control
The ability to engage in voluntary, goal-directed behavior requires activation of neural
circuitry that supports cognitive control mechanisms. Response inhibition is considered to be
a key component of cognitive control and refers to the ability to inhibit a response that is no
longer needed or inappropriate given a change in either internal or external states [115]. The
go/no-go task is a cognitive paradigm that can be used in conjunction with fMRI to evaluate
response inhibition [115, 116]. In the go/no-go task, participants are required to respond or
withhold a response depending on whether they are presented with a “go” stimulus or a “no-
go” stimulus, respectively.
The go/no-go task has been used to determine independent effects of prenatal alcohol, cocaine,
marijuana, and tobacco on response inhibition, allowing for a comparison across studies.
Results are summarized in Table 1(B). Children with prenatal tobacco [117] or marijuana [118]
exposure were more likely to commit commission errors while performing the go/no-go task,
but children with prenatal alcohol or cocaine exposure showed no behavioral differences in
task performance. Prenatal alcohol exposure was associated with increased brain activation in
prefrontal regions and less activation in the caudate compared to controls [119]. A similar
pattern is demonstrated in adolescents with prenatal alcohol exposure suggesting long-term
changes in brain function associated with response inhibition [120]. In contrast, prenatal
cocaine exposed children showed increased activation in inferior frontal cortex and caudate
and less activation in temporal and occipital regions [121]. Prenatal marijuana was associat‐
ed with differential activation of frontal regions including and increased BOLD response in
bilateral the prefrontal cortex and right premotor cortex, and a decreased response in the
cerebellum [118]. Children with prenatal tobacco exposure showed increased activation in a
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tivity within these networks. Negative connectivity is interpreted as a dysregulation in
excitatory and inhibitory inputs [109–111], and in this case, a failure to inhibit the amygdala
response from prefrontal cortex inputs.
A number of studies indicate that the effect of prenatal cocaine exposure on functional
differences within the DMN persist into childhood and adolescence. Adolescents with prenatal
cocaine exposure show overall reductions in regional cerebral blood flow at rest with
compensatory, relative increases in anterior and superior brain regions [112]. Additionally,
while in the resting state, adolescents with prenatal cocaine exposure show increased
functional connectivity in the DMN compared to controls [113], and less deactivation of the
network in the DMN, while performing a working memory task with emotional distracters.
Furthermore, the effects of prenatal cocaine and alcohol exposure on the DMN can be
dissociated. Similar to prenatal cocaine exposure, prenatal alcohol exposure is associated with
less deactivation in the DMN while performing a cognitive task [114]. In contrast to prenatal
cocaine exposure, prenatal alcohol exposure is associated with decreased functional connec‐
tivity within the DMN at rest [114]. These results suggests that the underlying mechanism for
prenatal cocaine or alcohol exposure effects on cognitive ability are due, in part, to changes in
baseline levels of arousal and dysregulation of excitatory and inhibitory control of neural
resources allocated to perform cognitive tasks.
4.2. Inhibitory control
The ability to engage in voluntary, goal-directed behavior requires activation of neural
circuitry that supports cognitive control mechanisms. Response inhibition is considered to be
a key component of cognitive control and refers to the ability to inhibit a response that is no
longer needed or inappropriate given a change in either internal or external states [115]. The
go/no-go task is a cognitive paradigm that can be used in conjunction with fMRI to evaluate
response inhibition [115, 116]. In the go/no-go task, participants are required to respond or
withhold a response depending on whether they are presented with a “go” stimulus or a “no-
go” stimulus, respectively.
The go/no-go task has been used to determine independent effects of prenatal alcohol, cocaine,
marijuana, and tobacco on response inhibition, allowing for a comparison across studies.
Results are summarized in Table 1(B). Children with prenatal tobacco [117] or marijuana [118]
exposure were more likely to commit commission errors while performing the go/no-go task,
but children with prenatal alcohol or cocaine exposure showed no behavioral differences in
task performance. Prenatal alcohol exposure was associated with increased brain activation in
prefrontal regions and less activation in the caudate compared to controls [119]. A similar
pattern is demonstrated in adolescents with prenatal alcohol exposure suggesting long-term
changes in brain function associated with response inhibition [120]. In contrast, prenatal
cocaine exposed children showed increased activation in inferior frontal cortex and caudate
and less activation in temporal and occipital regions [121]. Prenatal marijuana was associat‐
ed with differential activation of frontal regions including and increased BOLD response in
bilateral the prefrontal cortex and right premotor cortex, and a decreased response in the
cerebellum [118]. Children with prenatal tobacco exposure showed increased activation in a
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more diverse set of brain regions including left frontal, right occipital, bilateral temporal, and
parietal regions, and less activation in the cerebellum [117]. Young adults with prenatal tobacco
exposure showed a similar pattern of results with increased activation inferior frontal, inferior
parietal, basal ganglia, and cerebellum [122].
Results across multiple studies indicate that prenatal drug exposure leads to differential
activation in frontal–striatal circuits, while performing the go/no-go task. In addition, across
studies, prenatal drug-related increases in activation were reported in many brain regions,
which indicates an increase in the demand for cognitive resources, while performing the
response inhibition task. This pattern of results is indicative of an immature brain circuitry.
Across development, the typical pattern observed in neuroimaging data is that for response
inhibition, there is an increase in the magnitude of activation and a decrease in the extent of
activation in frontal–striatal brain regions [123, 124]. Increased efficiency of neural process‐
ing is also associated with a peak in behavioral performance. Younger children show greater
activation in similar brain regions as reported in the prenatal drug imaging studies [125, 126].
Although, the data collected in each of the studies were cross-sectional, the reported effects of
prenatal drug exposure in childhood, adolescence, and adulthood indicate that the changes in
brain circuitry underlying response inhibition may not be due to developmental delay, but
instead due to long-term changes in the activation of the circuit.
4.3. Working memory
Working memory refers to the cognitive ability to hold and manipulate information for a short
period of time. Brain imaging studies have shown a load-dependent role for the prefrontal
cortex in working memory [127, 128]. Using fMRI methods, prenatal drug exposure is
associated with differential brain activation within the prefrontal cortex, while performing
working memory tasks. Results are summarized in Table 1(C). For example, children
prenatally exposed to tobacco experience more activation in the inferior parietal regions of the
cortex, whereas children not exposed showed activation in the bilateral inferior frontal region
of the cortex [129]. Prenatal marijuana is also associated with patterns of increased activation
associated with working memory including the inferior and middle frontal gyri [130].
fMRI methods have also been used to demonstrate specific effects of prenatal drug exposure
in both the visual–spatial and verbal working memory domains. Prenatal alcohol exposure
leads to increased activation of the frontal–parietal–cerebellar network including the left dorsal
frontal and left inferior parietal cortices, and bilateral posterior temporal regions during verbal
working memory compared to controls [131]. The results showed that individuals prenatal‐
ly exposed to alcohol recruit a larger, more extensive neural network than their peers. Across
three studies, prenatal alcohol exposure was also associated with differential patterns of
activation, while performing spatial working memory tasks [132–134]. In contrast, offspring
with prenatal methamphetamine exposure had less activation than their unexposed counter‐
parts in both the frontal and striatal regions; primarily in the left hemisphere of the brain on a
spatial working memory task [135], but increased activation in bilateral temporal regions in
response to performing a verbal working memory task [136].
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(A) Default mode network
Drug Effects on network Behavioral effects References
Alcohol Increased activity in DMN
during cognitive tasks
Deficits in arousal regulation [101–107, 114]
Decreased activation of
DMN at rest
Increased risk of ADHD diagnosis
Cocaine Increased activity in
DMN during cognitive tasks
Deficits in arousal regulation [101–107, 113, 114]
Increased activation of
DMN at rest
Increased risk of ADHD diagnosis
(B) Inhibitory control
Alcohol Increased activity in prefrontal
regions
Increased effort required for response inhibition [119]
Decreased activity in the caudate
Tobacco Increased activity in left frontal,
right occipital, bilateral temporal,
and parietal regions
Increased effort required for
response inhibition
[117]
Decreased activity in the
cerebellum
More likely to commit
commission errors
Cocaine Increased activity in inferior
frontal cortex and caudate




temporal and occipital regions
(C) Working memory
Alcohol Increased activation in bilateral
dorsal frontal, bilateral
posterior temporal, and left
inferior parietal regions
More effort required to maintain
working memory
[131, 137, 138]
Tobacco Activation of inferior
parietal cortex as opposed
to bilateral inferior frontal
cortex
Different mechanisms are employed




Decreased activation in frontal
and striatal regions,




Table 1. Summary of prenatal drug exposure effects on (A) default mode network, (B) working memory, and (C)
inhibitory control.
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The impact of prenatal alcohol exposure can be dissociated from other potential explanatory
variables. When examined in relation to family history of alcohol use disorders, prenatal
alcohol exposure independently predicted increased activation in left middle and superior
frontal brain regions [137]. In a direct comparison of adolescents with prenatal alcohol
exposure or ADHD, behavioral profiles were similar but the two groups showed differences
in how cortical brain regions were recruited for spatial working memory [138]. Overall,
prenatal alcohol exposure was associated with an increased effort to compensate in relation to
increasing task demands compared to the ADHD group.
Alterations in behavioral and brain function measures of working memory extend to prena‐
tal cocaine exposure as well. The aforementioned deficits in arousal regulation associated with
prenatal cocaine exposure appear to underlie brain and behavior-related working memory
function. Li et al. [139] showed differential patterns of activation as a function of emotion–
memory interactions. Increased demands on memory load diminished emotion-related
activation in the amygdala in controls but not in the exposed group. In contrast, the exposed
group failed to show an expected decrease in activation in the prefrontal cortex as memory
load decreased in the presence of emotional stimuli. Results suggest that the impact of prenatal
cocaine exposure on arousal regulation acts through both the dorsal cognitive and ventral
emotional systems.
Overall, multiple studies demonstrate the complexities of prenatal drug-related effects on
working memory. Patterns of brain activation associated with working memory are differ‐
ent by type of prenatal drug exposure, are present in the absence of behavioral differences,
and show more extensive networks of activation compared to controls. Specific alterations in
prefrontal cortex activation in response to working memory demand suggest that these regions
are taxed to a greater degree as a result of prenatal drug exposure. Furthermore, changes in
activation remained after controlling for other explanatory variables such as intelligence.
Collectively, studies demonstrate that the effect of prenatal drug exposure on brain activa‐
tion associated with working memory is less efficient and that increased levels of activation
serve to compensate for any deficits in working memory function. Compensatory action,
however, may not be sufficient in real-life situations characterized by increased demands on
working memory function.
4.4. Novel applications of imaging methods and statistical techniques
Recently, a number of novel applications of functional neuroimaging and statistical methods
have been employed to improve upon the limitations of current methods in detecting the subtle
effects of prenatal drug exposure on brain function, develop connectivity maps, and aid in
diagnosis. First, a variety of model-based or data-driven methods have been employed to
analyze functional neuroimaging data. General linear modeling has been used most widely
because it is effective, simple, and robust [140]. However, typical approaches to the statisti‐
cal analysis of fMRI data are limited in that they are not able to detect activation in heteroge‐
neous brain regions that have the potential to play diverse roles in multiple types of task
performance [141]. A recent study successfully demonstrated the advantages of group-wise
sparse representation of fMRI data and statistical coefficient mapping to evaluate the effect of
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prenatal alcohol exposure on functional activity. The advantages reported for this method
included increased adaptability, more systematic in detecting diverse brain networks, and
better able to identify commonalities and differences across subjects and groups [141].
fMRI data can also be analyzed to show how components of a neural system are working
together when performing a specific task. The identification of associations between anatom‐
ically distinct time series is referred to as “functional connectivity” [140]. The ability to identify
consistent, reproducible, and accurate regions of interest is the key to developing connectivi‐
ty maps [142]. Using a new strategy to develop cortical landmarks (dense individualized and
common connectivity-based cortical landmarks, DICCOLs), Li et al. [143] used functional
connectomics signatures to identify 10 brain regions with structurally disrupted landmarks
that could be used to distinctly identify prenatal cocaine exposed brains from that of controls.
Finally, a novel application of machine learning has been used to test whether brain images
can be used to correctly identify prenatal cocaine-exposed young adults from socioeconomi‐
cally matched controls [144]. Regional features were extracted from both structural and
functional MR images, and the power of each to discriminate between prenatal cocaine
exposed and control brains was accomplished through machine learning methods. The
method accurately identified 91.8% of prenatally cocaine-exposed brains. The use of both
structural and functional images was critical to improving the accuracy of the classification
system compared to either type of image alone.
5. Conclusions
Prenatal drug exposure is a risk factor for increased vulnerability to difficulties in both
behavior and cognition. Continued research to identify the structural and functional targets
of prenatal drug-related neurotoxicity is important. Identifying biomarkers of prenatal drug-
related changes in brain development and relating those changes to behavior, or in the case of
alcohol to physical features, has the potential to inform diagnostic and treatment strategies.
MRI, fMRI, and DTI neuroimaging methods provide powerful tools for visualizing the brain
and, because they are noninvasive, are especially suited for research in young children. The
impact of prenatal drug exposure on brain structure and function is subtle and often ac‐
count for a small amount of variance that contributes to deficits in behavior regulation and
cognition. These subtle effects can be explained by the complex interactions of the pattern of
prenatal drug exposure both in terms of the timing and dose as well as the combination of
multiple drugs, genetic, and environmental factors. Changes in brain structure and function
in children and adolescents with prenatal drug exposure can be difficult to assess for a number
of other reasons. To date, a neuropsychological profile for prenatal drug-related deficits in
cognitive function has not been identified and there are diffuse individual differences in the
expression of the impact of prenatal drug exposure on the brain and behavior. Furthermore,
limitations in statistical approaches to the analysis of neuroimaging data can often lead to
difficulty in detecting these subtle effects. Future studies will require large sample sizes and
longitudinal research designs, and increasingly sophisticated neuroimaging and statistical
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methods. A focus on connectivity measures will provide a better understanding of underly‐
ing mechanisms for the associations between brain structure and function, and behavior.
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Although it is well-accepted that drug addiction is a major public health concern, how 
we address it as a society continues to evolve as recent advances in the lab and clinic 
clarify the nature of the problem and influence our views. This unique collection of 
eight chapters reviews key findings on the neurobiology and therapeutics of addiction 
while capturing the diversity of perspectives that shape these concepts, which range 
from evolutionary biology to psychiatry to the legal system. This book discusses in 
depth how technological advances have led to important discoveries and how these 
discoveries, in turn, are increasingly being translated into clinical practice. It also 
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